carbapenems has been researched along with meropenem in 587 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (meropenem) | Trials (meropenem) | Recent Studies (post-2010) (meropenem) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 3,803 | 284 | 2,253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (5.28) | 18.7374 |
| 1990's | 81 (13.80) | 18.2507 |
| 2000's | 107 (18.23) | 29.6817 |
| 2010's | 222 (37.82) | 24.3611 |
| 2020's | 146 (24.87) | 2.80 |
| Authors | Studies |
|---|---|
| Ichihara, Y; Mikami, Y; Miyaji, M; Nishimura, C; Ohashi, S; Yazawa, K | 1 |
| Hopkins, JA; Lami, JL; Wilson, SE | 1 |
| García Sánchez, JE; García-Rodriguez, JA; Sánchez de San Lorenzo, A; Trujillano, I | 1 |
| Cullmann, W; Dick, W | 1 |
| Fukasawa, M; Inoue, T; Kato, M; Matsumura, H; Sunagawa, M | 1 |
| Avlamis, A; Giamarellou, H; Mavroudis, T; Voutsinas, D | 1 |
| Drusano, GL; Margaret, BS; Standiford, HC | 1 |
| Crokaert, F; Glupczynski, Y; Lismont, MJ; Van der Linden, MP; Yourassowsky, E | 1 |
| Chubb, H; Mohammed, Z; Ronald, A; Slaney, L | 1 |
| Nadler, HL; Pitkin, DH; Sheikh, W | 1 |
| Andrews, JM; Ashby, JP; Wise, R | 1 |
| Lindmark, A; Nord, CE; Persson, I | 1 |
| Livermore, DM; Yang, YJ | 2 |
| Eliopoulos, GM; Moellering, RC; Sentochnik, DE | 1 |
| Wiedemann, B; Zühlsdorf, M | 1 |
| Easmon, CS | 1 |
| Edwards, JR; Nairn, K; Williams, S | 1 |
| Goonetilleke, UR; Jones, DV; Murgatroyd, LB; Topham, JC; Wright, J | 1 |
| Chezzi, C; Leone, F; Menozzi, MG; Molinari, G; Pirali, F; Ravizzola, G; Sanna, A; Schito, GC | 1 |
| Hadorn, K; Kayser, FH; Morenzoni, G; Strässle, A | 1 |
| Naden, M; Watt, B | 1 |
| Acar, JF; Gutmann, L; Kitzis, MD | 1 |
| Chanal, C; Chanal, M; Cluzel, M; Cluzel, R; Sirot, D; Sirot, J | 1 |
| Powell, M; Seetulsingh, P; Williams, JD | 1 |
| Iaconis, JP; Sanders, CC; Sanders, WE; Thomson, KS | 1 |
| Chanal, C; Labia, R; Morand, A; Sirot, D; Tiwari, K | 1 |
| Ferrara, A; Gialdroni Grassi, G; Grassi, FA; Grassi, G; Piccioni, PD | 1 |
| Nadler, H; Pitkin, DH; Sheikh, W | 1 |
| Case, DE; Featherstone, A; Fowkes, AG; Harrison, MP; Moss, SR; Sanders, AM | 1 |
| Giles, RE; Patel, JB | 1 |
| Boothman, C; King, A; Phillips, I | 1 |
| Bastain, W; Bax, RP; Featherstone, A; Haworth, SJ; Hutchison, M; Wilkinson, DM | 1 |
| Clarke, AM; Zemcov, SJ | 1 |
| Inderlied, CB; Lancero, MG; Young, LS | 1 |
| Iaconis, JP; Nadler, HL; Sheikh, W | 1 |
| Kim, EN; Kim, JK; Kim, JW; Kim, KK; Lee, CR; Lee, HW; Son, HJ | 1 |
| Govan, JR; Hunter, R; Simpson, IN | 1 |
| Bonner, DP; Fung-Tomc, J; Gradelski, E; Huczko, E; Kessler, RE; Kolek, B; Minassian, B | 1 |
| Banville, J; Bonner, DP; Fung-Tomc, JC; Gradelski, E; Huczko, E; Kessler, RE; Kolek, B; Ménard, M | 1 |
| Andrews, JM; Boswell, FJ; Gill, MJ; Wise, R | 1 |
| Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P | 2 |
| Cavallo, JD; Crenn, Y; Fabre, R; Meyran, M | 1 |
| Brismar, B; Eklund, AE; Nord, CE | 1 |
| Hewlins, MJ; Roy, AB | 1 |
| Fukatsu, H; Hashizume, T; Matsuda, K; Nakagawa, S; Okamoto, O; Sanada, M; Tanaka, N | 1 |
| Cho, JH; Oh, CH | 1 |
| Gutmann, L; Kitzis, MD; Zhou, XY | 1 |
| Barry, AL; Fuchs, PC | 1 |
| Cipriani, P; Filadoro, F; Giordano, A; Magni, A; Papa, F | 1 |
| Edwards, JR | 1 |
| Cravarezza, P; Romanelli, G | 1 |
| Diwok, K; Hamacher, J; Kohl, FV; Lichey, J; Lode, H; Vogel, F; Wendel, H | 1 |
| Byrne, S; Connor, P; David, TJ; Dodd, M; Doughty, I; Jenney, M; Maddison, J; Webb, AK | 1 |
| Beuscart, C; Mouton, YJ | 1 |
| Sjursen, H; Solberg, CO | 1 |
| Baker, LW; Hoogkamp-Korstanjep, JA; Huizinga, WK; Karran, SJ; Pezet, DM; Valleur, P; Warren, BL | 1 |
| Sirot, D | 1 |
| Geroulanos, SJ | 1 |
| Faulkner, KL; Lesky, W; Newell, PA; Norrby, SR | 1 |
| Haworth, SJ; Hutchison, M; Kelly, HC | 1 |
| Faulkner, KL; Haworth, SJ; Hutchison, M; Nadler, H; Pitkin, DH; Sheikh, W; Turner, PJ | 1 |
| Kelly, HC; Newsom, SW; Palsingh, J; Wells, FC | 1 |
| Blumer, JL; Hutchison, M; Parker, EM | 1 |
| Edwards, JR; Nairn, K; Shepherd, GL | 1 |
| Chmelik, V; Featherstone, A; Pfausler, B; Schmutzhard, E; Vukmirovits, G; Williams, KJ | 1 |
| Schuler, D | 1 |
| Hashizume, T; Hazumi, N; Kato, Y; Matsuda, K | 1 |
| Deguchi, K; Fukayama, S; Fukumoto, T; Ishihara, R; Koguchi, M; Nakane, Y; Oda, S; Suzuki, Y; Tanaka, S | 1 |
| Barry, AL; Brown, SD; Fuchs, PC | 2 |
| Aujard, Y | 1 |
| Baldassarre, R; Comunale, L; Poletti, G; Tallarigo, C | 1 |
| Blumer, JL | 1 |
| Kumazawa, J; Matsumoto, T; Nagayama, A | 1 |
| Norrby, SR | 2 |
| Jiang, GZ; Kato, Y; Kido, N; Koide, N; Kusumi, A; Narita, K; Sugiyama, T; Takahashi, K; Yokochi, T | 1 |
| Elkhaïli, H; Jehl, F; Leveque, D; Linger, L; Niedergang, S; Pompei, D | 1 |
| Cometta, A; Glauser, MP | 1 |
| Belousov, IuB; Shatunov, SM | 1 |
| Adachi, Y; Fuse, A; Hashizume, T; Kato, E; Nagano, R; Nakagawa, S; Ohtake, N; Okamoto, O; Shibata, K | 1 |
| Kanazawa, K; Nouda, H; Sunagawa, M | 1 |
| Cornaglia, G; Fontana, R; Mazzariol, A; Satta, G | 1 |
| Keil, S; Wiedemann, B | 1 |
| Livermore, DM | 1 |
| Howe, RA; Millar, MR; Walsh, TR; Wilson, MP | 1 |
| Chang, DC; Wilson, SE | 1 |
| Hirata, Y; Igari, J; Imafuku, Y; Inoue, M; Ishigo, S; Kawaguchi, R; Kobayashi, I; Kumasaka, K; Matsuoka, K; Murakami, E; Nishino, T; Oguri, T; Ohtaki, Y; Okada, J; Okamoto, E; Saeki, H; Satou, S; Shibano, T; Takahashi, A; Tokuda, K; Uchida, K; Uehara, N; Watanabe, N; Yomoda, S; Yoshida, H | 1 |
| Kimpara, I; Kudo, E; Kudo, H; Kudo, Y; Miura, T; Saitoh, Y; Sato, S; Tsujino, M | 1 |
| Garau, J; Martínez Lacasa, J | 1 |
| Bouza, E; Peláez, T | 1 |
| Azami, H; Barrett, D; Hattori, K; Kamimura, T; Kuroda, S; Matsuda, K; Murata, M; Nakajima, T; Tsutsumi, H | 1 |
| Blanquer, J; Cobo, L; Corcia, S; Daguerre, M; de Latorre, FJ; Del Nogal, F; Garau, J; León, C; Net, A; Rello, J | 1 |
| Ljungberg, B; Nilsson-Ehle, I; Nyhlén, A | 1 |
| Awaya, Y; Fujiue, Y; Kodomari, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y | 1 |
| Benali, K; Bingen, E; Bonacorsi, S; Doit, C; Fitoussi, F; Geslin, P | 1 |
| Ambrose, PG; Nightingale, CH; Quintiliani, R; Richerson, MA | 1 |
| Igarashi, J; Nishimura, T; Sasaki, A; Sunagawa, M | 1 |
| Alarcón, T; López-Brea, M; López-Hernández, S | 1 |
| Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N | 1 |
| Kinoshita, S; Kumagai, S | 1 |
| Bryant, RE; Kohlhepp, SJ; Meyer, MM; Munar, MY | 1 |
| Horii, T; Ichiyama, S; Kobayashi, M; Ohta, M | 1 |
| Afzal-Shah, M; Livermore, DM; Villar, HE | 1 |
| Hirata, Y; Hongo, T; Igari, J; Imafuku, Y; Inoue, M; Kawaguchi, R; Kobayashi, I; Kobayasi, Y; Kumasaka, K; Matsumoto, N; Nakasaki, N; Nishino, T; Oguri, T; Ohtaki, Y; Okada, J; Saeki, H; Sasaki, T; Satou, S; Shibano, T; Takahashi, A; Tokuda, K; Uehara, N; Watanabe, N; Yomoda, S; Yoshida, H | 1 |
| Allerberger, F; Feierl, G; Hirschl, A; Krause, R; Mittermayer, H; Reisinger, EC; Wendelin, I | 1 |
| Arita, K; Daido, K; Kohara, T; Nakamura, K; Ohashi, N; Takeshima, Y | 1 |
| Cho, JH; Jin, C; Jung, I; Kim, DH; Kim, M; Ku, HJ; Oh, CH; Yook, J | 1 |
| Fujimura, S; Gomi, K; Honda, Y; Kikuchi, T; Kobayashi, T; Nukiwa, T; Shoji, S; Takahashi, H; Tokue, Y; Watanabe, A; Yasui, S | 1 |
| Deguchi, K; Endo, H; Ishihara, R; Matsumoto, Y; Nishinari, C; Suzuki, Y | 1 |
| Jacolot, A; Leotard, S; Louchahi, K; Mimoz, O; Nordmann, P; Padoin, C; Petitjean, O | 1 |
| Aoki, N; Hashimoto, T; Hirata, Y; Hongo, T; Igari, J; Imafuku, Y; Inoue, M; Ishigo, S; Kajimura, K; Kawaguchi, R; Kobayashi, I; Kobayashi, Y; Kumasaka, K; Matsumoto, N; Matsuoka, K; Murakami, E; Nakasaki, N; Nishino, T; Oguri, T; Ohba, Y; Ohtaki, Y; Okada, J; Okamoto, E; Ono, J; Saeki, H; Sasaki, T; Satou, S; Shibano, T; Takahashi, A; Takata, T; Tokuda, K; Uehara, N; Watanabe, N; Yomoda, S; Yoshida, H | 1 |
| Christenson, JC; Daly, JA; Korgenski, EK | 1 |
| Bou, G; Cerveró, G; Domínguez, MA; Martínez-Beltrán, J; Quereda, C | 1 |
| Cassetta, MI; Conti, S; Fallani, S; Mazzei, T; Novelli, A | 1 |
| Kim, DC; Kim, DJ; Lee, KS; Park, SW; Seo, KJ; Shin, KJ; Yoo, KH | 1 |
| Alberti, S; Anderson, GJ; Biddle, JW; Bush, K; Domenech-Sanchez, A; Queenan, AM; Steward, CD; Tenover, FC; Yigit, H | 1 |
| Dascal, A; Miller, MA; Zaharatos, GJ | 1 |
| Endo, H; Nishinari, C; Suzuki, Y; Tamura, C | 1 |
| Aboul-Enein, HY; Küçükgüzel, I; Ozkan, SA; Ozkan, Y | 1 |
| Kang, YK; Kim, DJ; Koo, KD; Park, SW; Shin, KJ; Yoo, KH | 1 |
| Endo, H; Jinbo, K; Nishinari, C; Suzuki, Y; Tamura, C | 1 |
| Anthony, L; Appelbaum, PC; Credito, K; Ednie, LM; Hoellman, DB; Jacobs, MR; Kelly, LM | 1 |
| Jones, RN | 1 |
| Choi, SH; Kim, GW; Park, HS; Park, SW; We, JS | 1 |
| Hikida, M; Inoue, M; Okamoato, R; Sato, Y; Terashima, S | 1 |
| Majtán, V; Majtánová, L | 1 |
| Belkina, IuE; Bondarenko, IV; Ivanova, OV; Kirsanov, AI; Panasenko, VV; Sleptsov, VP; Stepkina, OI; Usachenko, VP | 1 |
| Nagayama, A; Nomura, S | 1 |
| Chinzei, T; Ishida, A; Tasaka, K | 1 |
| Abe, T; Fukuoka, T; Inoue, M; Ishii, C; Kakuta, M | 1 |
| Bachinskaia, EN; Beloborodova, NV | 1 |
| Chan, YL; Chen, CF; Chou, MH; Lin, MF; Tsai, TH | 1 |
| Giller, RH; Nelson, WK; Quinones, R; Rayback, PA | 1 |
| Ho, SE; Navaratnam, P; Palasubramaniam, S; Subramaniam, G | 1 |
| Kang, YK; Kim, DC; Kim, DJ; Kong, JY; Lee, CS; Lee, KS; Shin, KJ; Yoo, KH | 1 |
| Cravarezza, P; Donati, P; Franchino, L; Grassi, V; Pozzi, A; Prometti, P; Ravizzola, G; Romanelli, G; Zulli, R | 1 |
| Mikamo, H; Ninomiya, M; Tamaya, T | 1 |
| Araake, M; Hara, T; Watabe, H | 1 |
| Greenhalgh, JM; Turner, PJ | 1 |
| Hashimoto, H; Horii, T; Kanno, T; Maekawa, M; Morita, M; Muramatsu, H | 1 |
| Ergen, K; Karadenizli, A; Kolayli, F; Leblebicioglu, H; Okay, E; Oz, S; Savli, H; Vahaboglu, H | 1 |
| Hashimoto, K; Ito, K; Ogata, H | 1 |
| Alberti, S; Biddle, JW; Bush, K; Domenech-Sanchez, A; Queenan, AM; Rasheed, JK; Tenover, FC; Yigit, H | 1 |
| Orlov, VA; Shenderovich, VA; Smirnova, LB; Sokolova, VI | 1 |
| Inoue, M; Kaku, M; Nasu, M; Sagawa, K; Yokoyama, T | 1 |
| Aihara, M; Baba, H; Fujita, N; Hashikita, G; Hirakata, Y; Hiramatsu, K; Horii, T; Ichiyama, S; Igari, J; Ishigo, S; Ishii, Y; Itaha, H; Itoh, K; Iwata, M; Kaku, M; Kambe, M; Kanemitsu, K; Kanno, H; Kasai, T; Kinoshita, S; Komori, T; Kubo, S; Kusano, N; Maeda, S; Maesaki, S; Matsuda, J; Mihara, E; Miyamoto, H; Murakami, M; Murase, M; Murata, Y; Nakashima, H; Negayama, K; Obata, R; Oguri, T; Okada, J; Ono, J; Saikawa, T; Satoh, T; Shibuya, Y; Suwabe, A; Takahashi, A; Takemura, H; Taminato, T; Tazawa, Y; Uehara, N; Watanabe, N; Yamaguchi, K; Yamanaka, K; Yasujima, M; Yoshida, H; Yoshimura, H | 1 |
| Calvo, F; Canduela, MJ; Gallego, L; Martín, G; Pujana, I; Sevillano, E; Umaran, A | 1 |
| Bernabeu-Wittel, M; García-Curiel, A; Jiménez-Mejías, ME; Pachón, J; Pachón-Ibáñez, ME; Pichardo, C | 1 |
| Drusano, GL; Kuti, JL; Mattoes, HM; Nicolau, DP | 1 |
| Axtell, SS; Callahan, J; Shekar, R; Sodhi, M | 1 |
| Brink, AJ; Feldman, C; Grolman, DC; Muckart, D; Pretorius, J; Richards, GA; Senekal, M; Sieling, W | 1 |
| Burgess, DS; Frei, CR; Moczygemba, LR | 1 |
| Bernabéu-Wittel, M; de Cueto, M; del Carmen Conejo, M; García, I; Jiménez-Mejías, ME; Martínez-Martínez, L; Pachón, J; Pachón-Ibáñez, ME; Pascual, A; Pichardo, C | 1 |
| Anderson, VE; Bonomo, RA; Buynak, JD; Caspers, P; Ge, X; Gerken, T; Hujer, AM; Kania, M; Page, MG; Rice, LB | 1 |
| El Amin, N; Giske, CG; Jalal, S; Keijser, B; Kronvall, G; Wretlind, B | 1 |
| Chae, HS; Chang, E; Cho, SG; Kang, CS; Kim, JY; Lee, HK; Park, YJ | 1 |
| Engel, AE; Glass, D; Li, C; Wexler, HM | 1 |
| Akan, OA; Uysal, S | 1 |
| Endo, S; Hakozaki, M; Kojika, M; Sato, N; Suzuki, K; Suzuki, Y; Takahasi, G; Wakabayasi, G | 1 |
| Aihara, M; Baba, H; Fujita, N; Hashikita, G; Hirakata, Y; Hiramatsu, K; Horii, T; Ichiyama, S; Ishigo, S; Ishii, Y; Itaha, H; Itoh, K; Iwata, M; Kaku, M; Kambe, M; Kanemitsu, K; Kanno, H; Kasai, T; Kinoshita, S; Kobayashi, S; Komatsu, M; Komori, T; Kusano, N; Maeda, S; Maesaki, S; Matsuda, J; Mihara, E; Miyake, K; Miyamoto, H; Murakami, M; Murase, M; Mutara, Y; Nakashima, H; Negayama, K; Nishiyama, K; Nomura, F; Oguri, T; Okada, J; Okada, M; Ono, J; Oohara, T; Saikawa, T; Suwabe, A; Takahashi, A; Takemura, H; Taminato, S; Taminato, T; Tazawa, Y; Uehara, N; Watanabe, M; Watanabe, N; Yamaguchi, K; Yamahata, K; Yamanaka, K; Yasujima, M; Yoshida, H; Yoshimura, H | 1 |
| Abe, K; Arai, T; Hasebe, N; Horiuchi, M; Kimura, M; Tokumura, M | 1 |
| Fritsche, TR; Jones, RN; Rhomberg, PR; Sader, HS | 1 |
| Doi, M; Fujiue, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y; Yano, S | 1 |
| Fujimoto, S; Ike, Y; Sakyo, S; Tanimoto, K; Tomita, H | 1 |
| Biddle, JW; Carey, RB; Hanna, B; Kalsi, RK; Lonsway, D; McGowan, JE; Rasheed, JK; Stocker, S; Tenover, FC; Williams, PP | 1 |
| Ikonomidis, A; Markogiannakis, A; Pournaras, S; Spanakis, N; Tsakris, A | 1 |
| Hernández, JR; Martínez-Martínez, L; Pascual, A; Romero, L; Velasco, C | 1 |
| Bernander, S; Ericson, E; Fraenkel, CJ; Larsson, P; Melhus, A; Rydberg, J; Törnqvist, E; Ullberg, M | 1 |
| Edwards, R; Fang, H; Hedberg, M; Nagy, E; Nord, CE; Sóki, J | 1 |
| Alp, E; Aygen, B; Metan, G; Sumerkan, B | 1 |
| Hirota, T; Ikeda, T; Matsushita, Y; Shibayama, T; Tokui, T; Yamamura, N | 1 |
| Ikonomidis, A; Maniatis, AN; Markogiannakis, A; Pournaras, S; Spanakis, N; Tsakris, A | 1 |
| Sakata, H | 1 |
| Falagas, ME; Manta, KG; Siempos, II; Vardakas, KZ | 1 |
| Ha, JR; Kim, HG; Kim, J; Kim, JG; Lee, DG; Lee, JM; Lee, SH; Oh, SW | 1 |
| Hirota, T; Ikeda, T; Kamiyama, E; Shibayama, T; Sugiyama, D; Tokui, T | 1 |
| Dilay, L; Hoban, DJ; Karlowsky, JA; Noreddin, AM; Rubinstein, E; Thomson, K; Wiebe, R; Zhanel, GG | 1 |
| Sinha, M; Srinivasa, H | 1 |
| Evans, JC; Segal, H | 1 |
| Katsube, T; Yamano, Y; Yano, Y | 1 |
| Amyes, SG; Walsh, F | 1 |
| Lister, PD | 1 |
| Amyes, S; Bracher, S; Turner, P; Walsh, F | 1 |
| Nicolau, DP | 1 |
| Joo, JY; Kim, JH; Kwon, OH; Lee, SG | 1 |
| Shah, PM | 1 |
| Malczynski, M; Parker, M; Qi, C; Scheetz, MH | 1 |
| Hori, S; Kizu, J; Kurihara, Y | 1 |
| Joseph, J; Rodvold, KA | 1 |
| Ivanov, DV | 1 |
| Kobayashi, Y; Sumitani, Y | 1 |
| Fukuoka, T; Kakuta, M; Koga, T; Masuda, N; Namba, E; Sugihara, C | 1 |
| Appelbaum, PC; Glupczynski, Y; Lemaire, S; Olivier, A; Tulkens, PM; Van Bambeke, F | 1 |
| Friedland, I; Jasovich, A; Jiang, J; Kaniga, K; Lucasti, C; Umeh, O | 1 |
| Chen, YG; Li, LJ; Qu, TT; Shen, P; Wei, ZQ; Yu, YS; Zhang, Y | 1 |
| Mikamo, H; Tanaka, K; Watanabe, K; Yamagishi, Y | 1 |
| Fujimoto, S; Ike, Y; Okuzumi, K; Tanimoto, K; Tomita, H | 1 |
| Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Morinaga, Y; Nakamura, S; Seki, M; Yamada, Y; Yamamoto, K; Yamamoto, Y; Yanagihara, K | 1 |
| Blanchet, B; Chhun, S; Jullien, V; Lanternier, F; Legrand, T; Pons, G; Rey, E; Zahar, JR | 1 |
| Carey, PR; Kalp, M | 1 |
| Goto, T; Ichiishi, T; Mikamo, H; Nakao, K; Tanaka, K; Watanabe, K; Yamagishi, Y | 1 |
| Alba, V; Marti, S; Sánchez-Céspedes, J; Vila, J | 1 |
| Porath, AD | 1 |
| Ha, JR; Kim, BO; Kim, HG; Kim, JG; Kim, JM; Lee, DG; Lee, JM; Lee, SH; Oh, SW | 1 |
| Díaz-De Alba, P; Egea, P; Fernández-Cuenca, F; López-Cerero, L; Pascual, A; Vila, J | 1 |
| Apisarnthanarak, A; Kiratisin, P; Laowansiri, P; Shah, S | 1 |
| Cho, JH; Kim, SJ; Oh, CH | 1 |
| Sahm, D | 1 |
| Amicosante, G; Falcone, M; Mancini, C; Mezzatesta, ML; Perilli, M; Stefani, S; Venditti, M | 1 |
| Anbazhagan, D; Mansor, MB; Ong, SY; Sekaran, SD; Wong, EW; Yusof, MY | 1 |
| Kawamura, H; Matsumoto, K; Miyanohara, H; Nishi, J; Orita, M; Shigemi, A; Shimodozono, Y; Takeda, Y; Tokuda, K; Yaji, K; Yamada, K | 1 |
| Higgins, PG; Lehmann, M; Nordmann, P; Poirel, L; Seifert, H | 1 |
| Adam, M; Haroutiunian, S; Hoffman, A; Rabinovich, B; Ratz, Y | 1 |
| Gogou, V; Ikonomidis, A; Neou, E; Pournaras, S; Tsakris, A; Vrioni, G | 1 |
| Bahram, F; Emaneini, M; Fatolahzadeh, B; Feizabadi, MM; Mehdi, FM; Mohammad, E; Morovat, T; Setareh, S; Soroush, S; Taherikalani, M | 1 |
| Bush, K; Flamm, R; Queenan, AM; Shang, W | 1 |
| Berthoin, K; Carryn, S; Le Duff, CS; Marchand-Brynaert, J; Tulkens, PM | 1 |
| Amornnopparattanakul, S; Dhiraputra, C; Fungwithaya, S; Leelarasamee, A; Nannha, P; Panapakdee, S; Pongpech, P | 1 |
| Appelbaum, PC; Credito, K; Kosowska-Shick, K | 1 |
| Esterly, JS; Malczynski, M; Qi, C; Scheetz, MH | 1 |
| Otük, G; Ozbek, B | 1 |
| Naenna, P; Noisumdaeng, P; Pongpech, P; Tribuddharat, C | 1 |
| Anderson, KF; Bonomo, RA; Endimiani, A; Hujer, AM; Kitchel, B; Patel, JB; Rasheed, JK | 1 |
| Crandon, JL; Keel, RA; Nicolau, DP; Sutherland, CA | 1 |
| Cohen, R; Durrmeyer, X | 1 |
| Cantón, R; García, A; Gimeno, C; Gobernado, M | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
| Cassettari, M; Chongthaleong, A; Christiansen, KJ; Cooper, D; Flamm, R; Garcia, J; Hsu, L; Ip, M; Ker, HB; Kiratisin, P; Mendoza, M; Morrissey, I; Okolo, P; Quintana, A; Redjeki, IS | 1 |
| Bowler, IC; Gaulton, T; Perry, C; Pike, R; Turton, J; Webster, DP; Woodford, N | 1 |
| Ko, KS; Lee, H; Peck, KR; Song, JH | 1 |
| Araki, N; Kamihira, S; Kohno, S; Morinaga, Y; Yamada, K; Yamada, Y; Yanagihara, K | 1 |
| Abbanat, D; Barron, A; Bunting, RA; Fernandez, J; Flamm, RK; Hall, L; Hilliard, JJ; Lynch, AS; Melton, JL; Ward, CK | 1 |
| Du, X; Jiang, X; Li, G; Wang, Y; Wei, Q; Zhao, Y | 1 |
| Gomersall, C; Kuti, JL; Kwa, A; Montakantikul, P; Nicolau, DP; Roberts, JA | 1 |
| Kakeya, N; Kasai, M; Kunishiro, K; Matsui, H; Shirahase, H; Tanaka, S | 1 |
| Cai, J; Liu, J; Wu, D | 1 |
| Abbasi, L; Farajnia, S; Hasani, A; Mirsalehian, A; Nahaei, MR; Peymani, A; Sohrabi, N | 1 |
| Albertí, S; Doménech-Sánchez, A; García-Sureda, L; Juan, C | 1 |
| Chiang, T; Colon-Urban, R; Eng, RH; Gomez, E; Huang, DB; Mariano, N; Urban, C | 1 |
| Ersoy, Y; Görgeç, S; Kuzucu, C; Yetkin, F | 1 |
| Cabot, G; Macia, MD; Martínez-Martínez, L; Moya, B; Ocampo-Sosa, AA; Oliver, A; Peña, C; Rodríguez, C; Suárez, C; Tubau, F; Zamorano, L | 1 |
| Flamm, RK; Korten, V; Laeuffer, JM; Morrissey, I; Mutters, R; Nordmann, P; Picazo, JJ; Quintana, A; Seak, JC | 1 |
| Hsueh, PR; Huang, WH; Ko, WC; Lee, NY; Tsui, KC | 1 |
| Apisarnthanarak, A; Apisarnthanarak, P; Kiratisin, P; Mundy, LM | 1 |
| Goessens, WH; Mol, M; Pitout, JD; van der Bij, AK; van Westreenen, M | 1 |
| Dihmess, A; Evans, A; Fiorenza, M; Graffunder, E; Harrington, S; Lodise, TP; Martis, P; Masoud, R; McNutt, LA; Patel, N; Woo, B | 1 |
| Hong, KW; Jeong, H; Kang, MW; Kim, SI; Kim, YJ; Kim, YR; Park, YJ; Wie, SH | 1 |
| Bethel, CR; Bonnet, R; Bonomo, RA; Distler, AM; Endimiani, A; Hujer, AM; Hujer, KM; Papp-Wallace, K; Shyr, T; Taracila, M; Thomson, JM | 1 |
| Akalın, H; Akova, M; Arman, D; Aygen, B; Başaran, S; Bayramoğlu, G; Dizbay, M; Dokuzoğuz, B; Eraksoy, H; Esener, H; Hasçelik, G; Köksal, I; Korten, V; Oğünç, D; Sınırtaş, M; Söyletir, G; Sümerkan, B; Tünger, A; Ulusoy, S; Yalçın, AN | 1 |
| Cabot, G; Cantón, R; del Campo, R; García-Castillo, M; Juan, C; Mulet, X; Oliver, A; Riera, E | 1 |
| Bogaerts, P; Cuzon, G; Glupczynski, Y; Huang, TD; Kostyanev, T; Naas, T; Nordmann, P; Ozsu, S | 1 |
| Kim, J; Kim, S; Kim, SM; Lee, HW; Seol, SY | 1 |
| Izumi, T; Kobayashi, N; Nakai, D; Okazaki, O; Suzuki, E; Yamamura, N | 1 |
| Amsler, K; Davies, TA; Flamm, RK; He, W; Lynch, AS; Marie Queenan, A; Morrow, BJ; Pillar, C; Shang, W | 1 |
| Akers, KS; Beckius, ML; Calvano, T; Hospenthal, DR; Markelz, AE; Mende, K; Murray, CK; Yu, X; Zera, WC | 1 |
| Choi, JY; Jung, SI; Kim, DH; Kim, SH; Ko, KS; Park, KH; Park, YK | 1 |
| Baek, JY; Kang, CI; Ko, KS; Peck, KR; Song, JH | 1 |
| Chen, K; Chen, L; Guang-Yang, C; Hong, Y; Jiang, H; Kong, X; Lan, L; Li, KK; Li, L; Liang, Z; Liu, H; Luo, C; Shen, X; Wang, Y; Zheng, M | 1 |
| Balkan, N; Ilki, A; Ozel, N; Söyletir, G; Toprak Ülger, N | 1 |
| Chang, SC; Chen, WC; Chen, YC; Hu, FC; Wang, JL; Wu, UI; Yang, CS | 1 |
| Borer, A; Eskira, S; Livshiz-Riven, I; Nativ, R; Peled, N; Riesenberg, K; Saidel-Odes, L; Schlaeffer, F; Sherf, M | 1 |
| Chen, CC; Chen, CH; Chiang, SR; Chuang, YC; Ko, WC; Lee, NY; Shieh, JM; Tang, HJ | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
| Hagihara, M; Kuti, JL; Nicolau, DP | 1 |
| Decker-Burgard, S; Laeuffer, J; Morrissey, I; Mutters, R; Seifert, H; Valenza, G | 1 |
| Martínez-Martínez, L; Ocampo-Sosa, AA; Revillo, MJ; Rezusta, A; Román, E; Ruiz, E; Torres, C | 1 |
| Almuzara, M; Docquier, JD; Gutkind, G; Pollini, S; Radice, M; Rossolini, GM; Santella, G | 1 |
| Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
| Chen, CC; Cheng, KC; Chiang, SR; Chiu, YH; Chuang, YC; Ko, WC; Ku, YH; Tang, HJ; Zhang, CC | 1 |
| Arthur, M; Dubée, V; Dubost, L; Ethève-Quelquejeu, M; Gutmann, L; Hugonnet, JE; Mainardi, JL; Marie, A; Triboulet, S | 1 |
| Ichikawa, M; Kurokawa, M; Nannya, Y; Narukawa, K; Toya, T | 1 |
| Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Ho, MW; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Tang, HJ; Toh, HS; Wang, JH; Yu, KW | 1 |
| Chan, KS; Choudhury, S; Koh, TH | 1 |
| Dundar, D; Kasap, M; Kolayli, F; Torol, S; Vahaboglu, H | 1 |
| Aiello, E; D'Ancona, F; Dematte, L; Goglio, A; Meledandri, M; Pantosti, A; Raglio, A; Rossolini, GM; Serra, R; Sisto, A | 1 |
| Hino, M; Kanamaru, A; Masaoka, T; Nakagawa, Y; Ohta, K; Ohyashiki, K; Suzuki, K; Tamura, K; Urabe, A | 1 |
| Dowzicky, MJ; Fernández-Canigia, L | 1 |
| Chang, SC; Dong, SX; Wang, JT | 1 |
| Keel, RA; Kiratisin, P; Nicolau, DP | 1 |
| Colakoğlu, S; Durmaz, S; Ekincioğlu, P; Perçin, D | 1 |
| Adamski, P; Bulanda, M; Drzewiecki, A; Sodo, A; Talaga, K | 1 |
| Dantier, C; Desarbre, E; Gebhardt, K; Hofer, B; Page, MG; Schmitt-Hoffmann, A | 1 |
| Apfalter, P; Hartl, R; Kerschner, H; Widhalm, S | 1 |
| Kaniga, K; Lee, M; Redman, R; Rice, DA | 1 |
| Baziaka, F; Galani, L; Giamarellou, H; Karaiskos, I | 1 |
| Bi, LJ; Hu, YL; Li, DF; Li, WJ; Wang, DC; Zhang, XE | 1 |
| Kemper, AL; Young, DC; Zobell, JT | 1 |
| Fusté, E; Gainza, E; López-Jiménez, L; Segura, C; Viñas, M; Vinuesa, T | 1 |
| Hiraki, Y; Inoue, D; Kamimura, H; Karube, Y; Kawano, F; Masuda, Y; Takaki, K; Tsuji, Y; Yoshida, M | 1 |
| Goff, DA; Nicolau, DP | 1 |
| Guzek, A; Korzeniewski, K; Nitsch-Osuch, A; Prokop, E; Rybicki, Z | 1 |
| Kirikae, T; Miyoshi-Akiyama, T; Shimada, K; Shimojima, M; Tada, T | 1 |
| Pal, A; Tripathi, A | 3 |
| Bozkurt, F; Dal, T; Dayan, S; Deveci, Ö; Tekin, A; Tekin, R | 1 |
| Antunes, NT; Chang, M; Kumarasiri, M; Mobashery, S; Smith, CA; Stewart, NK; Toth, M; Vakulenko, SB | 1 |
| Arthur, M; Cordillot, M; Dubée, V; Dubost, L; Hugonnet, JE; Mainardi, JL; Marie, A; Triboulet, S | 1 |
| Diza, E; Exindari, M; Haitoglou, C; Meletis, G; Pournaras, S; Protonotariou, E; Sianou, E; Sofianou, D; Vavatsi, N | 1 |
| Li, S; Nelson, DC; Shen, Y; Turko, IV; Wang, M | 1 |
| Chlebicki, MP; Kwa, AL; Lee, AL; Lee, W; Liew, LT; Lim, CL; Nah, SC; Wan, CN | 1 |
| Cheatham, SC; Chung, EK; Fleming, MR; Juenke, JM; Kays, MB | 1 |
| Chen, Z; Kang, M; Li, D; Tao, C; Wang, T; Xie, Y | 1 |
| Aubry, A; Bréchot, N; Brisson, H; Brossier, F; Chastre, J; Combes, A; Jarlier, V; Lu, Q; Luyt, CE; Micaelo, M; Rouby, JJ; Trouillet, JL | 1 |
| Fowler, RC; Hanson, ND | 1 |
| Fang, X; Gong, M; Xia, J; Xu, Y; Zhang, D; Zhou, Y | 1 |
| Cannon, JP; Clark, NM; Grim, SA; Lee, TA; Setlak, P | 1 |
| Bonomo, RA; Cline, M; Cober, E; Conlan, S; Evans, S; Fowler, VG; Fox, J; Hall, GS; Hanrahan, J; Jacobs, MR; Kalayjian, RC; Kaye, KS; Mason, P; Perez, F; Richter, SS; Rudin, SD; Salata, RA; Segre, JA; van Duin, D; Webber, R; Ziegler, J | 1 |
| Barth, AL; da Silva, RC; Dalarosa, MG; Falci, DR; Luz, DI; Magagnin, CM; Ribeiro, VB; Rozales, FP; Sampaio, JM; Vieira, FJ; Zavascki, AP | 1 |
| Arslan, U; Kus, H; Tuncer, I; Turk Dagi, H | 1 |
| Courvalin, P; Meziane-Cherif, D | 1 |
| Coombes, BK; De Pascale, G; King, AM; King, DT; Reid-Yu, SA; Strynadka, NC; Walsh, TR; Wang, W; Wright, GD | 1 |
| Abbasi, SA; Day, KM; Paterson, DL; Perry, JD; Raza, MW; Sartor, AL; Sidjabat, HE | 1 |
| Antachopoulos, C; Dimou, V; Drossou-Agakidou, V; Iosifidis, Ε; Karampatakis, T; Katragkou, A; Orfanou, A; Roilides, E; Sarafidis, K; Tsakris, A; Tsiatsiou, O | 1 |
| Wu, H; Xie, W; Ye, Z; Zhang, W; Zhao, C | 1 |
| He, Y; Jiang, Y; Pan, X; Wong, WT; Zhao, Y | 1 |
| Bonomo, RA; June, CM; Leonard, DA; Ulberg, LS; Vaughan, RM; Witucki, LA | 1 |
| Costa, SF; Dos Santos, LC; Fu, L; Guimaraes, T; Leite, G; Levin, AS; Ramos, J; Rizek, C; Rossi, F | 1 |
| Gu, B; Mei, Y; Wen, Y; Xia, W; Zhang, X | 1 |
| Gong, WT; Li, X; Liu, W; Wang, L; Xu, B; Yang, Y; Zhang, XJ; Zhu, YQ | 1 |
| Danishuddin, M; Faheem, M; Khan, A; Khan, AU | 1 |
| Chen, Z; Li, L; Sun, Z; Tian, L; Wang, Y; Yan, S; Zhang, B; Zhu, X | 1 |
| Abe, J; Fujita, A; Hino, M; Hirose, A; Kakeya, H; Kaneko, Y; Nakaie, K; Nakamura, Y; Okada, Y; Takizawa, E; Yamada, K | 1 |
| Alcántar-Curiel, MD; Fernández-Vázquez, JL; García-Torres, LF; Gayosso-Vázquez, C; Giono-Cerezo, S; González-Chávez, MI; Jarillo-Quijada, MD; Morfín-Otero, R; Rodríguez-Noriega, E; Santos-Preciado, JI | 1 |
| Ahn, S; Han, WD; Kim, ES; Kim, HB; Kim, NH; Kim, TS; Park, KU; Seo, HK; Shin, MJ; Song, KH; Yoo, JS | 1 |
| Cheng, C; Rui, Y; Sun, J; Zheng, F | 1 |
| Black, DJ; Frase, H; Smith, CA; Stewart, NK; Vakulenko, SB | 1 |
| Bai, KJ; Chang, FY; Chen, RJ; Chen, YH; Chen, YS; Hsu, CW; Hsueh, PR; Jean, SS; Ko, WC; Lee, WS; Liao, CH; Liu, CY; Liu, JW; Lu, MC; Wu, JJ; Yu, KW | 1 |
| Dong, D; Huang, L; Huang, S; Huang, Y; Li, H; Liu, W; Tong, Y; Wang, X; Wei, X; Yan, X; Yang, Z; Yuan, J; Zhao, X; Zou, D | 1 |
| Decosterd, LA; Eggimann, P; Fournier, A; Marchetti, O; Pagani, JL; Pannatier, A; Que, YA; Revelly, JP; Voirol, P | 1 |
| Liu, W; Miao, J; Qin, YP; Shu, SQ; Wang, Y; Zhang, L; Zheng, J | 1 |
| Ikawa, K; Ishihara, N; Isobe, T; Karino, F; Miura, K; Morikawa, N; Naora, K; Nishimura, N; Tamaki, H | 1 |
| Carlson, EE; Kocaoglu, O; Tsui, HC; Winkler, ME | 1 |
| Fusegawa, K; Goda, R; Ikenaga, H; Izumi, T; Kobayashi, N; Kuga, H; Nakai, D; Suzuki, E | 1 |
| Chia, JH; Hsu, PC; Kuo, AJ; Lee, CH; Lee, MH; Su, TY; Ye, JJ | 1 |
| Kaushik, A; Lamichhane, G; Makkar, N; Pandey, P; Parrish, N; Singh, U | 1 |
| Anh, NQ; Kirikae, T; Miyoshi-Akiyama, T; Nhung, PH; Ohmagari, N; Phuong, DM; Shimada, K; Tada, T | 1 |
| Abbo, LM; Aragon, L; Beduschi, T; Camargo, JF; Cantón, R; Morris, MI; Pérez-Cardona, A; Prado, CE; Simkins, J; Tekin, A | 1 |
| Barbara, CS; Caresta, E; Ceccarelli, G; D'Abramo, A; d'Ettorre, G; Mascellino, MT; Moretti, C; Oliva, A; Papoff, P; Venditti, M; Visca, P; Vullo, V | 1 |
| Alby, K; Han, JH; Mills, JP; Talati, NJ | 1 |
| Arora, R; Chakotiya, AS; Chawla, R; Goel, R; Narula, A; Sharma, RK; Tanwar, A; Thakur, P | 1 |
| Balasubramanian, D; Mathee, K; Silver, LL; Zincke, D | 1 |
| Barnett, AG; Diab, S; Fraser, JF; Fung, YL; Roberts, JA; Shekar, K; Wallis, SC | 1 |
| Jeon, H; Kang, HY; Kim, BR; Kim, CH; Lee, JC; Lee, SH; Lee, YC | 1 |
| Asık, G; Atasoy, AR; Aykan, SB; Ciftci, IH; Karakece, E; Terzi, HA | 1 |
| Ji, S; Li, C; Li, S; Liang, X; Zhang, F; Zhu, Y | 1 |
| Cipolla, A; D'Abramo, A; De Angelis, M; Favaro, M; Ferretti, G; Gizzi, F; Iannetta, M; Mascellino, MT; Mastroianni, CM; Oliva, A; Russo, G; Vullo, V | 1 |
| Millar, M; Sanz, MG; Tiberi, S | 1 |
| Centis, R; D'Ambrosio, L; Dore, S; Esposito, S; Migliori, GB; Sotgiu, G; Spanevello, A; Tiberi, S | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Maitte, A; Potel, G | 1 |
| Aktaş, Z; Akyön, Y; Aşçı Toraman, Z; Ay, S; Ayaş, R; Aydemir, Ş; Aydın, F; Bakıcı, Z; Bayramoğlu, G; Baysallar, M; Büyüktaş, A; Çağatay, M; Çakar, A; Çelik, C; Çöplü, N; Dündar, D; Erçal, BD; Güdücüoğlu, H; Gülay, Z; Günaydın, M; Gür, D; Hasdemir, U; Karatuna, O; Kayacan, Ç; Kılıç, A; Kılıç, H; Öğünç, D; Özhak Baysan, B; Parlak, M; Tünger, A; Yanık, K; Zer, Y | 1 |
| Fang, YP; Pan, YP; Shen, JL; Wang, ZX; Xu, YH | 1 |
| Hu, Q; Hu, Y; Lin, X; Lv, H; Xu, X; Zhang, R | 1 |
| Arakawa, Y; Jin, W; Kimura, K; Kurosaki, H; Mori, S; Wachino, J; Yamaguchi, Y | 1 |
| Abdollahi, A; Aliramezani, A; Boroumand, MA; Douraghi, M; Ghalavand, Z; Ghourchian, S; Mohammadzadeh, M; Nateghi Rostami, M; Rahbar, M; Zeraati, H | 1 |
| Chang, FY; Chen, TL; Chiu, CH; Chuang, MF; Kuo, SC; Lee, YT; Lin, JC; Wang, YC; Yang, YS | 1 |
| Corso, A; Fatouraei, M; Fernandez, R; Gagetti, P; Gu, J; Martinez, MP; Pasteran, F; Paz, L; Rosato, AE; Rose, WE | 1 |
| Dowzicky, MJ; Rodloff, AC | 1 |
| Aubry, A; Chastre, J; Crandon, JL; Luyt, CE; Nicolau, DP | 1 |
| Arai, K; Kashiwa, M; Nagano, N; Saito, R; Yamada, K | 1 |
| Al-Masaudi, S; Elawady, S; Elsherif, R; Harakeh, S; Ismail, D; Jastaniah, S; Karrouf, G | 1 |
| Furuyama, T; Hanson, ND; Ishii, Y; Nonomura, H; Shimizu-Ibuka, A | 1 |
| Anandan, S; Balaji, V; Bhuvaneshwari, T; Devi, BY; Elakkiya, M; Laishram, S; Peter, JV; Priyanka, B; Subramani, K | 1 |
| Dinic, M; Kocic, B; Mitic, R; Mladenovic-Antic, S; Petrovic, J; Randjelovic, G; Velickovic-Radovanovic, R | 1 |
| Hu, YF; Liu, CP; Shih, SC; Wang, NY | 1 |
| Akova, M; Metan, G | 1 |
| Álvarez, C; Ardila, N; Ariza, B; Caro, MA; Gil, F; González, PF; Valderrama, SL | 1 |
| Bian, X; Chen, Y; Li, Y; Liu, X; Shi, J; Zhang, J; Zhao, M | 1 |
| Arenas, J; Goessens, WH; Tommassen, J; van Boxtel, R; Wattel, AA | 1 |
| Goodman, KE; Harris, AD; Roberts, A; Simner, PJ; Taiwo, A; Tamma, PD; Tekle, T | 1 |
| Ardebili, A; Mardaneh, J; Razavi Nikoo, H | 1 |
| Gatermann, SG; Gerigk, S; Gohlke, F; Kaase, M; Lange, F; Oberdorfer, K; Pfennigwerth, N; Purr, I; Roggenkamp, A; Wohanka, N | 1 |
| Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
| Fatemi, SM; Rabbani Khorasgani, M; Shokri, D; Soleimani-Delfan, A | 1 |
| Ajao, AO; Albrecht, JS; Furuno, JP; Harris, AD; Johnson, JK; Pineles, LL; Robinson, GL; Thom, KA; Zhao, L | 1 |
| Barmpouti, E; Galani, L; Giamarellou, H; Karaiskos, I; Masgala, A; Souli, M | 1 |
| Livermore, DM; Mushtaq, S; Vickers, A; Woodford, N | 1 |
| Bulitta, JB; Forrest, A; Garonzik, SM; Kaye, KS; Lenhard, JR; Li, J; Nation, RL; Silveira, FP; Soo Shin, B; Tao, X; Thamlikitkul, V; Tsuji, BT | 1 |
| Azizi, E; Bajrami, R; Kurti, A; Lila, G; Mulliqi-Osmani, G; Raka, L | 1 |
| Cancelli, F; Castaldi, D; Ciardi, MR; Cipolla, A; D'Abramo, A; D'Agostino, C; Mascellino, MT; Mastroianni, CM; Oliva, A; Russo, G; Scorzolini, L; Vullo, V | 1 |
| Falagas, ME; Legakis, NJ; Skalidis, T; Vardakas, KZ | 1 |
| D'Arcy, S; Doumith, M; Findlay, J; Hopkins, KL; Howe, R; Mather, B; Meunier, D; Mustafa, N; Pike, R; Woodford, N; Wootton, M | 1 |
| Chudejova, K; Hrabak, J; Papagiannitsis, CC; Rotova, V; Skalova, A | 1 |
| Bhamidimarri, SP; Soundararajan, G; Winterhalter, M | 1 |
| Chiba, K; Goda, R; Koyama, K; Kuga, H; Nakai, D; Suzuki, E | 1 |
| Fakhar, Z; Govender, T; Honarparvar, B; Kruger, HG; Lamichhane, G; Maguire, GEM; Walker, RC | 1 |
| Dou, Q; Hu, Y; Li, J; Liu, W; Wang, H; Zou, M | 1 |
| Cho, B; Chung, NG; Han, SB; Jeong, DC; Kang, JH; Kim, HS; Kim, SK; Lee, DG; Lee, JW; Park, BK | 1 |
| Martin, NI; Tehrani, KHME | 1 |
| Abdallah, M; Alharthy, A; Alodat, M; Amirah, MF; Badawi, M; Mady, AF; Rasheed, A | 1 |
| Lewis, S; Opene, BNA; Simner, PJ; Tamma, PD; Wang, R | 1 |
| Chandler, CE; Ernst, RK; Han, K; Lory, S; Tjaden, B; Zhang, YF | 1 |
| Abbo, LM; Aragon, L; Bonomo, RA; Camargo, JF; Hujer, AM; Martinez, O; Nicolau, DP; Perez, F; Perez-Cardona, A; Rojas, LJ; Rosa, R; Rudin, SD; Tekin, A | 1 |
| Agüera, A; Bertakis, Y; Brebou, C; Martínez-Piernas, AB; Reina, AC; Sánchez Pérez, JA; Xekoukoulotakis, NP | 1 |
| Davies, M; Hayashi, W; Hobson, J; Koide, S; Kubo, R; Nagano, N; Nagano, Y; Ohsaki, Y; Osaka, S; Taniguchi, Y | 1 |
| Achard, MES; Anderson, GJ; Djoko, KY; Hancock, SJ; Harris, PN; Lo, AW; McEwan, AG; Miraula, M; Mitić, N; Paterson, DL; Peters, KM; Phan, MD; Prombhul, S; Schembri, MA; Schenk, G; Shafer, WM; Sidjabat, HE; Walsh, TR | 1 |
| Menon, T; Mohanam, L | 1 |
| Akamatsu, N; Hasegawa, H; Kaku, N; Kawamoto, Y; Kosai, K; Matsuda, J; Morinaga, Y; Uno, N; Yamakawa, H; Yanagihara, K | 1 |
| Feng, H; Fleming, J; Liu, W; Liu, X; Wang, DC; Wang, S | 1 |
| Baumgardner, DJ; Kram, JJ; Patel, K | 1 |
| Liu, C; Martinez, J; Nguyen, M; Quinn, B; Ramirez, MS | 1 |
| Bonomo, RA; Perez, F | 1 |
| Ascher, DB; Cleland, H; Hawkey, J; Holt, KE; Judd, LM; Kostoulias, X; Padiglione, A; Peleg, AY; Spelman, DW; Wick, RR | 1 |
| Abdul, W; Grigoriu, A; Smoke, SM; Vasant, D | 1 |
| Aubry, A; Bréchot, N; Brossier, F; Jarlier, V; Lu, Q; Luyt, CE; Micaëlo, M; Monsel, A | 1 |
| Antachopoulos, C; Karampatakis, T; Roilides, E; Tsakris, A | 1 |
| Hao, M; Hu, F; Qin, X; Shen, Z; Wang, M; Wu, S; Xu, X; Yang, Y; Ye, M; Zhu, S | 1 |
| Zavascki, AP | 1 |
| Giacobbe, DR | 1 |
| Carmeli, Y; Daikos, GL; Durante-Mangoni, E; Leibovici, L; Mouton, JW; Paul, M; Theuretzbacher, U | 1 |
| Biggs, AD; Dudley, SW; Erstad, BL; French, RNE; Huckleberry, YC; Khobrani, MA; Kopp, BJ; Shirazi, FM | 1 |
| Ali, A; Gupta, D; Khan, AU; Sharma, A; Srivastava, G | 1 |
| Giske, CG; Haldorsen, B; Hansen, DS; Helgason, KO; Kahlmeter, G; Löhr, IH; Matuschek, E; Österblad, M; Rantakokko-Jalava, K; Samuelsen, Ø; Småbrekke, L; Sundsfjord, A; Wang, M | 1 |
| Hall, RM; Nigro, SJ | 1 |
| Abdollahi, A; Beigmohammadi, MT; Doomanlou, M; Khalili, H; Mohammadi, M; Shojaei, L | 1 |
| Bayet, M; Benvenuti, M; Bougnon, J; Bousquet, J; Castandet, J; Cerboni, G; Coelho, A; Cramp, MC; Davies, DT; De Luca, F; Docquier, JD; Everett, M; Jennings, N; Jones, MW; Juventhala, RR; Leiris, S; Lemonnier, M; Lozano, C; Mangani, S; Pallin, TD; Pattipati, R; Pothukanuri, S; Pottabathini, N; Pozzi, C; Raphy, G; Shankar, B; Sivasubrahmanyam, R; Soodhagani, AK; Sprynski, N; Zalacain, M | 1 |
| Gatermann, SG; Höfken, LM; Kaase, M; Lange, F; Pfennigwerth, N | 1 |
| Fujita, J; Kirikae, T; Kuwahara-Arai, K; Maeda, S; Mya, S; Nakasone, I; Sekiguchi, JI; Tada, T; Tin, HH; Tome, T; Uechi, K; Yanagisawa, I; Zan, KN | 1 |
| Kuroda, M; Matsui, M; Segawa, T; Sekizuka, T; Shibayama, K; Suzuki, S | 1 |
| Al Zaibag, M; Aljohany, SM; Alothman, AF; Arabi, YM; Baharoon, S; Balkhy, HH; El-Metwally, A; El-Saed, A | 1 |
| Bocharova, Y; Chebotar, IV; Mayanskiy, NA; Savinova, T; Shagin, DA; Shelenkov, AA | 1 |
| Adam, HJ; Domalaon, R; Golden, AR; Idowu, T; Karlowsky, JA; Lagacé-Wiens, PRS; Lawrence, CK; Lynch Iii, JP; Noreddin, A; Schweizer, F; Walkty, AJ; Wiebe, K; Zelenitsky, S; Zhanel, GG; Zhanel, MA | 1 |
| Alharbi, A; Alshehri, S; Eljaaly, K; Ortwine, JK; Pogue, JM | 1 |
| Hsu, AJ; Tamma, PD | 1 |
| Bhattacharjee, A; Bhowmik, D; Chakravarty, A; Chanda, DD; Chetri, S; Nath, K; Singha, M | 1 |
| Correa, A; De La Cadena, E; Gutiérrez, S; Hernández-Gómez, C; Pallares, C; Villegas, MV | 1 |
| Avery, LM; Nicolau, DP; Sutherland, CA | 1 |
| Abbas, HA; Goda, RM; Kadry, AA; Shaker, GH | 1 |
| Hagiya, H; Hamaguchi, S; Kokado, R; Morii, D; Okuno, H; Tomono, K; Ueda, A; Yamamoto, N; Yoshida, H | 1 |
| Bajaksouzian, S; Barnes, MD; Bonomo, RA; Good, CE; Haldimann, A; Jacobs, MR; Kreiswirth, BN; Papp-Wallace, KM; Rojas, LJ; Taracila, MA; van Duin, D | 1 |
| Azougagh, K; Barbier, F; Boulain, T; Boutrot, M; Guinard, J | 1 |
| Smith, CA; Stewart, NK; Toth, M; Vakulenko, SB | 1 |
| Nishiura, H; Terahara, F | 1 |
| Antonelli, A; Camarlinghi, G; Coppi, M; Giani, T; Mattei, R; Nardone, M; Parisio, EM; Riccobono, E; Rossolini, GM | 1 |
| Agüera, A; Bertakis, Y; Cabrera-Reina, A; Martínez-Piernas, AB; Sánchez Pérez, JA; Xekoukoulotakis, NP | 1 |
| Izmailyan, S; Lawrence, K; Olesky, M; Solomkin, JS; Sway, A; Tsai, L | 1 |
| Carroll, KC; Chambers, KK; Goodman, K; Kazmi, AQ; Lewis, S; Milstone, AM; Opene, BNA; Simner, PJ; Tamma, PD; Wang, R; Workneh, M | 1 |
| Akinci, E; Baran, I; Bodur, H; Mumcuoglu, I; Sertcelik, A | 1 |
| Byun, JH; Chong, Y; Kim, D; Kim, M; Lee, H; Lee, K; Seo, Y; Yong, D | 1 |
| Altunin, S; Antoniadou, A; Bernardo, M; Carmeli, Y; Daikos, GL; Daitch, V; Deliolanis, I; Dickstein, Y; Dishon Benattar, Y; Durante-Mangoni, E; Friberg, LE; Iossa, D; Leibovici, L; Lellouche, J; Mouton, JW; Nutman, A; Paul, M; Rakovitsky, N; Rognås, V; Schwartz, D; Skiada, A; Yahav, D | 1 |
| Li, X; Lu, C; Sun, S; Wang, D; Wang, Y | 1 |
| Anandan, S; Bhattacharya, S; Deotale, V; Kanthan, K; Kapil, A; Mathur, P; Ms, DP; Ohri, VC; Ray, P; Sistla, S; Veeraraghavan, B; Vijayabaskar, S; Vijayakumar, S; Walia, K; Wattal, C | 1 |
| Caroline, C; Chien-Boon Lye, D; Choon-Kiat Tan, N; Ding, YY; Hsien-Xiong Lee, R; Lim, JP; Neo, HY; Pei-Ying Ho, E; Tan, KT; Wei-Han Ng, D | 1 |
| Das, S; Ihssen, J; Shabat, D; Spitz, U; Wick, L | 1 |
| Cury, AP; Duarte, AJDS; Girardello, R; Rossi, F | 1 |
| Abad, CLR; Li, KL | 1 |
| Bustarret, O; Eisermann, M; Jugie, M; Kaminska, A; Minh Nguyen, K; Nabbout, R | 1 |
| Ackley, R; Anderson, WE; Capraro, GA; Meredith, J; Minor, S; Polk, C; Roshdy, D | 1 |
| Jing, X; Liu, R; Min, X; Wan, D; Wu, T; Zeng, J; Zhang, X; Zhou, H | 1 |
| Andresen, AMS; Åstrand, OAH; Bayer, A; Carlsen, TJO; Finke, S; Fröhlich, C; Gjøen, T; Heikal, A; Huber, S; Kildahl-Andersen, G; Lauksund, S; Leiros, HS; Rongved, P; Samuelsen, Ø; Schnaars, C; Skagseth, S; Økstad, OA | 1 |
| Bernardo, M; Bitterman, R; Carmeli, Y; Daikos, G; Daitch, V; Dishon-Benattar, Y; Durante-Mangoni, E; Friberg, LE; Iossa, D; Leibovici, L; Lellouche, J; Mouton, JW; Nutman, A; Paul, M; Skiada, A; Temkin, E; Theuretzbacher, U; Yahav, D; Zusman, O | 1 |
| Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H | 1 |
| Karakonstantis, S | 1 |
| Cotroneo, N; Critchley, IA; Pillar, C; Pucci, MJ; Rubio, A | 1 |
| Fan, X; Fu, Y; Li, C; Li, J; Wang, Y; Yu, L; Zhang, J; Zhang, X; Zhao, Y | 1 |
| Carmeli, Y; Nutman, A | 1 |
| Ali, A; Khan, A; Khan, AU; Kumar, R | 1 |
| Horikoshi, Y; Igarashi, T; Kasai, M; Kinoshita, N; Komura, M; Miyairi, I; Saitoh, J; Shinjoh, M; Shoji, K; Sugahara, Y; Watanabe, Y | 1 |
| Katip, W; Oberdorfer, P; Uitrakul, S | 1 |
| Ayfan, AK; Mohd Sazlly Lim, S; Naicker, S; Roberts, JA; Sime, FB; Zowawi, H | 1 |
| Cuba, GT; Ramos, JF; Veiga Kiffer, CR | 1 |
| Jeyakanthan, J; Lopes, BS; Ramachandran, B | 1 |
| Bryan, A; Bryson-Cahn, C; Chan, JD; Jain, R; Kim, HN; Krantz, EM; Lan, KF; Liu, C; Lynch, JB; Mani, NS; Pottinger, PS | 1 |
| Cha, YJ; Cho, H; Choi, JE; Heo, W; Kim, JO; Lee, H; Park, YJ; Yoo, IY | 1 |
| Aitta, AA; Causse, M; Diab, M; Egea, P; El-Defrawy, I; Elías, C; Fam, N; Fernández-Martínez, M; Gamal, D; Martínez-Martínez, L; Pérez-Nadales, E; Salem, D | 1 |
| Maquieira, Á; Morais, S; Peña-Mendizabal, E | 1 |
| Chen, C; Yang, K | 1 |
| Allison, N; Crisostomo, C; Lynch, B; Padilla, M; Quach-Cu, J; Reinke, RA | 1 |
| Chalam-Judge, N; Cooper, IR; Lee, S; Lee, VE; Newman, R; Ooi, N; Orr, D; Savage, VJ; Wilkinson, AJ | 1 |
| Aunins, TR; Chatterjee, A; Erickson, KE | 1 |
| Hirabayashi, A; Kajihara, T; Shibayama, K; Sugai, M; Yahara, K | 1 |
| Arthur, M; Braud, E; Edoo, Z; Etheve-Quelquejeu, M; Fonvielle, M; Iannazzo, L; Mayer, L; Saidjalolov, S | 1 |
| Castanheira, M; Johnson, JR; Johnston, BD; Porter, SB; Thuras, P | 1 |
| Dhandapani, S; Gunalan, A; Manoharan, M; Sastry, AS; Sistla, S; Sugumar, M | 1 |
| Dai, Y; Ma, H; Nangia, S; Ren, D; Vora, SR; Welsch, TA; Wu, M | 1 |
| Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N | 1 |
| Duan, R; Fan, Y; Huang, Z; Jing, H; Lv, D; Qin, S; Shi, X; Stirling, K; Wang, H; Wang, J; Wang, X; Zhang, L | 1 |
| Akella, J; Sanivarapu, R; Sharma, R | 1 |
| Dizaj, SM; Ghanbari, H; Memar, MY; Nabizadeh, E; Sharifi, S; Vahed, SZ; Yekani, M | 1 |
| Anugulruengkitt, S; Jantarabenjakul, W; Kawichai, S; Nakaranurack, C; Puthanakit, T; Rungsitsathian, K; Sakares, W; Usayaporn, S; Wacharachaisurapol, N | 1 |
| Adler, A; Andini, R; Antoniadou, A; Babich, T; Ben-Zvi, H; Benattar, YD; Bitterman, R; Carmeli, Y; Cavezza, G; Daikos, GL; Daitch, V; Dickstein, Y; Durante-Mangoni, E; Eliakim-Raz, N; Friberg, LE; Koppel, F; Leibovici, L; Levi, I; Mouton, JW; Nutman, A; Paul, M; Pavleas, I; Skiada, A; Theuretzbacher, U; Turjeman, A; Yahav, D; Zak-Doron, Y; Zampino, R; Zayyad, H; Zusman, O | 1 |
| Borghi, M; Devereux, M; Ferreira Ventura, R; FerreiraNunes, AP; McCann, M; Pinto Schuenck, R; Souza Dos Santos, AL; Vianez Peregrino, I | 1 |
| Cai, J; Cui, W; Huang, J; Qian, Z; Song, F; Zhang, G; Zhang, K; Zheng, C; Zhou, F; Zhou, H | 1 |
| Bonomo, RA; Le, C; Nishimura, B; Papp-Wallace, KM; Perez, F; Pimentel, C; Ramirez, MS; Subils, T; Tolmasky, ME; Traglia, GM; Tuttobene, MR | 1 |
| Carvalhaes, C; Castanheira, M; Deshpande, L; Shortridge, D | 1 |
| Chen, G; Feng, H; Fu, C; Guo, ZL; Ma, K; Wang, ZQ; Zhao, GY; Zhu, L | 1 |
| Castaño, GN; Lemos, E; Reyes, JM; Varón-Vega, FA | 1 |
| Bai, J; Ding, M; Li, Q; Liang, Q; Liang, S; Wang, G; Yan, X; Zhang, B; Zhang, F; Zhou, Y | 1 |
| Bonomo, RA; González, LJ; Maffía, PC; Martínez, MMB; Vila, AJ | 1 |
| Clark, K; Cunningham, D; Lord, K | 1 |
| Hinchliffe, P; Mulholland, AJ; Spencer, J; Twidale, RM | 1 |
| Al Sanabani, SS; Costa, SF; Guimarães, T; Leite, G; Levin, AS; Martins, RCR; Ramos, JF; Rizek, C; Rocha, V; Rossi, F | 1 |
| Köse, EO | 1 |
| Chitsombat, K; Chomnawang, MT; Kanathum, P; Khuntayaporn, P; Thirapanmethee, K | 1 |
| Cressman, L; Lautenbach, E; Zhang, HL | 1 |
| Armstrong, T; Fenn, SJ; Hardie, KR | 1 |
| He, Y; Li, Q; Sun, W; Wang, J; Zhang, J; Zhou, S | 1 |
| Gunawan, C; Hamidian, M; Harmer, CJ; Mann, R; Rafei, R | 1 |
| Tiwaskar, M; Vora, A | 1 |
| Altmann, D; Diercke, M; Eckmanns, T; Gatermann, SG; Pfennigwerth, N; Reichert, F; Reuss, A; Steffen, G; von Laer, A; Zacher, B | 1 |
| Albur, M; Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Liu, Q; Shi, S; Xu, M; Yao, Z; Ye, J; Zhang, X; Zhang, Y; Zhou, B; Zhou, C; Zhou, T | 1 |
| Devnath, K; Dubey, V; Gupta, VK; Kalyan, G; Kothari, A; Omar, BJ; Pathania, R; Singh, M | 1 |
| Bush, K; Carpenter, J; Chu, TY; Divoky, C; Lee-Hsiao, C; Neidig, N; Sultana, R; Threatt, H; Zhang, Q | 1 |
| Cremanns, M; Gatermann, SG; Lange, F; Pfennigwerth, N | 1 |
| Atsuda, K; Azuma, S; Hoshiyama, T; Inagaki, R; Komatsu, T; Mochida, S; Nihonyanagi, S; Sato, Y; Seto, Y; Takayama, Y; Wada, T | 1 |
| Huang, L; Yang, X; Zhang, R; Zhang, Y | 1 |
| Al-Shamiri, MM; Gao, Y; Han, L; Han, S; Li, P; Liu, Y; Mi, P; Ouyang, Z; Wang, J; Wen, Y; Yao, S; Zhang, J; Zhang, S; Zhong, S | 1 |
| Becerra-Aparicio, F; Fuchs, F; Higgins, PG; Seifert, H; Xanthopoulou, K | 1 |
| Hussein Al-Kakei, SN; Hussein, NH; Mohammed Kareem, S; Taha, BM | 1 |
| Albay, A; Aydoğan, CN; Bedir, O; Gümral, R; Hoşbul, T; Kaya, S | 1 |
| Cicioğlu Arıdoğan, B; Köle, M; Sesli Çetin, E; Şirin, MC | 1 |
| Ju, YG; Lee, HJ; Lee, MG; Sohn, JW; Yim, HS; Yoon, YK | 1 |
| Ahmed, F; Biboy, J; Boll, JM; Boutte, CC; Dörr, T; Gray, J; Islam, N; Kang, KN; Kazi, MI; Schargel, RD; Vollmer, W | 1 |
| Fujita, K; Sugiyama, H; Takashima, H; Takata, I; Yoshida, I | 1 |
| Bacci, C; Bisceglie, F; Giovanardi, D; Pelosi, G; Pinelli, S; Rega, M; Scaccaglia, M | 1 |
| Bauer, MJ; Flora, MS; Forde, BM; Habib, ZH; Harris, P; Islam, K; Roberts, JA; Shirin, T; Sime, FB; Wallis, SC | 1 |
| Birgy, A; Bonacorsi, S; Courroux, C; Danjean, M; Gits-Muselli, M; Hobson, CA; Monjault, A | 1 |
| Cohen, RD; Martin, GE; Sherer, EC; Wang, X | 1 |
| Chibabhai, V; Nana, T; Perovic, O | 1 |
| Bergman, Y; Cosgrove, SE; Jacobs, EB; Lee, JH; Lewis, S; Simner, PJ; Tamma, PD | 1 |
| Chang, H; Lee, CM; Lee, MC; Lu, CH; Sun, FJ; Wu, AY | 1 |
| Abe, R; Akeda, Y; Hamada, S; Iida, T | 1 |
| Arthur, M; Barnier, JP; Bouchet, F; Braud, E; Edoo, Z; Ethève-Quelquejeu, M; Iannazzo, L; Mainardi, JL; Mayer, L; Saidjalolov, S; Sayah, I | 1 |
| Bissell, A; Cleveland, KO; Hobbs, ALV; Johnson, AJ; Lukas, JG; Mason, D; Wells, DA | 1 |
| Cerboni, G; Corsica, G; De Luca, F; Docquier, JD; Galleni, M; Gavara, L; Hadjadj, M; Hernandez, JF; Legru, A; Licznar-Fajardo, P; Nauton, L; Sandra Mercuri, P; Sannio, F; Sevaille, L; Verdirosa, F; Vo Hoang, Y | 1 |
| Findlay, J; Nordmann, P; Poirel, L; Rens, C | 1 |
| Abdel-Halim, MS; Askoura, M; El-Ganiny, AM; Mansour, B; Yahya, G | 1 |
| Hayashi, C; Kai, D; Kamoshida, G; Kanda, N; Kaya, Y; Morimoto, H; Nakamura, T; Okada, T; Sakaguchi, M; Sawada, T; Takemoto, N; Yahiro, K; Yamada, N; Yamaguchi, D; Yamashita, M | 1 |
| Kurisu, G; Nakano, R; Sakai, H; Tanaka, H; Yamamoto, K; Yano, H | 1 |
| Ahmed, SS; Ajami, NJ; Alousi, AM; Brown, AN; Champlin, RE; Chang, CC; Chapa, VA; Chemaly, RF; Davey, L; El-Himri, RK; Flores, II; Frenk, AC; Galloway-Peña, J; Glowacki, RWP; Halsey, T; Hayase, E; Hayase, T; Heckel, BE; Jamal, MA; Jenq, RR; Jin, Y; Karmouch, JL; Liu, C; Lorenzi, PL; Martens, EC; McDaniel, LK; Miyama, T; Molldrem, JJ; Ortega, MR; Pham, D; Prasad, R; Rondon, G; Sanchez, CA; Shelburne, S; Shpall, EJ; Tan, L; Tsai, WB; Valdivia, RH; Veillon, L; Wargo, JA | 1 |
| Gao, Z; Guan, J; He, Y; Li, Y; Ma, X; Ni, W; Wang, Y; Zhao, J | 1 |
| Luo, Q; Shen, P; Xiao, Y; Xiong, L; Yu, W | 1 |
| Bai, Y; Fan, X; Fu, L; Tian, C; Wang, S; Xing, M; Zhao, Y | 1 |
| Martinez, AI; Santos, CAQ; Trick, WE; Tseng, M; Varughese, CA; Won, SY; Zhang, H | 1 |
| Maseda, E; Suárez de la Rica, A | 1 |
| Jarjees, KK; Jarjees, RK; Qader, GM | 1 |
| Ishaq, M; Zahra, N; Zeshan, B | 1 |
| Bajinath, S; Govender, T; Kruger, HG; Mdanda, S; Naicker, T; Ntshangase, S; Omolabi, KF; Reddy, N; Singh, SD | 1 |
| A Katouah, H; Acker, M; Al Hadi, R; Ali, M; Alserihi, R; Alyami, J; Alzahrani, E; Amirazodi, M; Amrillah, T; Andreassen, OA; Ardiccioni, C; Ask, H; Atzori, C; Ayorech, Z; Azambuja, JH; Azmi, R; Badem, S; Balci, AB; Bali, H; Baranova, NS; Barantsevich, ER; Barocci, S; Bauer, RJ; Bauermeister, JA; Bazhenova, TA; Biagetti, G; Bigdeli, F; Bonar, EE; Bouloumis, T; Bu, Y; Cai, Z; Cakiroglu, B; Canetto, SS; Cao, J; Caucci, S; Cerbo, I; Chen, C; Chen, J; Chen, Q; Chen, Y; Cheng, B; Cheng, X; Chinappi, M; Choya, A; Cicconardi, F; Cipolletta, S; Colasurdo, G; Costabile, BK; Coughlin, LN; Crippa, P; D'Agostino, M; D'Annessa, I; Daryanoosh, F; Das, R; Davey Smith, G; Davidson, BR; Davies, NM; Davis, TME; Davis, WA; de Rivas, B; Demir, D; Deng, Z; Dhanya, TM; Di Marino, D; Divya, KM; Dong, N; Drinkwater, JJ; Ekholuenetale, M; El-Bindary, AA; El-Bindary, MA; El-Desouky, MG; Elsayed, H; Ema, K; Endraswari, PD; Entilli, L; Ettl, T; Eyado, A; Fan, X; Fang, W; Farina, M; Florimbio, AR; Fowobaje, KR; Gaeini, A; Gao, XM; Gao, Y; Ghaemi, R; Ghelardi, E; Gilmutdinov, IF; Gochicoa-Rangel, L; Goncu, MT; Gözüküçük, R; Grammatikopoulos, P; Gu, Y; Guan, ZJ; Gucu, A; Guldberg, R; Gungor, O; Guo, W; Gutiérrez-Ortiz, JI; Guzmán-Boulloud, N; Guzmán-Valderrábano, C; Głuszko, A; Hama, A; Hamada, M; Han, J; Hashimoto, T; Havdahl, A; Hayashita, T; He, X; Helgeland, Ø; Hinck, AP; Hinck, CS; Holtzapple, M; Hou, Y; Howe, LD; Hu, B; Hu, H; Huang, L; Huang, Z; Hughes, AM; Hussain, G; Ibidoja, OJ; Ichikawa, D; Imber, C; Islam, MR; Iype, S; Jaber, J; Jacobs, R; Jafry, AT; Ji, L; Ji, X; Jiang, L; Jiang, Y; Jie, HFM; Jie, HM; Johansen, MP; Johansson, S; Juan, LX; Juan, W; Kahraman, N; Kallinger, I; Kang, H; Karakulova, YV; Kärmer, T; Kataoka, S; Kato, K; Kawashima, N; Kazim, AH; Khalil, MR; Kitazawa, H; Klimesova, YM; Kojima, S; Kose, M; Kostakis, ID; Koushkie Jahromi, M; Krishna, GA; Krizova, D; La Teana, A; Lan, K; Li, J; Li, JZ; Li, M; Li, R; Li, S; Li, Y; Li, Z; Liu, H; Liu, J; Liu, KG; Liu, L; Liu, Q; Liu, T; Liu, X; Lomachenko, KA; López-Fonseca, R; Ludwig, N; Luo, A; Luo, L; Luo, Y; Lupetti, A; M El-Metwaly, N; Ma, K; Maemura, R; Magnus, P; Manakin, YV; Mancia, F; Mashood, LO; Matsumoto, K; Mehrabi, A; Meier, JK; Mekonnen, Y; Mencarelli, D; Menzo, S; Mikagi, A; Mironov, VS; Misawa-Suzuki, T; Miwata, S; Mizuta, Y; Mohanan, PV; Mondal, J; Morici, P; Morita, K; Morozzo Della Rocca, B; Morris, T; Morsali, A; Morzhukhina, MV; Motta, S; Muramatsu, H; Naidu, R; Narita, A; Narita, K; Nasralla, D; Nemcokova, M; Netukova, M; Nishikawa, E; Nishio, N; Niu, X; Niu, Y; Njølstad, P; Notarstefano, V; Nugroho, MA; Nørgård, BM; Okuno, Y; Olokede, O; Ong, SP; Osailan, A; Ouyang, Z; Ozyazicioglu, AF; Pan, F; Parui, A; Paul, R; Pavoni, E; Payne, TE; Peng, X; Pérez-Padilla, R; Perta, N; Peter, SC; Pierantoni, L; Pietrowska, M; Pissanou, T; Pollok, JM; Prasetio, A; Putra, FS; Qiang, C; Qiao, L; Qutob, HMH; Raptis, DA; Razzo, BM; Reichborn-Kjennerud, T; Reichert, TE; Remigio-Luna, A; Rexha, J; Rivani, E; Rizzato, C; Romagnoli, A; Rossolini, GM; Sa, LY; Saad, RA; Sakaguchi, H; Salesi, M; Salsabilla, Z; Sanderson, E; Sanderson, P; Savitha, DP; Schulz, D; Seker, IB; Selvaganapathy, PR; Sha, D; Shah, SF; Shaikhomar, OA; Sharma, D; Shi, C; Shi, P; Shrotri, A; Sidiq, DH; Simonov, SV; Singh, AK; Song, C; Song, T; Spanier, G; Spoerl, S; Staropoli, A; Statsenko, ME; Steinhauer, S; Stosic, A; Studeny, P; Sugaya, T; Sun, S; Sun, X; Sunbul, SA; Supandi, AR; Suzuki, K; Suzuki, Y; Szczepański, MJ; Takahashi, Y; Taniguchi, R; Tao, Y; Tesli, M; Thirión-Romero, I; Tong, D; Trucchi, E; Tsuchido, Y; Turchetti, C; Turkina, SV; Turner, AW; Uldbjerg, N; Vinale, F; Wakamatsu, M; Walton, MA; Wang, C; Wang, Q; Wang, W; Wang, Y; Wang, Z; Wehberg, S; Wei, ZL; Wen, B; Whiteside, TL; Whittingham, MS; Widodo, ADW; Widłak, P; Wright, AI; Wu, H; Wu, Y; Wu, YL; Xiang, LG; Xiao, G; Xie, B; Xie, L; Xin, H; Xiong, J; Xiong, X; Xu, C; Xu, S; Yagubskii, EB; Yakushev, IA; Yang, H; Yang, J; Yao, J; Yao, ZX; Ye, J; Yerneni, SS; Yirgu, A; Yoshida, N; Yoshida, T; Young, SD; Yu, DN; Yuksel, A; Zac, J; Zac, S; Zarifkar, AH; Zhai, Y; Zhang, F; Zhang, H; Zhang, JW; Zhang, L; Zhang, Q; Zhang, X; Zhang, Y; Zhao, D; Zhao, J; Zhao, M; Zheng, D; Zheng, J; Zhou, G; Zhou, H; Zhu, P; Zhu, T; Zhu, Y; Zimmerman, MA; Zou, X | 1 |
| Hu, L; Hu, P; Weng, Y | 1 |
| Bitar, I; Hrabak, J; Moravec, J; Novak, P; Paskova, V; Pompach, P; Studentova, V; Sudova, V; Volny, M | 1 |
| Dargahi, Z; Etemad, A; Ghasemian, E; Hashemian, M; Kaviar, VH; Lohrasbi, A; Saadh, MJ | 1 |
| Alzahrani, FM; Alzahrani, KJ; Amoa-Owusu, F; Bannah, V; Dayie, NTKD; Donkor, ES; Dwomoh, FP; Egyir, B; Halawani, IF; Kotey, FCN; Osei, MM | 1 |
| Chen, CH; Ho, MW; Hsueh, PR; Lu, MC; Wu, PH | 1 |
| Arora, V; Jindal, A; Maiwall, R; Prakash, V; Sarin, SK | 1 |
| George Priya Doss, C; Gopikrishnan, M | 1 |
| Asai, Y; Ooi, H; Sato, Y | 1 |
| Chen, F; Gong, X; He, X; Liu, X; Wang, L | 1 |
| Abdurahim, SA; Alameen, AA; Aloufi, AS; Elsayim, R; Eltayb, WA; Modafer, Y | 1 |
| Feng, Y; Li, GB; Wang, S; Wang, X; Wu, S; Yang, Y; Zhu, K; Zong, Z | 1 |
| Chen, X; Jian, Z; Liang, X; Liu, P; Liu, W; Tang, B; Wang, Z; Yan, Q; Yang, A | 1 |
| Carvalhaes, CG; Castanheira, M; Duncan, L; Kimbrough, JH; Mendes, RE; Sader, HS | 1 |
| Chan, EWC; Chen, D; Chen, E; Chen, K; Chen, S; Chen, W; Guo, J; Jelsbak, L; Wang, J; Xie, L; Xie, M; Zhao, Y | 1 |
| Chau, RWY; Chen, WT; DeRyke, CA; Ip, M; Karlowsky, JA; Khan, TK; Leung, SWM; Lob, SH; Motyl, MR; Sahm, DF; Seto, WH; Wong, QW; Woo, PCY; Young, K | 1 |
| Ding, L; Guo, Y; Han, R; Hu, F; Jiang, B; Shen, S; Wang, C; Wu, S; Yin, D; Zhang, H | 1 |
| Çakıral, K; Güran, M; Kandemir, T; Köksal, F; Nagiyev, T; Öcal, MM; Şanlıtürk, G; Teralı, K | 1 |
| Ahmed Al-Bayati, M; Kareem Musafer, H; Nabeeh Jaafar, F | 1 |
| Buynak, JD; Quan, P; Smith, CA; Stewart, NK; Toth, M; Vakulenko, SB | 1 |
| Adaleti, R; Aksaray, S; Arıcı, N; Çalık, Ş; Kansak, N; Nakipoğlu, Y; Şenbayrak, S | 1 |
| Karłowicz, K; Kierzkowska, M; Majewska, A; Pituch, H | 1 |
| Cao, SS; Cui, B; Cui, F; Cui, J; Fan, BY; Fan, TT; Guan, Y; Ji, B; Li, MY; Li, SR; Wang, JW; Wang, L; Yan, CY; Zhang, W | 1 |
| Gu, Y; Hu, D; Hu, M; Liang, R; Wang, D; Wang, M; Zhu, M | 1 |
| Hsueh, PR; Ko, WC; Lee, YL | 1 |
| Abe, R; Akeda, Y; Hamada, S; Iida, T; Matsumoto, Y; Motooka, D; Sugawara, Y | 1 |
| Maraolo, AE; Ong, DSY | 1 |
| Arslanyürekli, U; Deveci, İ; Karsligil, T; Koçer, İ; Sağlam, M; Şahin, E | 1 |
| Arcari, G; Bruno, F; Capitani, V; Carattoli, A; Garcia-Fernandez, A; Gentile, G; Polani, R; Raponi, G; Sacco, F; Santilli, S; Villa, L | 1 |
| Abdellatif, GR; Aboshanab, KM; Mabrouk, SS; Zaid, ASA | 1 |
| Neupane, L; Pokhrel, A; Rayamajhee, B; Sah, AK; Singh, A | 1 |
| Cai, J; Chen, C; Liu, Y; Shi, J; Wang, Z | 1 |
| Deng, X; Ding, R; Feng, H; Gao, Y; Guo, Y; Liu, H; Niu, X; Qiu, J; Wang, J; Yang, M | 1 |
| Ageevets, VA; Alieva, KN; Avdeeva, AA; Dovzhenko, SA; Golikova, MV; Kobrin, MB; Sidorenko, SV; Strukova, EN; Sulian, OS; Zinner, SH | 1 |
| Bouvier, M; Kerbol, A; Nordmann, P; Poirel, L; Raro, OHF; Sadek, M | 1 |
| Bouvier, M; Le Terrier, C; Nordmann, P; Poirel, L | 1 |
| Barretti, P; Camargo, CH; Campos, KR; Cunha, MPV; de Souza, AR; Dos Santos, MB; Ferraro, PSP; Freire, MP; Sacchi, CT; Tiba-Casas, MR; Yamada, AY | 1 |
| Li, GB; Li, R; Li, SR; Liang, GQ; Qin, S; Wang, SY; Wang, XY; Wei, LL; Yan, YH; Yang, LL; Yang, ZB; Zhang, TT; Zhu, KR | 1 |
| Aydemir, Ö; Ayhancı, T; Köroğlu, M; Ormanoğlu, G; Zengin, M | 1 |
| Gill, CM; Lee, SY; Nicolau, DP | 1 |
| El Chaar, M; Jisr, T; Moussa, J; Nassour, E; Tahan, E; Tokajian, S | 1 |
| Chen, F; Chen, X; Wang, Y; Wei, B; Xu, B; Yang, M; Yao, L | 1 |
| Akrami, S; Al-Dahmoshi, HOM; Al-Khafaji, NSK; Bannazadeh Baghi, H; Jafari-Sales, A; Judi, HK; Nasiri, R; Sadeghi Deylamdeh, Z; Saki, M; Shariat, A | 1 |
40 review(s) available for carbapenems and meropenem
| Article | Year |
|---|---|
The carbapenems: new broad spectrum beta-lactam antibiotics.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Chemical Phenomena; Chemistry, Physical; Humans; Meropenem; Thienamycins | 1989 |
Meropenem: a microbiological overview.
Topics: Animals; Bacterial Infections; Carbapenems; Humans; Meropenem; Thienamycins | 1995 |
Extended-spectrum plasmid-mediated beta-lactamases.
Topics: beta-Lactamases; Carbapenems; Humans; Meropenem; Plasmids; Thienamycins | 1995 |
Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.
Topics: Bacterial Infections; Carbapenems; Child; Clinical Trials, Phase III as Topic; Humans; Meropenem; Prospective Studies; Randomized Controlled Trials as Topic; Thienamycins; Treatment Outcome | 1995 |
[Carbapenems in pediatrics].
Topics: Carbapenems; Child; Child, Preschool; Humans; Imipenem; Infant; Infant, Newborn; Meningitis, Bacterial; Meropenem; Thienamycins | 1996 |
[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract].
Topics: Adult; Aged; Carbapenems; Chi-Square Distribution; Cilastatin; Cross Infection; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Protease Inhibitors; Thienamycins; Urinary Tract Infections | 1995 |
Pharmacokinetic determinants of carbapenem therapy in neonates and children.
Topics: Area Under Curve; Carbapenems; Child; Child, Preschool; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Infant; Infant, Newborn; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1996 |
Neurotoxicity of carbapenem antibacterials.
Topics: Animals; Carbapenems; Child; Cilastatin; Humans; Imipenem; Meropenem; Receptors, GABA; Seizures; Thienamycins | 1996 |
Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Therapy, Combination; Fever; Hematologic Neoplasms; Humans; Meropenem; Neutropenia; Randomized Controlled Trials as Topic; Thienamycins | 1996 |
[Meropenem].
Topics: Carbapenems; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Molecular Structure; Thienamycins; Treatment Outcome | 1996 |
Acquired carbapenemases.
Topics: Acinetobacter; Bacillus cereus; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cell Cycle Proteins; Endopeptidases; Enterobacter cloacae; Fungal Proteins; Imipenem; Intracellular Signaling Peptides and Proteins; Meropenem; Protein Kinases; Protein Serine-Threonine Kinases; Pseudomonas aeruginosa; Saccharomyces cerevisiae Proteins; Serratia marcescens; Thienamycins | 1997 |
Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections.
Topics: Abdomen; Bacterial Infections; Carbapenems; Drug Therapy, Combination; Humans; Imipenem; Meropenem; Randomized Controlled Trials as Topic; Thienamycins | 1997 |
[The role of carbapenems in the treatment of nosocomial infection].
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cross Infection; Drug Therapy, Combination; Humans; Imipenem; Meningitis, Bacterial; Meropenem; Pneumonia, Bacterial; Skin Diseases, Infectious; Thienamycins | 1997 |
[Carbapenems in pediatric practice].
Topics: Adolescent; Bacterial Infections; Carbapenems; Child; Child, Preschool; Clinical Trials as Topic; Humans; Imipenem; Infant; Infant, Newborn; Meropenem; Postoperative Complications; Thienamycins | 2001 |
Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
Topics: Anti-Bacterial Agents; Carbapenems; Humans; Meropenem; Thienamycins | 2004 |
Appropriate use of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Cilastatin; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Ertapenem; Humans; Imipenem; Lactams; Meropenem; Patient Selection; Pneumonia, Bacterial; Practice Patterns, Physicians'; Protease Inhibitors; South Africa; Surgical Wound Infection; Thienamycins; Urinary Tract Infections | 2004 |
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aminoglycosides; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Multiple; Drug Therapy, Combination; Fluoroquinolones; Humans; Immunocompetence; Intensive Care Units; Meropenem; Pneumonia, Bacterial; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiration, Artificial; Survival Rate; Thienamycins; Treatment Outcome | 2007 |
Comparative review of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Thienamycins | 2007 |
Carbapenems in the USA: focus on doripenem.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Structure-Activity Relationship; Thienamycins; United States | 2007 |
Carbapenems: a potent class of antibiotics.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Molecular Structure; Structure-Activity Relationship; Thienamycins | 2008 |
Parenteral carbapenems.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Humans; Imipenem; Infusions, Parenteral; Meropenem; Thienamycins | 2008 |
The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Doripenem; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Patient Selection; Pneumonia, Bacterial; Respiratory Tract Infections; Severity of Illness Index; Thienamycins; Treatment Outcome | 2008 |
[Pediatric use of carbapenems].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Child; Drug Tolerance; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Thienamycins | 2010 |
The risk of seizures among the carbapenems: a meta-analysis.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Meropenem; Risk; Seizures; Thienamycins | 2014 |
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Clinical Studies as Topic; Ertapenem; Extensively Drug-Resistant Tuberculosis; Humans; Imipenem; Meropenem; Thienamycins; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Reducing the impact of carbapenem-resistant Enterobacteriaceae on vulnerable patient groups: what can be done?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Ceftazidime; Colistin; Critical Illness; Drug Combinations; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Retrospective Studies; Thienamycins | 2016 |
Systematic Review of Antimicrobial Resistance of Clinical Acinetobacter baumannii Isolates in Iran: An Update.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Iran; Meropenem; Microbial Sensitivity Tests; Minocycline; Polymyxin B; Rifampin; Thienamycins; Tigecycline | 2017 |
Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Greece; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Epidemiology; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2018 |
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Molecular Structure; Randomized Controlled Trials as Topic; Siderophores | 2019 |
Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Clinical Trials as Topic; Colistin; Dose-Response Relationship, Drug; Drug Approval; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Randomized Controlled Trials as Topic; Sisomicin; United States; United States Food and Drug Administration; Urinary Tract Infections | 2019 |
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
Treatment of valproic acid overdose with meropenem in an epileptic patient.
Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Carbapenems; Drug Overdose; Epilepsy; Female; Humans; Meropenem; Valproic Acid | 2022 |
JMM Profile: Carbapenems: a broad-spectrum antibiotic.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Meropenem | 2021 |
Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: Results from phase II and III trials.
Topics: beta-Lactamase Inhibitors; Carbapenems; Cilastatin, Imipenem Drug Combination; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Controversies in the management of ESBL-producing Enterabacterales. Clinical Implications.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2022 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
Meropenem for the Pharmacological Treatment of Severe Infections in Critically Ill Pediatric Patients: Breakthrough Standard Treatment Strategies Based on PK/PD.
Topics: Anti-Bacterial Agents; Carbapenems; Child; Critical Illness; Humans; Meropenem | 2023 |
Phenotypic and genotypic identification of carbapenem resistance in Bacteroides fragilis clinical strains.
Topics: Anti-Bacterial Agents; Bacterial Infections; Bacterial Proteins; Bacteroides fragilis; Carbapenems; Humans; Meropenem; Microbial Sensitivity Tests | 2023 |
Colistin plus meropenem versus colistin alone for invasive infections caused by carbapenem-resistant Acinetobacter baumannii: a rapid systematic review of randomized controlled trials using Bayesian meta-analysis.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bayes Theorem; Carbapenems; Colistin; Humans; Meropenem; Microbial Sensitivity Tests; Randomized Controlled Trials as Topic | 2023 |
33 trial(s) available for carbapenems and meropenem
| Article | Year |
|---|---|
Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems.
Topics: Adult; Aged; Bacterial Infections; Carbapenems; Cefmetazole; Cefoperazone; Cefotetan; Cefoxitin; Cephalosporins; Drug Combinations; Drug Resistance, Microbial; Escherichia coli Infections; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Prospective Studies; Remission Induction; Skin Diseases, Infectious; Staphylococcal Infections; Streptococcal Infections; Thienamycins | 1991 |
In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Ciprofloxacin; Gram-Negative Aerobic Bacteria; Gram-Negative Anaerobic Bacteria; Humans; Italy; Meropenem; Microbial Sensitivity Tests; Multicenter Studies as Topic; Thienamycins | 1989 |
The pharmacokinetics of meropenem in volunteers.
Topics: Adult; Carbapenems; Chromatography, High Pressure Liquid; Drug Interactions; Half-Life; Humans; Male; Meropenem; Probenecid; Reference Values; Thienamycins | 1989 |
Immune response in patients with intra-abdominal infections treated with carbapenems.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Antibodies, Bacterial; Bacteria, Aerobic; Bacteria, Anaerobic; Carbapenems; Cilastatin; Fluorescent Antibody Technique; Humans; Imipenem; Injections, Intravenous; Meropenem; Middle Aged; Thienamycins | 1994 |
Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.
Topics: Bacterial Infections; Carbapenems; Ceftazidime; Cilastatin; Humans; Imipenem; Injections, Intramuscular; Meropenem; Respiratory Tract Infections; Thienamycins; Treatment Outcome; Urinary Tract Infections | 1995 |
Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
Topics: Bacterial Infections; Bronchitis; Carbapenems; Cilastatin; Drug Therapy, Combination; Drug Tolerance; Hospitalization; Humans; Imipenem; Lung Diseases, Obstructive; Meropenem; Prospective Studies; Thienamycins; Treatment Outcome | 1995 |
Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.
Topics: Adolescent; Adult; Carbapenems; Ceftazidime; Cephalosporins; Child, Preschool; Cystic Fibrosis; Drug Tolerance; Humans; Liver; Meropenem; Microbial Sensitivity Tests; Nausea; Pseudomonas Infections; Spirometry; Sputum; Thienamycins; Transaminases; Treatment Outcome; Vomiting | 1995 |
Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.
Topics: Adolescent; Adult; Aged; Amikacin; Bacterial Infections; Carbapenems; Ceftazidime; Community-Acquired Infections; Cross Infection; Drug Therapy, Combination; Drug Tolerance; Hospitalization; Humans; Meropenem; Middle Aged; Respiratory Tract Infections; Sepsis; Thienamycins; Time Factors; Treatment Outcome; Urinary Tract Infections | 1995 |
Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin.
Topics: Adult; Aged; Amikacin; Carbapenems; Ceftazidime; Drug Therapy, Combination; Drug Tolerance; Hospitalization; Humans; Meropenem; Middle Aged; Sepsis; Thienamycins; Treatment Outcome | 1995 |
Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections.
Topics: Abdomen; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Carbapenems; Cefotaxime; Drug Therapy, Combination; Drug Tolerance; Humans; Meropenem; Metronidazole; Middle Aged; Thienamycins; Treatment Outcome | 1995 |
Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Topics: Abdomen; Adolescent; Adult; Aged; Bacterial Infections; Carbapenems; Cilastatin; Drug Therapy, Combination; Humans; Imipenem; Injections, Intravenous; Meropenem; Middle Aged; Thienamycins; Treatment Outcome | 1995 |
Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.
Topics: Bacterial Infections; Carbapenems; Child; Clinical Trials, Phase III as Topic; Humans; Meropenem; Prospective Studies; Randomized Controlled Trials as Topic; Thienamycins; Treatment Outcome | 1995 |
A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group.
Topics: Adult; Carbapenems; Cefotaxime; Ceftriaxone; Humans; Meningitis, Bacterial; Meropenem; Thienamycins; Treatment Outcome | 1995 |
Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cefotaxime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Drug Tolerance; Humans; Infant; Meropenem; Metronidazole; Thienamycins | 1995 |
[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract].
Topics: Adult; Aged; Carbapenems; Chi-Square Distribution; Cilastatin; Cross Infection; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Protease Inhibitors; Thienamycins; Urinary Tract Infections | 1995 |
Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Prospective Studies; Thienamycins | 1997 |
Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients.
Topics: Adolescent; Bacterial Infections; Bone Marrow Transplantation; Carbapenems; Child; Child, Preschool; Cilastatin; Drug Costs; Female; Humans; Imipenem; Male; Meropenem; Postoperative Complications; Prospective Studies; Protease Inhibitors; Thienamycins; Vomiting | 2002 |
Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Clarithromycin; Community-Acquired Infections; Costs and Cost Analysis; Drug Combinations; Drug Costs; Drug Therapy, Combination; Female; Hospitalization; Humans; Imipenem; Male; Meropenem; Pneumonia, Bacterial; Prospective Studies; Thienamycins; Treatment Outcome | 2002 |
[Investigation on administration method of carbapenems].
Topics: Adult; Aged; beta-Alanine; Body Temperature; C-Reactive Protein; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Administration Schedule; Drug Combinations; Female; Humans; Imipenem; Leukocyte Count; Meropenem; Middle Aged; Parametritis; Thienamycins | 2002 |
[A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time].
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Bacteremia; Carbapenems; Drug Administration Schedule; Female; Humans; Male; Meropenem; Middle Aged; Thienamycins | 2005 |
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Double-Blind Method; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Injections, Intravenous; Male; Meropenem; Middle Aged; Prospective Studies; Thienamycins | 2008 |
A comparative analysis of meropenem and doripenem in febrile patients with hematologic malignancies: a single-center retrospective study.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Female; Fever; Hematologic Neoplasms; Humans; Male; Meropenem; Middle Aged; Retrospective Studies; Risk Factors; Thienamycins; Treatment Outcome | 2012 |
Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Female; Fever; Hematologic Diseases; Humans; Male; Meropenem; Neutropenia; Prospective Studies; Thienamycins; Treatment Outcome; Young Adult | 2013 |
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Female; Humans; Imipenem; Intraabdominal Infections; Male; Meropenem; Ofloxacin; Pneumonia; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Doripenem; Female; Gram-Negative Bacteria; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Obesity; Thienamycins | 2014 |
Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas Infections; Thienamycins | 2014 |
Successful management of an outbreak due to carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Colistin; Disease Outbreaks; Feces; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Meropenem; Prospective Studies; Thienamycins | 2015 |
Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Ampicillin; Anti-Bacterial Agents; Carbapenems; Colistin; Drug Combinations; Drug Resistance, Bacterial; Female; Humans; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sulbactam | 2018 |
Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Data Interpretation, Statistical; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Ertapenem; Female; Humans; Intraabdominal Infections; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Tetracyclines; Young Adult | 2019 |
Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests | 2020 |
Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
Topics: Aged; Aged, 80 and over; Carbapenems; Colistin; Cross Infection; Drug Resistance, Bacterial; Drug Synergism; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2020 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
Combination of GM CSF and carbapenem is superior to carbapenem monotherapy in difficult-to-treat spontaneous bacterial peritonitis: A randomized controlled trial.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Liver Cirrhosis; Meropenem; Peritonitis | 2023 |
517 other study(ies) available for carbapenems and meropenem
| Article | Year |
|---|---|
In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp.
Topics: Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Nocardia; Thienamycins | 1992 |
Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group.
Topics: Bacteroides fragilis; Carbapenems; Drug Evaluation, Preclinical; Imipenem; Kinetics; Meropenem; Microbial Sensitivity Tests; Thienamycins; Time Factors | 1991 |
Heterogeneity of beta-lactamase production in Pseudomonas maltophilia, a nosocomial pathogen.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Microbial; Enzyme Induction; Imipenem; Kinetics; Meropenem; Pseudomonas; Thienamycins | 1990 |
A novel carbapenem antibiotic, SM-7338 structure-activity relationships.
Topics: Bacteria; Carbapenems; Chemical Phenomena; Chemistry; Meropenem; Microbial Sensitivity Tests; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Thienamycins | 1990 |
In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Microbial; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1989 |
Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa.
Topics: Bacterial Outer Membrane Proteins; Carbapenems; Drug Resistance, Microbial; Electrophoresis, Polyacrylamide Gel; Humans; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1989 |
Bactericidal activity of meropenem against Pseudomonas aeruginosa.
Topics: Carbapenems; Culture Media; Densitometry; Kinetics; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1989 |
In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya.
Topics: Anti-Bacterial Agents; Canada; Carbapenems; Gonorrhea; Haemophilus ducreyi; Haemophilus Infections; Haemophilus influenzae; Humans; Kenya; Meropenem; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Thienamycins | 1989 |
The postantibiotic effect of meropenem and imipenem on selected bacteria.
Topics: Bacteria; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Providencia; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Thienamycins | 1989 |
The antibacterial activity of meropenem in combination with gentamicin or vancomycin.
Topics: Carbapenems; Colony Count, Microbial; Culture Media; Drug Therapy, Combination; Gentamicins; Kinetics; Meropenem; Methicillin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Thienamycins; Vancomycin | 1989 |
Susceptibility of anaerobic bacteria to meropenem.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Carbapenems; Clostridium; Clostridium perfringens; Fusobacterium; Humans; Meropenem; Microbial Sensitivity Tests; Propionibacterium acnes; Thienamycins | 1989 |
Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
Topics: Bacterial Outer Membrane Proteins; beta-Lactamases; Carbapenems; Carbenicillin; Cell Membrane Permeability; DNA Transposable Elements; Drug Resistance, Microbial; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Genes, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1989 |
Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
Topics: Bacteria; beta-Lactamases; Carbapenems; Ceftazidime; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Plasmids; Thienamycins | 1989 |
Interaction of meropenem with humoral and phagocytic defences.
Topics: Antibody Formation; Carbapenems; Escherichia coli; Imipenem; Macrophages; Meropenem; Microbial Sensitivity Tests; Neutrophils; Opsonin Proteins; Phagocytosis; Staphylococcus aureus; Thienamycins | 1989 |
Therapeutic activity of meropenem in experimental infections.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Escherichia coli Infections; Guinea Pigs; Immunosuppression Therapy; Lung Diseases; Male; Meropenem; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Pseudomonas Infections; Respiratory Tract Infections; Thienamycins; Urinary Tract Infections | 1989 |
Safety evaluation of meropenem in animals: studies on the kidney.
Topics: Animals; Anti-Bacterial Agents; Blood Chemical Analysis; Carbapenems; Cefotaxime; Ceftazidime; Cephaloridine; Female; Kidney Diseases; Macaca fascicularis; Male; Meropenem; Rabbits; Rats; Rats, Inbred Strains; Species Specificity; Thienamycins | 1989 |
Meropenem (SM7338)--a new carbapenem. Twenty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, California, 1988. Fourth European Congress of Clinical Microbiology. Nice, France, 1989. Selected papers.
Topics: Animals; Bacteria; Carbapenems; Humans; Meropenem; Thienamycins | 1989 |
Activity of meropenem, against gram-positive bacteria.
Topics: Bacterial Proteins; Carbapenems; Carrier Proteins; Gram-Positive Bacteria; Hexosyltransferases; Meropenem; Methicillin; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillin Resistance; Penicillin-Binding Proteins; Penicillinase; Peptidyl Transferases; Staphylococcus aureus; Thienamycins | 1989 |
The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Clindamycin; Gram-Negative Anaerobic Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Metronidazole; Microbial Sensitivity Tests; Thienamycins | 1989 |
Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.
Topics: Bacterial Proteins; Carbapenems; Carrier Proteins; Cell Membrane Permeability; Culture Media; Drug Resistance, Microbial; Enterobacteriaceae; Gram-Negative Bacteria; Hexosyltransferases; Imipenem; Meropenem; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidyl Transferases; Staphylococcus; Thienamycins | 1989 |
Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
Topics: Bacteria; Bacteria, Anaerobic; Bacterial Infections; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Gram-Positive Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1989 |
In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin.
Topics: Ampicillin; Anti-Bacterial Agents; Carbapenems; Chloramphenicol; Ciprofloxacin; Culture Media; Haemophilus influenzae; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillin Resistance; Thienamycins | 1989 |
Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Drug Resistance, Microbial; Enterobacteriaceae; Enzyme Induction; Gram-Negative Bacteria; Meropenem; Microbial Sensitivity Tests; Spectrophotometry, Ultraviolet; Thienamycins | 1989 |
Interactions of meropenem with class I chromosomal beta-lactamases.
Topics: Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Chromosomes, Bacterial; Enzyme Induction; Kinetics; Meropenem; Microbial Sensitivity Tests; Mutation; Thienamycins | 1989 |
Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins.
Topics: Acylation; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Kinetics; Meropenem; Thienamycins | 1989 |
Bactericidal activity of meropenem and interactions with other antibiotics.
Topics: Anti-Bacterial Agents; Bacteria; Bacteria, Anaerobic; Carbapenems; Drug Interactions; Drug Therapy, Combination; Enterobacteriaceae; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1989 |
Development of a meropenem susceptibility disc: drug content, preliminary interpretive and quality control criteria and potency bioassay.
Topics: Bacteria; Carbapenems; Culture Media; Meropenem; Microbial Sensitivity Tests; Quality Control; Thienamycins | 1989 |
The disposition and metabolism of meropenem in laboratory animals and man.
Topics: Animals; Autoradiography; Carbapenems; Chromatography, High Pressure Liquid; Dogs; Feces; Female; Half-Life; Humans; Macaca fascicularis; Meropenem; Pregnancy; Rats; Rats, Inbred Strains; Species Specificity; Thienamycins; Tissue Distribution | 1989 |
Meropenem: evidence of lack of proconvulsive tendency in mice.
Topics: Animals; Carbapenems; Cilastatin; Imipenem; Male; Meropenem; Mice; Seizures; Thienamycins | 1989 |
Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom.
Topics: Bacteria; Bacterial Infections; Carbapenems; Culture Media; Enterobacteriaceae; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Thienamycins; United Kingdom | 1989 |
In-vitro activity of meropenem against clinical isolates obtained in Canada.
Topics: Bacteria; Bacterial Infections; Canada; Carbapenems; Drug Resistance, Microbial; Humans; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1989 |
Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex.
Topics: Amikacin; Bacteria; Bacterial Infections; Carbapenems; Drug Synergism; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Mycobacterium avium Complex; Thienamycins | 1989 |
Potential factors influencing carbapenem activity against Bacteroides fragilis group isolates.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacteroides fragilis; beta-Lactamases; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1995 |
Studies on the synthesis and antibacterial activity of new carbamoylpyrrolidinylthiocarbapenems.
Topics: Anti-Infective Agents; Carbapenems; Meropenem; Microbial Sensitivity Tests; Structure-Activity Relationship; Thienamycins | 1995 |
Are all carbapenems created equal?
Topics: beta-Lactam Resistance; Burkholderia cepacia; Carbapenems; Imipenem; Meropenem; Thienamycins | 1995 |
In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity.
Topics: Carbapenems; Guanidines; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas; Thienamycins | 1995 |
Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa.
Topics: Bacterial Proteins; Carbapenems; Carrier Proteins; Hexosyltransferases; Lysine; Meropenem; Muramoylpentapeptide Carboxypeptidase; Mutation; Penicillin-Binding Proteins; Peptidyl Transferases; Porins; Pseudomonas aeruginosa; Structure-Activity Relationship; Thienamycins | 1995 |
Postantibiotic effects of three carbapenems on Pseudomonas aeruginosa in the presence of lysine.
Topics: Carbapenems; Imipenem; Lysine; Meropenem; Pseudomonas aeruginosa; Thienamycins | 1995 |
In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple; Imipenem; Meropenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Thienamycins | 1995 |
[In vitro activity of meropenem and seven other beta-lactam antibiotics against K.pneumoniae and enterobacteriaceae producing beta-lactamases with extended spectrum].
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Dose-Response Relationship, Drug; Enterobacteriaceae; Escherichia coli; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Thienamycins | 1994 |
On the reactions of the carbapenem, meropenem, in the soluble fraction of rat kidney.
Topics: Animals; Carbapenems; Cysteine; Cytosol; Dithiothreitol; Endopeptidases; Hydrogen-Ion Concentration; Hydrolysis; Kidney; Kinetics; Magnetic Resonance Spectroscopy; Meropenem; Rats; Sulfhydryl Compounds; Thienamycins | 1994 |
In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftazidime; Dipeptidases; Drug Stability; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydrolysis; Imipenem; Kidney; Meropenem; Microbial Sensitivity Tests; Pseudomonas; Thienamycins | 1993 |
Studies on the synthesis and antibacterial activity of new zwitterionic carbapenems.
Topics: Carbapenems; Meropenem; Microbial Sensitivity Tests; Structure-Activity Relationship; Thienamycins | 1994 |
Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cephalosporinase; Drug Resistance, Microbial; Humans; Hydrolysis; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1993 |
BO-2727, meropenem and imipenem disc diffusion susceptibility testing criteria.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Diffusion; Imipenem; Meropenem; Microbial Sensitivity Tests; Predictive Value of Tests; Thienamycins | 1995 |
Outer membrane alterations in Pseudomonas aeruginosa after five-day exposure to quinolones and carbapenems.
Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; Carbapenems; Cell Membrane; Ciprofloxacin; Fluoroquinolones; Imipenem; Lipopolysaccharides; Meropenem; Microbial Sensitivity Tests; Naphthyridines; Pseudomonas aeruginosa; Thienamycins; Time Factors | 1995 |
A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.
Topics: Adolescent; Adult; Blood Pressure; Carbapenems; Dose-Response Relationship, Drug; Drug Tolerance; Heart Rate; Humans; Infusions, Intravenous; Injections, Intravenous; Meropenem; Thienamycins | 1995 |
A compilation of meropenem tissue distribution data.
Topics: Carbapenems; Drug Evaluation; Humans; Meropenem; Microbial Sensitivity Tests; Thienamycins; Tissue Distribution | 1995 |
Penetration of meropenem into heart valve tissue.
Topics: Aortic Valve; Carbapenems; Female; Heart Valves; Humans; Injections, Intravenous; Male; Meropenem; Mitral Valve; Myocardium; Thienamycins; Time Factors | 1995 |
The pharmacokinetics of meropenem in infants and children: a population analysis.
Topics: Age Factors; Analysis of Variance; Bacterial Infections; Body Weight; Carbapenems; Child; Child, Preschool; Creatinine; Humans; Infant; Meropenem; Models, Biological; Thienamycins | 1995 |
Efficacy of meropenem in experimental meningitis.
Topics: Ampicillin; Animals; Carbapenems; Ceftazidime; Ceftriaxone; Cephalosporins; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Drug Evaluation; Drug Resistance, Microbial; Escherichia coli Infections; Gentamicins; Guinea Pigs; Haemophilus Infections; Haemophilus influenzae; Listeriosis; Meningitis, Bacterial; Meropenem; Neisseria meningitidis; Penicillin G; Pneumococcal Infections; Thienamycins | 1995 |
[Significant role of carbapenem antibiotics: focused on meropenem (discussion)].
Topics: Bacteria; Bacterial Infections; Carbapenems; Clinical Trials as Topic; Drug Resistance, Microbial; Humans; Meropenem; Thienamycins | 1995 |
Effects of a beta-lactamase inhibitor, sulbactam, on the activity of carbapenems against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Drug Synergism; Enzyme Inhibitors; Imipenem; Meropenem; Pseudomonas aeruginosa; Sulbactam; Thienamycins | 1995 |
[Antimicrobial activities of meropenem against clinically isolated strains].
Topics: Bacteria; Bacterial Infections; Carbapenems; Drug Resistance, Microbial; Humans; Meropenem; Thienamycins | 1996 |
Pneumococcal susceptibility to meropenem.
Topics: beta-Lactam Resistance; Carbapenems; Drug Resistance, Microbial; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillin Resistance; Streptococcus pneumoniae; Thienamycins | 1996 |
In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Drug Interactions; Drug Resistance, Multiple; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1996 |
Sensitivities to four carbapenems of bacteria isolated from patients with refractory complicated urinary tract infections and the detection of carbapenemase-producing Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins; Urinary Tract Infections | 1996 |
Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide.
Topics: Carbapenems; Ceftazidime; Cephalosporins; Endotoxins; Imipenem; Lipopolysaccharides; Lymphotoxin-alpha; Meropenem; Nitric Oxide; Pseudomonas aeruginosa; Thienamycins; Tumor Necrosis Factor-alpha | 1996 |
High-performance liquid chromatographic assay for meropenem in serum.
Topics: Animals; Carbapenems; Chromatography, High Pressure Liquid; Drug Stability; Humans; Injections, Intravenous; Meropenem; Osmolar Concentration; Reproducibility of Results; Spectrophotometry, Ultraviolet; Swine; Swine, Miniature; Temperature; Thienamycins; Time Factors | 1996 |
In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
Topics: Animals; Carbapenems; Ceftazidime; Cephalosporins; Culture Media; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Imipenem; In Vitro Techniques; Male; Meropenem; Mice; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1997 |
Structure-activity relationships of carbapenem compounds to anti-Haemophilus influenzae activity and affinity for penicillin-binding proteins. Effect of 1 beta-methyl group and C-2 side chain.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Carrier Proteins; Haemophilus influenzae; Hexosyltransferases; Imipenem; Meropenem; Methylation; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Penicillins; Peptidyl Transferases; Protein Binding; Structure-Activity Relationship; Thienamycins | 1997 |
Diffusion of carbapenems through the outer membrane of enterobacteriaceae and correlation of their activities with their periplasmic concentrations.
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carbapenems; Cell Membrane Permeability; Diffusion; Enterobacter cloacae; Enterobacteriaceae; Escherichia coli; Genes, Bacterial; Imipenem; Meropenem; Thienamycins | 1996 |
Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.
Topics: Bacteremia; Carbapenems; Drug Administration Schedule; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1997 |
Susceptibility testing of Stenotrophomonas maltophilia to carbapenems.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Pseudomonadaceae; Thienamycins | 1997 |
[Survey of sensitivities of clinical isolates to antibacterial agents (annual report)].
Topics: 4-Quinolones; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Carbapenems; Cephalosporins; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Cocci; Haemophilus influenzae; Humans; Imipenem; Meropenem; Monobactams; Penicillins; Pseudomonas aeruginosa; Serratia marcescens; Thienamycins | 1997 |
[In vitro combination effect of vancomycin and carbapenems against carbapenem-resistant MRSA].
Topics: Anti-Bacterial Agents; Carbapenems; Imipenem; Meropenem; Methicillin Resistance; Staphylococcus aureus; Thienamycins; Vancomycin | 1997 |
[Anti-anaerobic activity of carbapenems].
Topics: Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Cross Infection; Drug Resistance, Microbial; Humans; Hydrogen-Ion Concentration; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1997 |
Synthesis and antibacterial activity of novel 4-pyrrolidinylthio carbapenems--I. 2-Alkoxymethyl derivatives.
Topics: Animals; Carbapenems; Dipeptidases; Drug Stability; Male; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pseudomonas Infections; Rats; Staphylococcal Infections; Thienamycins; Urine | 1997 |
Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group.
Topics: Adult; Aged; Aged, 80 and over; Carbapenems; Drug Administration Schedule; Female; Humans; Male; Meropenem; Middle Aged; Neutropenia; Thienamycins | 1997 |
[The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum].
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Monobactams; Penicillins; Piperacillin; Pseudomonas aeruginosa; Serotyping; Sputum; Thienamycins | 1998 |
Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meni
Topics: Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Cephalosporins; Child; Drug Therapy, Combination; Humans; Imipenem; Meningitis, Pneumococcal; Meropenem; Microbial Sensitivity Tests; Penicillin Resistance; Streptococcus pneumoniae; Thienamycins; Vancomycin | 1998 |
Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
Topics: Carbapenems; Cilastatin; Drug Combinations; Drug Costs; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Protease Inhibitors; Thienamycins | 1998 |
Structural comparison of 1 beta-methylcarbapenem, carbapenem and penem: NMR studies and theoretical calculations.
Topics: Anti-Bacterial Agents; Carbapenems; Crystallography, X-Ray; Magnetic Resonance Spectroscopy; Meropenem; Models, Molecular; Molecular Conformation; Molecular Structure; Thienamycins | 1998 |
Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain.
Topics: Acinetobacter; Acinetobacter Infections; Aged; Aged, 80 and over; beta-Lactam Resistance; Carbapenems; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1998 |
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom | 1998 |
[Antimicrobial activity of carbapenem antibiotics against gram-negative bacilli].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Imipenem; Meropenem; Monobactams; Norfloxacin; Tetracycline; Thienamycins | 1998 |
Meropenem pharmacokinetics in a patient with multiorgan failure from Meningococcemia undergoing continuous venovenous hemodiafiltration.
Topics: Adult; Bacteremia; Carbapenems; Chromatography, High Pressure Liquid; Hemodiafiltration; Humans; Male; Meningococcal Infections; Meropenem; Multiple Organ Failure; Thienamycins | 1999 |
Relationship between morphological changes and endotoxin release induced by carbapenems in Pseudomonas aeruginosa.
Topics: Carbapenems; Endotoxins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1999 |
Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina.
Topics: Acinetobacter; Argentina; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Imipenem; Isoelectric Focusing; Meropenem; Microbial Sensitivity Tests; Molecular Weight; Species Specificity; Sputum; Thienamycins; Urine | 1999 |
[Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)].
Topics: Carbapenems; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins; Time Factors | 1999 |
In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Topics: Acinetobacter; Anti-Bacterial Agents; Austria; beta-Lactam Resistance; Carbapenems; Cephalosporins; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonadaceae; Tazobactam; Thienamycins | 1999 |
[Study on antibiotics susceptibility and mechanism of carbapenem-resistance in clinical isolates of Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; beta-Lactam Resistance; Carbapenems; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Ofloxacin; Pseudomonas aeruginosa; Thienamycins | 1999 |
Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners.
Topics: Animals; Carbapenems; Cefazolin; Cephalosporins; GABA Agonists; Imipenem; Injections, Intraventricular; Male; Meropenem; Mice; Mice, Inbred ICR; Muscimol; Pentylenetetrazole; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Seizures; Synaptic Membranes; Thienamycins | 1999 |
Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis.
Topics: Animals; Carbapenems; Central Nervous System; Haemophilus influenzae; Humans; Meningitis, Bacterial; Meropenem; Neurotoxicity Syndromes; Randomized Controlled Trials as Topic; Seizures; Thienamycins | 2000 |
[In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998].
Topics: Bacteria; Carbapenems; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Penicillins; Piperacillin; Respiratory Tract Infections; Thienamycins; Time Factors | 1999 |
[Antimicrobial activities of meropenem against clinically isolated strains in 1997].
Topics: Bacteria; Carbapenems; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Thienamycins; Time Factors | 1999 |
Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Creatinine; Drug Resistance, Microbial; Enterobacter cloacae; Enterobacteriaceae Infections; Half-Life; Imipenem; Kidney Diseases; Male; Meropenem; Penicillinase; Pneumonia, Bacterial; Protein Binding; Rats; Rats, Wistar; Thienamycins; Uranyl Nitrate | 2000 |
[Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents].
Topics: Bacteria; Carbapenems; Drug Resistance, Microbial; Humans; Imipenem; Japan; Meropenem; Multicenter Studies as Topic; Thienamycins; Time Factors | 2000 |
In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Cystic Fibrosis; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 2000 |
Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactamases; Carbapenems; Child; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Drug Resistance, Multiple; Electrophoresis, Gel, Pulsed-Field; Humans; Hydrolysis; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Thienamycins | 2000 |
Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains.
Topics: Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Leukocytes; Meropenem; Neutrophils; Phagocytosis; Thienamycins | 2000 |
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Dipeptidases; Drug Stability; Gram-Negative Bacteria; Gram-Positive Bacteria; Isoxazoles; Meropenem; Microbial Sensitivity Tests; Models, Molecular; Structure-Activity Relationship; Swine; Thienamycins | 2000 |
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.
Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cloning, Molecular; Escherichia coli; Imipenem; Kinetics; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Sequence Homology, Amino Acid; Substrate Specificity; Thienamycins; Transformation, Bacterial | 2001 |
Discordant carbapenem susceptibility in Methylobacterium species and its application as a method for phenotypic identification.
Topics: Carbapenems; Drug Resistance, Microbial; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Methylobacterium; Microbial Sensitivity Tests; Phenotype; Thienamycins | 2001 |
Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria.
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Diffusion; Enterobacteriaceae; Imipenem; Meropenem; Microbial Sensitivity Tests; Pyrrolidines; Thienamycins | 2001 |
[Antimicrobial activities of meropenem against clinically isolated strains in 1999].
Topics: Bacteria, Anaerobic; Carbapenems; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Bacteria; Meropenem; Thienamycins | 2001 |
A rapid, sensitive high performance liquid chromatographic method for the determination of meropenem in pharmaceutical dosage form, human serum and urine.
Topics: Carbapenems; Chromatography, High Pressure Liquid; Humans; Meropenem; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Thienamycins | 2001 |
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Carbapenems; Drug Design; Drug Evaluation, Preclinical; Meropenem; Microbial Sensitivity Tests; Rats; Thienamycins | 2001 |
[Antimicrobial activities of carbapenems and fourth generation cephems against clinically isolated strains].
Topics: Bacteria; Carbapenems; Cefepime; Cefozopran; Cephalosporins; Imipenem; Meropenem; Thienamycins | 2001 |
In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.
Topics: Bacteria, Anaerobic; Carbapenems; Ceftriaxone; Cephalosporins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2002 |
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) conference. Hamburg, Germany, 10 May 2001.
Topics: beta-Lactam Resistance; Carbapenems; Communicable Disease Control; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Meropenem; Thienamycins | 2001 |
Stability of new carbapenem DA-1131 to renal dipeptidase (dehydropeptidase I).
Topics: Animals; Carbapenems; Dipeptidases; Enzyme Stability; Imipenem; Meropenem; Substrate Specificity; Thienamycins | 2002 |
[Comparative antibacterial activity of carbapenems against P. aeruginosa (1)].
Topics: beta-Lactamases; Carbapenems; Drug Resistance, Microbial; Imipenem; Meropenem; Pseudomonas aeruginosa; Thienamycins | 2001 |
Influence on Enterobacter cloacae metabolism, cell-surface hydrophobicity and motility of suprainhibitory concentrations of carbapenems.
Topics: Carbapenems; Enterobacter cloacae; Humans; Hydrophobic and Hydrophilic Interactions; Imipenem; Meropenem; Movement; Thienamycins; Time Factors | 2001 |
[Experience of application of meronem in the treatment of severe purulent sepsis in children].
Topics: Adolescent; Carbapenems; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Meropenem; Severity of Illness Index; Systemic Inflammatory Response Syndrome; Thienamycins | 2002 |
In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Ceftazidime; Doripenem; Humans; Imipenem; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Thienamycins; Urinary Tract Infections | 2002 |
[Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Drug Synergism; Drug Therapy, Combination; Imipenem; Meropenem; Pseudomonas aeruginosa; Thienamycins | 2002 |
[Rapid bactericidal activities of carbapenems against Pseudomonas aeruginosa in simulating human plasma concentrations].
Topics: Carbapenems; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microscopy, Electron, Scanning; Models, Biological; Pseudomonas aeruginosa; Thienamycins | 2002 |
Determination and pharmacokinetic study of meropenem in rat bile using on-line microdialysis and liquid chromatography.
Topics: Animals; Bile; Carbapenems; Chromatography, Liquid; Male; Meropenem; Microdialysis; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Thienamycins | 2002 |
Carbapenem-resistant Pseudomonas aeruginosa in malaysia producing IMP-7 beta-lactamase.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Child; Humans; Imipenem; Malaysia; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 2002 |
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Carbapenems; Half-Life; Indicators and Reagents; Meropenem; Mice; Microbial Sensitivity Tests; Oxidation-Reduction; Rats; Structure-Activity Relationship; Thienamycins | 2003 |
[Antibacterial activity of biapenem against recent clinical isolates].
Topics: Bacteria; Bacterial Infections; beta-Alanine; Carbapenems; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Thienamycins | 2003 |
The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000.
Topics: Acinetobacter; Acinetobacter baumannii; Acinetobacter calcoaceticus; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Europe; Humans; Meropenem; Thienamycins | 2003 |
Effect of basic amino acids on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates.
Topics: Amino Acids, Basic; Anti-Bacterial Agents; Aztreonam; Carbapenems; Ceftazidime; Culture Media; Humans; Hydrogen-Ion Concentration; Imipenem; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Thienamycins | 2003 |
Resistance emergence among P. aenrginosa in a rat thigh-abscess model. Comparison of imipenem and meropenem treatment.
Topics: Abscess; Animals; Carbapenems; Drug Resistance, Bacterial; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Selection, Genetic; Thienamycins | 2003 |
[Activity of cephems and carbapenems against clinically isolated Mycobacterium abscessus].
Topics: Carbapenems; Cefoxitin; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Thienamycins; Tuberculosis, Pulmonary | 2003 |
Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2.
Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; Blotting, Western; Carbapenems; Cloning, Molecular; Drug Resistance, Bacterial; Escherichia coli; Gene Dosage; Hydrolysis; Imipenem; Isoelectric Focusing; Kinetics; Klebsiella oxytoca; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Phenotype; Plasmids; Porins; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins; Transformation, Bacterial | 2003 |
[Clinical efficacy of carbapenems in the treatment of destructive pneumonia and chronic purulent bronchitis].
Topics: Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; Carbapenems; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Imipenem; Injections, Intramuscular; Injections, Intravenous; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Thienamycins | 2003 |
[Proper use of carbapenem antibiotics based on the feature in the treatment of infectious diseases (discussion)]].
Topics: Bacteria; Bacterial Infections; beta-Alanine; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Administration Schedule; Drug Combinations; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Thienamycins; Treatment Failure | 2004 |
[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002].
Topics: Bacteria; Bacterial Infections; Carbapenems; Drug Resistance, Bacterial; Humans; Japan; Meropenem; Product Surveillance, Postmarketing; Thienamycins; Time Factors | 2004 |
[Carbapenemase detection in Acinetobacter baumannii clones resistant to imipenem].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Multicenter Studies as Topic; Spain; Thienamycins | 2004 |
Morphological changes induced by imipenem and meropenem at sub-inhibitory concentrations in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Carbapenems; Cross Infection; Histocytochemistry; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pneumonia; Thienamycins | 2004 |
Is it safe to use carbapenems in patients with a history of allergy to penicillin?
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Reactions; Drug Combinations; Drug Hypersensitivity; Female; Humans; Imipenem; Incidence; Male; Meropenem; Middle Aged; Penicillins; Retrospective Studies; Thienamycins | 2004 |
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Klebsiella pneumoniae; Lactams; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Ofloxacin; Thienamycins | 2004 |
Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Colony Count, Microbial; Guinea Pigs; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Porins; Thienamycins; Treatment Outcome | 2005 |
Structure-activity relationships of different beta-lactam antibiotics against a soluble form of Enterococcus faecium PBP5, a type II bacterial transpeptidase.
Topics: Acylation; Algorithms; Anti-Bacterial Agents; Azlocillin; Binding Sites; Carbapenems; Drug Resistance, Bacterial; Enterococcus faecium; Kinetics; Meropenem; Models, Molecular; Penicillin G; Penicillin-Binding Proteins; Peptidyl Transferases; Plasmids; Structure-Activity Relationship; Thienamycins | 2005 |
Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; Carbapenems; Humans; Imipenem; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thienamycins; Transcription, Genetic | 2005 |
Prevalence of decreased susceptibility to carbapenems among Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii and investigation of carbapenemases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Citrobacter freundii; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Prevalence; Serratia marcescens; Thienamycins | 2005 |
In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Thienamycins | 2005 |
[Evaluation of disk diffusion test for carbapenem sensitivity in Acinetobacter baumannii and Pseudomonas aeruginosa strains].
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Quality Control; Reproducibility of Results; Thienamycins | 2005 |
[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004].
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Carbapenems; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Injections, Intravenous; Meropenem; Thienamycins | 2005 |
Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.
Topics: Alanine; Animals; Anti-Bacterial Agents; Anticonvulsants; Carbapenems; Convulsants; Dogs; Doripenem; Drug Interactions; Electroencephalography; Injections, Intravenous; Injections, Intraventricular; Male; Meropenem; Mice; Mice, Inbred ICR; Pentylenetetrazole; Rats; Rats, Wistar; Seizures; Thienamycins; Valproic Acid | 2006 |
Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Intensive Care Units; Linear Models; Longitudinal Studies; Meropenem; Microbial Sensitivity Tests; Population Surveillance; Thienamycins | 2006 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
Topics: Amikacin; Anti-Infective Agents; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Meropenem; Oxazines; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Urine | 2006 |
Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Colony Count, Microbial; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Polyacrylamide Gel; Gene Expression; Imipenem; Meropenem; Molecular Weight; Mutation; Pseudomonas aeruginosa; Thienamycins | 2006 |
Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing.
Topics: Anti-Bacterial Agents; Automation; Carbapenems; Drug Resistance, Bacterial; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Reference Standards; Thienamycins | 2006 |
Carriage of OXA-58 but not of OXA-51 beta-lactamase gene correlates with carbapenem resistance in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2006 |
Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Spain; Thienamycins | 2006 |
In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Enterobacteriaceae; Ertapenem; Gram-Negative Bacterial Infections; Humans; Imipenem; Klebsiella; Meropenem; Microbial Sensitivity Tests; Proteus; Sweden; Thienamycins | 2006 |
Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteroides fragilis; Bacteroides Infections; Base Sequence; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Population Surveillance; Thienamycins | 2006 |
Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Carbapenems; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meningitis, Bacterial; Meropenem; Microbial Sensitivity Tests; Middle Aged; Neurosurgical Procedures; Postoperative Complications; Thienamycins; Turkey | 2007 |
Renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in rabbits in comparison with meropenem.
Topics: Animals; Carbapenems; In Vitro Techniques; Kidney; Kidney Cortex; Kidney Tubules; Male; Meropenem; Metabolic Clearance Rate; Microsomes; Models, Animal; Rabbits; Thienamycins | 2006 |
Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems.
Topics: Anti-Bacterial Agents; Carbapenems; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Genetic Heterogeneity; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Time Factors | 2007 |
[Relationship between protein binding and antimicrobial activities of antibiotics against Streptococcus pneumoniae and Haemophilus influenzae].
Topics: Administration, Oral; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Child; Haemophilus influenzae; Humans; Injections, Intravenous; Meropenem; Microbial Sensitivity Tests; Protein Binding; Streptococcus pneumoniae; Thienamycins | 2006 |
CW-270033, a novel pyrrolidinyl-thio carbapenem, has potent antimicrobial activity in vitro and in vivo.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Cilastatin; Dose-Response Relationship, Drug; Enterococcus faecalis; Escherichia coli; Injections, Intravenous; Meropenem; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Molecular Structure; Protease Inhibitors; Pseudomonas aeruginosa; Pyrrolidines; Staphylococcus aureus; Thienamycins; Vancomycin Resistance | 2007 |
Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters.
Topics: Algorithms; Anti-Bacterial Agents; Biological Transport, Active; Carbapenems; Carrier Proteins; Cationic Amino Acid Transporter 2; Cell Line; Humans; Kidney; Kinetics; Meropenem; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Organic Cation Transporter 1; Thienamycins | 2007 |
Mechanisms of resistance to carbapenems in meropenem- resistant Acinetobacter isolates from clinical samples.
Topics: Acinetobacter; Acinetobacter Infections; Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamases; Biological Transport, Active; Carbapenems; Child; Drug Resistance, Bacterial; Female; Humans; Infant; Infant, Newborn; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Thienamycins | 2007 |
A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
Topics: Anti-Bacterial Agents; Carbapenems; DNA Transposable Elements; DNA, Bacterial; Drug Resistance, Bacterial; Gene Dosage; Humans; Imipenem; Meropenem; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2007 |
Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Carbapenems; Cilastatin; Disease Models, Animal; Doripenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Models, Biological; Thienamycins | 2008 |
Carbapenem resistance in clinical isolates of Pseudomonas aeruginosa.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Carbapenems; Codon, Terminator; Drug Resistance, Bacterial; Glutamine; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Porins; Pseudomonas aeruginosa; Repressor Proteins; Sequence Analysis, DNA; Thienamycins | 2007 |
Preferential selection of IMP and VIM metallo-beta-lactamases by imipenem in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Binding, Competitive; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2007 |
[Seven cases of decreased serum valproic acid concentration during concomitant use of carbapenem antibiotics].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anticonvulsants; Carbapenems; Drug Interactions; Drug Therapy, Combination; Epilepsy; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Thienamycins; Valproic Acid | 2007 |
Characterization of genetic diversity of carbapenem-resistant Acinetobacter baumannii clinical strains collected from 2004 to 2007.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genetic Variation; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2008 |
Simple and rapid determination of serum carbapenem concentrations by high-performance liquid chromatography.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Chromatography, High Pressure Liquid; Imipenem; Male; Meropenem; Mice; Thienamycins | 2008 |
[Antibiotic susceptibility and molecular mechanisms of cephalosporins resistance in Klebsiella isolates from patients with hospital-acquired infections].
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporin Resistance; Cross Infection; Humans; Imipenem; Klebsiella; Klebsiella Infections; Meropenem; Thienamycins | 2006 |
[Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Administration Schedule; Drug Resistance, Bacterial; Humans; Infusions, Intravenous; Meropenem; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2007 |
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Carbapenems; Imipenem; Meropenem; Methicillin Resistance; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Thienamycins | 2008 |
Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefepime; Cefuroxime; Cell Line; Cells, Cultured; Cephalosporins; Cloxacillin; Humans; Hydrogen-Ion Concentration; Imipenem; Meropenem; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Oxacillin; Phagocytosis; Staphylococcus aureus; Thienamycins | 2008 |
In vivo development of carbapenem resistance in clinical isolates of Enterobacter aerogenes producing multiple beta-lactamases.
Topics: Adult; Amino Acid Sequence; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacter aerogenes; Enterobacteriaceae Infections; Fatal Outcome; Humans; Imipenem; Liver Transplantation; Male; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA; Thienamycins | 2008 |
[Clinical investigation on target value of T>MIC in carbapenems].
Topics: Adult; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Drug Administration Schedule; Drug Resistance, Microbial; Escherichia coli; Female; Humans; Meropenem; Middle Aged; Pelvic Inflammatory Disease; Staphylococcus aureus; Thienamycins | 2008 |
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
Topics: Base Sequence; beta-Lactam Resistance; Carbapenems; DNA Primers; DNA, Bacterial; Doripenem; Fluoroquinolones; Genes, Bacterial; Humans; In Vitro Techniques; Meropenem; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2008 |
In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Colony Count, Microbial; Humans; Lung; Male; Meropenem; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Serum; Thienamycins | 2008 |
Simultaneous determination of three carbapenem antibiotics in plasma by HPLC with ultraviolet detection.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftazidime; Chromatography, High Pressure Liquid; Drug Stability; Ertapenem; Humans; Imipenem; Meropenem; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Thienamycins | 2008 |
Carbapenems and SHV-1 beta-lactamase form different acyl-enzyme populations in crystals and solution.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Crystallography, X-Ray; Ertapenem; Imipenem; Meropenem; Molecular Structure; Solutions; Spectrum Analysis, Raman; Thienamycins | 2008 |
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Carbapenems; Doripenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2009 |
In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2009 |
Lucasti et al in the May 2008 issue of Clinical Therapeutics.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Thienamycins | 2008 |
Comparison of in vivo nephrotoxicity in the rabbit by a pyrrolidinyl-thio Carbapenem CW-270031.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Cilastatin; Imipenem; Kidney; Kidney Diseases; Male; Meropenem; Pyrrolidines; Rabbits; Thienamycins | 2008 |
[Comparison of 3 methods for determining sensitivity to imipenem and meropenem in Acinetobacter baumannii with a carbapenem-heteroresistant phenotype].
Topics: Acinetobacter baumannii; Carbapenems; Drug Resistance, Multiple, Bacterial; Indicator Dilution Techniques; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2008 |
A role for carbapenem in the treatment of melioidosis in developing countries?
Topics: Anti-Bacterial Agents; Bacteremia; Burkholderia pseudomallei; Carbapenems; Debridement; Developing Countries; Humans; Leg; Male; Melioidosis; Meropenem; Middle Aged; Thailand; Thienamycins; Treatment Outcome | 2009 |
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in-vitro biological activity - part II.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Evaluation, Preclinical; Imipenem; Meropenem; Microbial Viability; Molecular Structure; Structure-Activity Relationship; Sulfonamides; Thienamycins | 2009 |
In vitro activity of doripenem.
Topics: Anti-Bacterial Agents; Carbapenems; Culture Media; Doripenem; Drug Therapy, Combination; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2009 |
Prolonged bacteraemia caused by VIM-1 metallo-beta-lactamase-producing Proteus mirabilis: first report from Italy.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Chromosomes, Bacterial; DNA, Bacterial; Humans; Integrons; Italy; Male; Meropenem; Plasmids; Proteus Infections; Proteus mirabilis; Surgical Wound Infection; Thienamycins; Treatment Failure; Treatment Outcome | 2010 |
Disruption of adeB gene has a greater effect on resistance to meropenems than adeA gene in Acinetobacter spp. isolated from University Malaya Medical Centre.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Drug Resistance, Multiple, Bacterial; Humans; Malaysia; Membrane Transport Proteins; Meropenem; Models, Genetic; Mutation; Plasmids; Polymerase Chain Reaction; Sequence Analysis, DNA; Thienamycins | 2009 |
Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Doripenem; Drug Utilization; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Statistics as Topic; Thienamycins | 2009 |
OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Escherichia coli; Imipenem; Meropenem; Molecular Sequence Data; Oxacillin; Penicillins; Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Thienamycins | 2009 |
Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study.
Topics: Anticonvulsants; Carbapenems; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Meropenem; Middle Aged; Retrospective Studies; Thienamycins; Time Factors; Valproic Acid | 2009 |
Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Greece; Humans; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Thienamycins | 2009 |
Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran hospitals.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefotaxime; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Hospitals; Humans; Imipenem; Iran; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2009 |
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; Carbapenems; Doripenem; Enzyme Inhibitors; Hydrolysis; Imipenem; Kinetics; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2010 |
Stability of meropenem and doripenem solutions for administration by continuous infusion.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Stability; Humans; Infusions, Intravenous; Meropenem; Solutions; Thienamycins | 2010 |
Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Analysis of Variance; Anti-Bacterial Agents; Area Under Curve; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Imipenem; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Sulbactam; Thienamycins | 2010 |
Mutant prevention concentrations of four carbapenems against gram-negative rods.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Mutation; Phenotype; Pseudomonas aeruginosa; Thienamycins | 2010 |
Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.
Topics: Acinetobacter baumannii; beta-Lactamases; Carbapenems; Doripenem; Genotype; Hospitals; Humans; Imipenem; Meropenem; Oxytocin; Polymerase Chain Reaction; Thienamycins | 2010 |
In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Colistin; Cross Infection; Drug Resistance, Bacterial; Drug Synergism; Humans; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Minocycline; Sulbactam; Thienamycins; Tigecycline | 2010 |
Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates.
Topics: Antibodies, Bacterial; Carbapenems; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Thienamycins | 2010 |
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
Topics: Bacterial Proteins; beta-Lactamases; Blotting, Western; Carbapenems; Imipenem; Klebsiella pneumoniae; Meropenem; Phylogeny; Porins; Thienamycins | 2010 |
Stability of doripenem, imipenem and meropenem at elevated room temperatures.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Stability; Drug Storage; Imipenem; Meropenem; Temperature; Thienamycins; Time Factors | 2011 |
[Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Enterobacteriaceae Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas Infections; Spain; Thienamycins | 2010 |
Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Blood; Carbapenems; Disease Models, Animal; Doripenem; Female; Imipenem; Infusions, Intravenous; Lung; Meropenem; Plasma; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Spleen; Thienamycins; Treatment Outcome | 2010 |
In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study.
Topics: Anti-Bacterial Agents; Asia; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pacific Islands; Thienamycins | 2010 |
Emergence of carbapenem resistance due to porin loss in an extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain during meropenem therapy.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Electrophoresis, Polyacrylamide Gel; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Porins; Thienamycins | 2010 |
Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Korea; Meropenem; Microbial Sensitivity Tests; Republic of Korea; Thienamycins; Urinary Tract Infections | 2011 |
In vivo efficacy of doripenem (DRPM) against Pseudomonas aeruginosa in murine chronic respiratory tract infection model.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Male; Meropenem; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Specific Pathogen-Free Organisms; Thienamycins | 2011 |
Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; Carbapenems; Cytokines; Disease Models, Animal; Doripenem; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Meropenem; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Pneumonia, Bacterial; Thienamycins; Treatment Outcome | 2011 |
Novel genetic environment of the plasmid-mediated KPC-3 gene detected in Escherichia coli and Citrobacter freundii isolates from China.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; China; Citrobacter freundii; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Isoelectric Focusing; Meropenem; Microbial Sensitivity Tests; Middle Aged; Plasmids; Polymerase Chain Reaction; Sequence Analysis, DNA; Thienamycins | 2011 |
Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Topics: Anti-Bacterial Agents; Asia; Australia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Injections, Intravenous; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Thienamycins | 2011 |
Novel prodrugs of meropenem with two lipophilic promoieties: synthesis and pharmacokinetics.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Carbapenems; Male; Meropenem; Prodrugs; Pyrrolidines; Rats; Thienamycins | 2011 |
Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae.
Topics: Age Factors; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Case-Control Studies; Chi-Square Distribution; Confidence Intervals; Cross Infection; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Logistic Models; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Odds Ratio; Risk Factors; Thienamycins | 2011 |
High prevalence of metallo-beta-lactamase-producing acinetobacter baumannii in a teaching hospital in Tabriz, Iran.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Female; Hospitals, Teaching; Humans; Imipenem; Iran; Male; Meropenem; Middle Aged; Polymerase Chain Reaction; Prevalence; Thienamycins; Young Adult | 2011 |
Role of Klebsiella pneumoniae LamB Porin in antimicrobial resistance.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Cefoxitin; Electrophoresis, Polyacrylamide Gel; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Mutation; Porins; Thienamycins | 2011 |
Phenotypic and genotypic screening and clonal analysis of carbapenem-resistant Klebsiella pneumoniae at a single hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Doripenem; Electrophoresis, Gel, Pulsed-Field; Ertapenem; Genotype; Hospitals, Urban; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phylogeny; Polymerase Chain Reaction; Sensitivity and Specificity; Thienamycins; United States | 2011 |
[Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Klebsiella Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2011 |
Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Imipenem; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2011 |
Comparative activity of carbapenem testing: the COMPACT study.
Topics: Africa; Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle East; Thienamycins | 2011 |
Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome | 2011 |
Gastrointestinal selective capacity of doripenem, meropenem, and imipenem for carbapenem-resistant gram-negative bacilli in treated patients with pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Rectum; Stenotrophomonas maltophilia; Thienamycins | 2011 |
The laboratory diagnosis of Pseudomonas aeruginosa that produce metallo-β-lactamases in a Dutch tertiary care centre.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Edetic Acid; Humans; Imipenem; Laboratories; Meropenem; Microbial Sensitivity Tests; Netherlands; Pseudomonas aeruginosa; Pseudomonas Infections; Reproducibility of Results; Thienamycins | 2011 |
Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae.
Topics: Academic Medical Centers; Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Case-Control Studies; Drug Utilization; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Male; Meropenem; Middle Aged; Risk Factors; Thienamycins | 2011 |
Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Chi-Square Distribution; Cluster Analysis; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Molecular Epidemiology; Republic of Korea; Risk Factors; Statistics, Nonparametric; Thienamycins | 2012 |
Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Clavulanic Acid; Enzyme Inhibitors; Escherichia coli Proteins; Kinetics; Meropenem; Molecular Dynamics Simulation; Molecular Structure; Penicillanic Acid; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sulbactam; Tazobactam; Thienamycins | 2011 |
[Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Thienamycins; Turkey | 2011 |
Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Plasmids; Population Surveillance; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Spain; Thienamycins | 2011 |
Silent spread of IMP-13-producing Pseudomonas aeruginosa belonging to sequence type 621 in Belgium.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; Belgium; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2011 |
Providencia isolates carrying bla (PER-1) and bla (VIM-2) genes: biofilm-forming capacity and biofilm inhibitory concentrations for carbapenem antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactamases; Biofilms; Carbapenems; Enterobacteriaceae Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Providencia; Thienamycins | 2011 |
Inhibition mechanism of carbapenem antibiotics on acylpeptide hydrolase, a key enzyme in the interaction with valproic acid.
Topics: Animals; Carbapenems; Cytosol; Dialysis; Humans; Hydrolysis; Isoflurophate; Kinetics; Liver; Meropenem; Peptide Hydrolases; Sus scrofa; Thienamycins; Time Factors; Valproic Acid | 2011 |
Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Genotype; Imipenem; Klebsiella pneumoniae; Longitudinal Studies; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Thienamycins; United States | 2011 |
Carbapenem susceptibility testing errors using three automated systems, disk diffusion, Etest, and broth microdilution and carbapenem resistance genes in isolates of Acinetobacter baumannii-calcoaceticus complex.
Topics: Acinetobacter baumannii; Acinetobacter calcoaceticus; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2011 |
Changes in antimicrobial susceptibility and major clones of Acinetobacter calcoaceticus-baumannii complex isolates from a single hospital in Korea over 7 years.
Topics: Acinetobacter; Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Genotype; Hospitals; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Republic of Korea; Species Specificity; Thienamycins | 2012 |
In vitro antibacterial activities of doripenem, imipenem, and meropenem against recent Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Streptococcus pneumoniae; Thienamycins | 2011 |
Molecular basis of NDM-1, a new antibiotic resistance determinant.
Topics: Anti-Bacterial Agents; beta-Lactamases; Biocatalysis; Carbapenems; Conserved Sequence; Drug Resistance, Microbial; Enzyme Assays; Hydrolysis; Meropenem; Models, Molecular; Point Mutation; Protein Binding; Sequence Alignment; Structural Homology, Protein; Thienamycins; Zinc | 2011 |
[Can meropenem E-test be used to estimate the presence of carbapenem resistance gene cfiA among Bacteroides fragilis strains?].
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteroides fragilis; Bacteroides Infections; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Feces; Humans; Imipenem; Meropenem; Metalloproteins; Microbial Sensitivity Tests; Thienamycins; Turkey | 2011 |
Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Propensity Score; Thienamycins | 2012 |
A multifaceted intervention strategy for eradication of a hospital-wide outbreak caused by carbapenem-resistant Klebsiella pneumoniae in Southern Israel.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Feces; Female; Humans; Infection Control; Israel; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Nursing Homes; Patient Isolation; Thienamycins; Young Adult | 2011 |
Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Acute Disease; Animals; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Colistin; Cytokines; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Female; Imipenem; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pneumonia, Bacterial; Stem Cells; Thienamycins | 2012 |
Evaluation of doripenem in an experimental model of resistant Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactam Resistance; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Doripenem; Humans; Imipenem; Lung; Meropenem; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Thienamycins; Treatment Outcome | 2012 |
Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Reference Standards; Thienamycins | 2012 |
Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Topics: Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Germany; Humans; Imipenem; Intensive Care Units; Intraabdominal Infections; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quality Control; Thienamycins | 2012 |
Acquisition of carbapenem resistance in multiresistant Klebsiella pneumoniae strains harbouring blaCTX-M-15, qnrS1 and aac(6')-Ib-cr genes.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Drug Resistance, Multiple, Bacterial; Electrophoresis, Polyacrylamide Gel; Female; Genes, Bacterial; Humans; Infant; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Mutation; Porins; Thienamycins | 2012 |
[Carbapenem resistance in Pseudomonas aeruginosa isolates: an example of interaction between different mechanisms].
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; DNA Mutational Analysis; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Humans; Imipenem; Membrane Transport Proteins; Meropenem; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thienamycins | 2011 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.
Topics: Animals; beta-Lactams; Carbapenems; Cell Line; Doripenem; Ertapenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peritonitis; Salmonella; Thienamycins | 2012 |
Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt₁ by carbapenems and cephalosporins.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Clavulanic Acid; Extensively Drug-Resistant Tuberculosis; Meropenem; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Peptidoglycan; Peptidyl Transferases; Thienamycins | 2012 |
Correlation between carbapenem consumption and resistance to carbapenems among Enterobacteriaceae isolates collected from patients with intra-abdominal infections at five medical centers in Taiwan, 2006-2010.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Intraabdominal Infections; Linear Models; Meropenem; Microbial Sensitivity Tests; Prevalence; Prospective Studies; Taiwan; Thienamycins | 2012 |
Use of meropenem Adatabs dissolved in MacConkey agar for screening NDM-1 positive Enterobacteriaceae in faecal surveillance cultures.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Culture Media; Drug Stability; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Middle Aged; Thienamycins | 2012 |
OXA-162, a novel variant of OXA-48 displays extended hydrolytic activity towards imipenem, meropenem and doripenem.
Topics: beta-Lactamases; Biocatalysis; Carbapenems; Cloning, Molecular; DNA Transposable Elements; Doripenem; Drug Resistance, Bacterial; Humans; Hydrolysis; Imipenem; Klebsiella pneumoniae; Meropenem; Models, Molecular; Plasmids; Thienamycins | 2013 |
Carbapenem non-susceptible Klebsiella pneumoniae from Micronet network hospitals, Italy, 2009 to 2012.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Hospitals; Humans; Imipenem; Italy; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Sentinel Surveillance; Thienamycins | 2012 |
Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacter; Escherichia coli; Imipenem; Klebsiella oxytoca; Klebsiella pneumoniae; Latin America; Meropenem; Microbial Sensitivity Tests; Minocycline; Serratia marcescens; Thienamycins; Tigecycline; United States; United States Food and Drug Administration | 2012 |
Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Hospitals, University; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Taiwan; Thienamycins | 2012 |
Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pacific Islands; Thienamycins; Time Factors | 2013 |
[Comparison of ertapenem-EMB Agar with traditional methods for screening carbapenem-resistant Klebsiella pneumoniae from rectal swabs].
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Culture Media; Doripenem; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Multiplex Polymerase Chain Reaction; Rectum; Sensitivity and Specificity; Thienamycins; Time Factors | 2012 |
Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
Topics: Acinetobacter; Acinetobacter baumannii; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Carbapenems; Doripenem; Enterobacteriaceae; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Poland; Pseudomonas; Species Specificity; Sputum; Thienamycins | 2012 |
Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli.
Topics: Acinetobacter; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Enterobacteriaceae; Imipenem; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Monobactams; Pseudomonas aeruginosa; Thiazoles; Thienamycins | 2013 |
Temocillin and meropenem to discriminate resistance mechanisms leading to decreased carbapenem susceptibility with focus on OXA-48 in Enterobacteriaceae.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillins; Thienamycins | 2013 |
Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Combinations; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
Crystal structure of L,D-transpeptidase LdtMt2 in complex with meropenem reveals the mechanism of carbapenem against Mycobacterium tuberculosis.
Topics: Amino Acid Substitution; Antitubercular Agents; Bacterial Proteins; Binding Sites; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Meropenem; Mycobacterium tuberculosis; Peptidyl Transferases; Thienamycins | 2013 |
The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages.
Topics: Adolescent; Anti-Bacterial Agents; Burkholderia cenocepacia; Burkholderia Infections; Carbapenems; Child; Cystic Fibrosis; Disease Progression; Doripenem; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Pseudomonas stutzeri; Rhodospirillaceae; Thienamycins; Tobramycin; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
Carbapenem-resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; Base Sequence; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Dipeptides; Drug Resistance, Multiple, Bacterial; Drug Synergism; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Porins; Pseudomonas aeruginosa; Thienamycins; Tobramycin | 2013 |
Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Drug Therapy, Combination; Female; Humans; Meropenem; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Soft Tissue Infections; Sulbactam; Thienamycins; Treatment Outcome | 2013 |
When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Drug Costs; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2013 |
In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients.
Topics: Acinetobacter baumannii; Bacterial Infections; Carbapenems; Doripenem; Electrophoresis, Gel, Pulsed-Field; Europe; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sensitivity and Specificity; Species Specificity; Thienamycins; United States; United States Food and Drug Administration | 2013 |
IMP-43 and IMP-44 metallo-β-lactamases with increased carbapenemase activities in multidrug-resistant Pseudomonas aeruginosa.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Catalytic Domain; Doripenem; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Hydrophobic and Hydrophilic Interactions; Imipenem; Japan; Meropenem; Phylogeny; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship; Thienamycins | 2013 |
An in silico approach for understanding the molecular evolution of clinically important metallo-beta-lactamases.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Binding Sites; Carbapenems; Enterobacteriaceae Infections; Evolution, Molecular; Humans; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Phylogeny; Protein Binding; Receptors, Cell Surface; Sequence Alignment; Sequence Analysis, DNA; Thienamycins | 2013 |
Carbapenem resistance in Acinetobacter baumannii: where is it heading?
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cross Infection; Hospitals, University; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Prognosis; Risk Factors; Thienamycins; Turkey | 2013 |
Structural basis for carbapenemase activity of the OXA-23 β-lactamase from Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Binding Sites; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Bacterial; Hydrogen-Ion Concentration; Kinetics; Meropenem; Molecular Dynamics Simulation; Protein Structure, Tertiary; Recombinant Proteins; Thienamycins | 2013 |
In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.
Topics: Antitubercular Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cell Wall; Clavulanic Acid; Doripenem; Enzyme Assays; Ertapenem; Escherichia coli; Gene Expression; Imipenem; Kinetics; Meropenem; Mycobacterium tuberculosis; Peptidoglycan; Peptidyl Transferases; Recombinant Proteins; Thienamycins | 2013 |
Accumulation of carbapenem resistance mechanisms in VIM-2-producing Pseudomonas aeruginosa under selective pressure.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Imipenem; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Selection, Genetic; Thienamycins | 2014 |
Determining carbapenemase activity with 18O labeling and targeted mass spectrometry.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bacterial Proteins; beta-Lactamases; Carbapenems; Chromatography, Liquid; Drug Resistance, Neoplasm; Meropenem; Oxygen Radioisotopes; Tandem Mass Spectrometry; Thienamycins | 2013 |
Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, General; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Singapore; Thienamycins; Young Adult | 2013 |
[Analysis of the carbapenemase-producing mechanism of Enterobacteriaceae with decreased susceptibility to carbapenems].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Enterobacteriaceae; Ertapenem; Gene Amplification; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Thienamycins | 2013 |
Emergence of carbapenem resistance due to the novel insertion sequence ISPa8 in Pseudomonas aeruginosa.
Topics: Base Sequence; Blotting, Southern; Carbapenems; Cell Membrane; Drug Resistance, Microbial; Electrophoresis, Gel, Pulsed-Field; Gene Dosage; Gene Expression Regulation, Bacterial; Meropenem; Microbial Sensitivity Tests; Mutagenesis, Insertional; Mutation; Polymerase Chain Reaction; Pseudomonas aeruginosa; Thienamycins | 2014 |
A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Topics: Acinetobacter baumannii; Aged; Aged, 80 and over; Anti-Bacterial Agents; C-Reactive Protein; Carbapenems; Cefoperazone; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Humans; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Minocycline; Pneumonia, Bacterial; Retrospective Studies; Sulbactam; Thienamycins | 2014 |
Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Female; Genome, Bacterial; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Molecular Epidemiology; Polymerase Chain Reaction; Public Health Surveillance; Survival Analysis; Thienamycins; Treatment Outcome | 2014 |
Heteroresistance to carbapenems in New Delhi metallo-β-lactamase-1-producing isolates: a challenge for detection?
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Disease Susceptibility; Drug Resistance, Multiple; Enterobacteriaceae Infections; Ertapenem; Humans; Meropenem; Providencia; Thienamycins | 2014 |
[In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cefoperazone; Cross Infection; Drug Combinations; Drug Synergism; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Sulbactam; Thienamycins | 2014 |
Antibiotic resistance: to the rescue of old drugs.
Topics: Animals; Aspartic Acid; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Female; Gram-Negative Bacteria; Meropenem; Thienamycins | 2014 |
Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance.
Topics: Animals; Anti-Bacterial Agents; Aspartic Acid; Aspergillus; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Biological Products; Carbapenems; Drug Evaluation, Preclinical; Drug Synergism; Female; Gram-Negative Bacteria; Klebsiella pneumoniae; Meropenem; Mice; Thienamycins | 2014 |
Molecular epidemiology of NDM-1-producing Enterobacteriaceae and Acinetobacter baumannii isolates from Pakistan.
Topics: Acinetobacter baumannii; Amdinocillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; DNA, Bacterial; Doripenem; Enterobacteriaceae; Fosfomycin; Humans; Meropenem; Methyltransferases; Microbial Sensitivity Tests; Molecular Epidemiology; Multilocus Sequence Typing; Pakistan; Thienamycins | 2014 |
[Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Drug Resistance; Humans; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 2014 |
Perturbing the general base residue Glu166 in the active site of class A β-lactamase leads to enhanced carbapenem binding and acylation.
Topics: Acylation; Amino Acid Substitution; Bacillus; beta-Lactamases; Binding Sites; Carbapenems; Catalytic Domain; Cephaloridine; Crystallography, X-Ray; Glutamic Acid; Kinetics; Meropenem; Models, Molecular; Protein Conformation; Thienamycins | 2014 |
A fluorescent carbapenem for structure function studies of penicillin-binding proteins, β-lactamases, and β-lactam sensors.
Topics: Bacterial Proteins; beta-Lactamases; Biocatalysis; Boron Compounds; Carbapenems; Electrophoresis, Polyacrylamide Gel; Fluorescein-5-isothiocyanate; Hydrolysis; Kinetics; Meropenem; Penicillin-Binding Proteins; Penicillins; Thienamycins | 2014 |
Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Colistin; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Genotype; Hospitals; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Typing; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2014 |
Increasing resistance rate to carbapenem among blood culture isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa in a university-affiliated hospital in China, 2004-2011.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; China; Drug Resistance, Bacterial; Gram-Negative Bacteria; Hospitals, University; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2015 |
Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Humans; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2014 |
Evaluation of inhibitory action of novel non β-lactam inhibitor against Klebsiella pneumoniae carbapenemase (KPC-2).
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cell Line; Ertapenem; HeLa Cells; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Protein Binding; Thienamycins | 2014 |
First report in China of Enterobacteriaceae clinical isolates coharboring blaNDM-1 and blaIMP-4 drug resistance genes.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Plasmids; Quinolones; Thienamycins | 2015 |
[A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
Topics: Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2014 |
Molecular mechanisms associated with nosocomial carbapenem-resistant Acinetobacter baumannii in Mexico.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biological Transport; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Hospitals; Humans; Hydrazones; Imipenem; Meropenem; Mexico; Microbial Sensitivity Tests; Thienamycins | 2014 |
Successful containment of carbapenem-resistant Enterobacteriaceae by strict contact precautions without active surveillance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Containment of Biohazards; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals, Teaching; Humans; Imipenem; Incidence; Infection Control; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phenotype; Prevalence; Prospective Studies; Republic of Korea; Retrospective Studies; Thienamycins | 2014 |
Molecular characteristics of carbapenem-resistant gram-negative bacteria in southern China.
Topics: Anti-Bacterial Agents; ATP-Binding Cassette Transporters; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Drug Resistance, Bacterial; Genes, Bacterial; Glutathione Transferase; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Integrons; Meropenem; Mutagenesis, Insertional; Thienamycins | 2015 |
Kinetic and structural requirements for carbapenemase activity in GES-type β-lactamases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Doripenem; Ertapenem; Escherichia coli; Kinetics; Meropenem; Models, Molecular; Thienamycins | 2015 |
Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Enterobacter cloacae; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Escherichia coli; Hospitals, Teaching; Humans; Imipenem; Intensive Care Units; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Taiwan; Thienamycins | 2015 |
A novel New Delhi metallo-β-lactamase variant, NDM-14, isolated in a Chinese Hospital possesses increased enzymatic activity against carbapenems.
Topics: Acinetobacter; Acinetobacter Infections; Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; China; Cross Infection; Drug Resistance, Bacterial; Humans; Imipenem; Intensive Care Units; Kinetics; Meropenem; Molecular Sequence Data; Plasmids; Thienamycins | 2015 |
Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Body Surface Area; Burn Units; Burns; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Cohort Studies; Computer Systems; Critical Illness; Drug Combinations; Drug Monitoring; Female; Humans; Imipenem; Length of Stay; Male; Meropenem; Middle Aged; Retrospective Studies; Thienamycins; Young Adult | 2015 |
[Pharmacokinetics study of injected doripenemin healthy volunteers].
Topics: Carbapenems; Chromatography, High Pressure Liquid; Doripenem; Healthy Volunteers; Humans; Infusions, Intravenous; Meropenem; Thienamycins | 2015 |
Evaluation of a pharmacokineticpharmacodynamic approach using software to optimize the carbapenem antibiotic regimen.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Computer Simulation; Doripenem; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Drug Therapy, Computer-Assisted; Female; Humans; Kidney; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Pneumonia, Bacterial; Prospective Studies; Software; Thienamycins; Treatment Outcome | 2015 |
Profiling of β-lactam selectivity for penicillin-binding proteins in Streptococcus pneumoniae D39.
Topics: Amdinocillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Doripenem; Electrophoresis, Polyacrylamide Gel; Meropenem; Penicillin-Binding Proteins; Streptococcus pneumoniae; Thienamycins | 2015 |
In vivo inhibition of acylpeptide hydrolase by carbapenem antibiotics causes the decrease of plasma concentration of valproic acid in dogs.
Topics: Administration, Intravenous; Animals; Carbapenems; Cytosol; Dogs; Drug Interactions; Enzyme Inhibitors; Hydrolysis; Kidney; Liver; Male; Meropenem; Peptide Hydrolases; Protease Inhibitors; Thienamycins; Valproic Acid | 2016 |
Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Blood Culture; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Case-Control Studies; Cephalosporins; Ciprofloxacin; Cross Infection; Female; Hospitals; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Mortality; Multivariate Analysis; Odds Ratio; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Severity of Illness Index; Taiwan; Thienamycins | 2017 |
Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Doripenem; Drug Synergism; Meropenem; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium tuberculosis; Rifampin; Thienamycins | 2015 |
IMP-51, a novel IMP-type metallo-β-lactamase with increased doripenem- and meropenem-hydrolyzing activities, in a carbapenem-resistant Pseudomonas aeruginosa clinical isolate.
Topics: beta-Lactamases; Carbapenems; Cefoxitin; Doripenem; Escherichia coli; Meropenem; Microbial Sensitivity Tests; Moxalactam; Pseudomonas aeruginosa; Thienamycins | 2015 |
Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.
Topics: Anti-Bacterial Agents; Antiviral Agents; Azabicyclo Compounds; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Ceftazidime; Colectomy; Colistin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Ganciclovir; Humans; Immunosuppressive Agents; Intestine, Small; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Middle Aged; Minocycline; Thienamycins; Tigecycline; Trimethoprim, Sulfamethoxazole Drug Combination; Valganciclovir | 2015 |
The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Anti-Bacterial Agents; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Infant; Intensive Care Units, Pediatric; Male; Meropenem; Microbial Sensitivity Tests; Thienamycins; Vancomycin; Young Adult | 2015 |
The Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Colonization and Infection among Long-Term Acute Care Hospital Residents.
Topics: Aged; Anti-Bacterial Agents; Carbapenems; Carrier State; Case-Control Studies; Drug Resistance, Bacterial; Fecal Incontinence; Female; Hospitals; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Metronidazole; Middle Aged; Organ Transplantation; Respiration, Artificial; Risk Factors; Stem Cell Transplantation; Thienamycins; Time Factors; Vancomycin | 2016 |
Camellia sinensis Ameliorates the Efficacy of Last Line Antibiotics Against Carbapenem Resistant Escherichia coli.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactams; Camellia sinensis; Carbapenems; Colistin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Flavonoids; Free Radical Scavengers; Meropenem; Microbial Sensitivity Tests; Minocycline; Phytochemicals; Plant Extracts; Plant Leaves; Thienamycins; Tigecycline | 2016 |
Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.
Topics: Azabicyclo Compounds; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Gene Deletion; Gene Expression Regulation, Bacterial; Imipenem; Meropenem; Microbial Sensitivity Tests; Operon; Porins; Pseudomonas aeruginosa; Thienamycins | 2016 |
Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.
Topics: Animals; Anti-Infective Agents; Carbapenems; Caspofungin; Ceftriaxone; Ciprofloxacin; Critical Illness; Doripenem; Echinocandins; Extracorporeal Membrane Oxygenation; Fluconazole; Gentamicins; Lipopeptides; Meropenem; Models, Theoretical; Sheep; Sheep, Domestic; Thienamycins; Vancomycin | 2015 |
Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Multidrug Resistance-Associated Proteins; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Republic of Korea; Thienamycins | 2016 |
Association of doripenem resistance with OXA-type carbapenemases in Acinetobacter baumannii isolates.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Retrospective Studies; Thienamycins | 2016 |
[Analysis of carbapenems by hydrophilic interaction chromatography and its application].
Topics: beta-Lactams; Carbapenems; Chromatography; Doripenem; Drinking Water; Ertapenem; Humans; Hydrophobic and Hydrophilic Interactions; Meropenem; Thienamycins | 2015 |
Severe Bloodstream Infection due to KPC-Producer E coli in a Renal Transplant Recipient Treated With the Double-Carbapenem Regimen and Analysis of In Vitro Synergy Testing: A Case Report.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Drug Synergism; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Kidney Transplantation; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Middle Aged; Surgical Wound Infection; Thienamycins | 2016 |
The Need for Global Regulation of Antibiotics: The Case of a Generic Oral Penem.
Topics: Anti-Bacterial Agents; Carbapenems; Drugs, Generic; Humans; Meropenem; Thienamycins | 2016 |
MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2016 |
[Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Proteins; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Multiplex Polymerase Chain Reaction; Phenotype; Thienamycins; Turkey | 2016 |
Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Genes, Regulator; Humans; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Mutation; Phenotype; Pseudomonas aeruginosa; Real-Time Polymerase Chain Reaction; Repressor Proteins; Thienamycins | 2016 |
Emergence of Serratia marcescens isolates possessing carbapenem-hydrolysing β-lactamase KPC-2 from China.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; China; DNA, Bacterial; Ertapenem; Female; Genotype; Hospitals; Humans; Hydrolysis; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Molecular Typing; Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Thienamycins; Young Adult | 2016 |
Structural Insights into Recognition of Hydrolyzed Carbapenems and Inhibitors by Subclass B3 Metallo-β-Lactamase SMB-1.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; beta-Lactamases; Captopril; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Doripenem; Imipenem; Meropenem; Mesna; Protein Structure, Secondary; Protein Structure, Tertiary; Serratia marcescens; Thienamycins | 2016 |
Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cross Infection; Doripenem; Humans; Imipenem; Iran; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2016 |
Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Biofilms; Carbapenems; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Minocycline; Sulbactam; Thienamycins; Tigecycline | 2016 |
Modeling Meropenem Treatment, Alone and in Combination with Daptomycin, for KPC-Producing Klebsiella pneumoniae Strains with Unusually Low Carbapenem MICs.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Daptomycin; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Staphylococcus aureus; Thienamycins | 2016 |
Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004-2014).
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Europe; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Minocycline; Pseudomonas aeruginosa; Thienamycins; Tigecycline | 2017 |
Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Thienamycins; Treatment Outcome | 2016 |
Comparison of the Modified-Hodge test, Carba NP test, and carbapenem inactivation method as screening methods for carbapenemase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Ertapenem; Imipenem; Meropenem; Microbial Sensitivity Tests; Sensitivity and Specificity; Thienamycins | 2016 |
Boronic acid disk diffusion for the phenotypic detection of polymerase chain reaction-confirmed, carbapenem-resistant, gram-negative bacilli isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Boronic Acids; Carbapenems; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meropenem; Phenotype; Polymerase Chain Reaction; Thienamycins | 2016 |
Structural and Mutagenic Analysis of Metallo-β-Lactamase IMP-18.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Catalytic Domain; Kinetics; Meropenem; Mutagens; Pseudomonas aeruginosa; Thienamycins | 2016 |
Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Drug Resistance, Bacterial; Drug Synergism; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Sulbactam; Thienamycins | 2016 |
Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Drug Utilization; Gentamicins; Hospitals; Humans; Imipenem; Meropenem; Pseudomonas aeruginosa; Serbia; Thienamycins | 2016 |
In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Taiwan; Thienamycins | 2016 |
Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital.
Topics: Bacteremia; beta-Lactams; Carbapenems; Case-Control Studies; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Hospitals; Humans; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Thienamycins | 2016 |
Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Asian People; beta-Lactam Resistance; Carbapenems; Colistin; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Models, Biological; Thienamycins | 2016 |
Acquisition of Carbapenem Resistance by Plasmid-Encoded-AmpC-Expressing Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Meropenem; Microbial Sensitivity Tests; Mutation; Plasmids; Porins; Thienamycins | 2017 |
Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cohort Studies; DNA, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Meropenem; Middle Aged; Retrospective Studies; Thienamycins; Treatment Outcome | 2017 |
Dissemination of blaOXA-58 in Proteus mirabilis isolates from Germany.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Germany; High-Throughput Nucleotide Sequencing; Humans; Meropenem; Microbial Sensitivity Tests; Plasmids; Proteus mirabilis; Thienamycins | 2017 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Resistotyping, phenotyping and genotyping of New Delhi metallo-β-lactamase (NDM) among Gram-negative bacilli from Iranian patients.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cluster Analysis; Drug Resistance, Bacterial; Genotype; Humans; Iran; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Thienamycins | 2017 |
Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Critical Care; Doripenem; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Gene Expression; Genotype; Humans; Imipenem; Klebsiella; Klebsiella Infections; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Thienamycins; United States | 2017 |
Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Catheter-Related Infections; Female; Greece; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Prospective Studies; Salvage Therapy; Thienamycins; Treatment Outcome; Urinary Tract Infections; Young Adult | 2017 |
WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cyclooctanes; Drug Discovery; Drug Resistance, Multiple, Bacterial; Drug Synergism; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2017 |
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Anti-Bacterial Agents; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Meropenem; Microbial Sensitivity Tests; Polymyxin B; Thienamycins | 2017 |
The prevalence and resistance patterns of Pseudomonas aeruginosa in a tertiary care hospital in Kosovo.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Hospitals, University; Humans; Imipenem; Intensive Care Units; Kosovo; Male; Meropenem; Microbial Sensitivity Tests; Prevalence; Pseudomonas Infections; Retrospective Studies; Tertiary Care Centers; Thienamycins | 2017 |
In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2017 |
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Inpatients; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Minocycline; Pseudomonas aeruginosa; Thienamycins; Tigecycline | 2017 |
IMI-2 carbapenemase in a clinical Klebsiella variicola isolated in the UK.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Ertapenem; Gene Transfer, Horizontal; Humans; Imipenem; Klebsiella; Meropenem; Plasmids; Thienamycins; United Kingdom | 2017 |
Comparison of imipenem and meropenem antibiotics for the MALDI-TOF MS detection of carbapenemase activity.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteriological Techniques; beta-Lactamases; Carbapenems; Enterobacteriaceae; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thienamycins | 2017 |
Understanding Carbapenem Translocation through OccD3 (OpdP) of Pseudomonas aeruginosa.
Topics: Bacterial Proteins; Binding Sites; Carbapenems; Imipenem; Ion Channels; Lipid Bilayers; Membranes, Artificial; Meropenem; Mutagenesis, Site-Directed; Pseudomonas aeruginosa; Substrate Specificity; Thienamycins | 2017 |
Observation of Clinically Relevant Drug Interaction in Chimeric Mice with Humanized Livers: The Case of Valproic Acid and Carbapenem Antibiotics.
Topics: Animals; Carbapenems; Drug Interactions; Humans; Liver; Meropenem; Mice; Peptide Hydrolases; Thienamycins; Transplantation Chimera; Valproic Acid | 2017 |
Differential flap dynamics in l,d-transpeptidase2 from mycobacterium tuberculosis revealed by molecular dynamics.
Topics: beta-Lactams; Carbapenems; Ertapenem; Imipenem; Meropenem; Molecular Dynamics Simulation; Mycobacterium tuberculosis; Principal Component Analysis; Thienamycins | 2017 |
[AdeABC efflux pump and resistance of Acinetobacter baumannii against carbapenem].
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Real-Time Polymerase Chain Reaction; Thienamycins | 2017 |
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Topics: Adolescent; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Fever; Fluoroquinolones; Humans; Male; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Thiol-Containing Metallo-β-Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cefoperazone; Drug Resistance, Bacterial; Gram-Negative Bacteria; Meropenem; Molecular Structure; Sulfhydryl Compounds; Thienamycins | 2017 |
Impact of carbapenem restriction on the antimicrobial susceptibility pattern of Pseudomonas aeruginosa isolates in the ICU.
Topics: Adult; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Drug Resistance, Bacterial; Drug Utilization; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Is There a Carbapenem MIC Cutoff Value That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem Non-Susceptible Pseudomonas and Acinetobacter Isolates?
Topics: Academic Medical Centers; Acinetobacter; Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Centers for Disease Control and Prevention, U.S.; Drug Resistance, Microbial; Humans; Imipenem; Maryland; Meropenem; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections; ROC Curve; Sensitivity and Specificity; Thienamycins; United States | 2017 |
Probing the sRNA regulatory landscape of P. aeruginosa: post-transcriptional control of determinants of pathogenicity and antibiotic susceptibility.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Genes, Regulator; Host Factor 1 Protein; Lipid A; Meropenem; Polymyxins; Porins; Pseudomonas aeruginosa; Regulon; RNA, Messenger; RNA, Small Untranslated; Thienamycins; Trans-Activators; Type III Secretion Systems | 2017 |
Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Female; Fosfomycin; Humans; Intestines; Kidney Transplantation; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Postoperative Complications; Precision Medicine | 2017 |
Photochemical degradation of the carbapenem antibiotics imipenem and meropenem in aqueous solutions under solar radiation.
Topics: Carbapenems; Chromatography, Liquid; Humic Substances; Imipenem; Kinetics; Meropenem; Photolysis; Rivers; Sunlight; Thienamycins; Wastewater; Water; Water Pollutants, Chemical | 2018 |
MASTDISCS combi Carba plus, a simple method for discriminating carbapenemase-producing Enterobacteriaceae, including OXA-48-type producers.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Disk Diffusion Antimicrobial Tests; Enterobacteriaceae; Enterobacteriaceae Infections; Enzyme Assays; Enzyme Inhibitors; Humans; Meropenem; Sensitivity and Specificity; Thienamycins | 2018 |
Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants.
Topics: Adjuvants, Pharmaceutic; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Coordination Complexes; Copper; Ertapenem; Escherichia coli; Humans; Ions; Meropenem; Microbial Sensitivity Tests; Urinary Tract Infections | 2018 |
Coexistence of metallo-beta-lactamase-encoding genes in
Topics: beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Humans; Integrons; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Tertiary Care Centers; Thienamycins | 2017 |
Performance evaluation of BD Phoenix™, an automated microbiology system, for the screening of IMP-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Automation, Laboratory; Bacterial Proteins; Carbapenems; DNA, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Imipenem; Inosine Monophosphate; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2018 |
The mechanism of NDM-1-catalyzed carbapenem hydrolysis is distinct from that of penicillin or cephalosporin hydrolysis.
Topics: beta-Lactamases; Carbapenems; Cephalosporins; Crystallization; Crystallography, X-Ray; Escherichia coli; Hydrolysis; Imipenem; Magnetic Resonance Spectroscopy; Meropenem; Models, Molecular; Penicillins; Thienamycins | 2017 |
Risk Factors Associated With Carbapenem-Resistant
Topics: Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Retrospective Studies; Risk Factors; Thienamycins | 2017 |
The effect of sub-inhibitory concentrations of antibiotics on natural transformation in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Dose-Response Relationship, Drug; Humans; Meropenem; Microbial Sensitivity Tests; Mitomycin; Transformation, Bacterial | 2018 |
Evidence to improve the treatment of infections caused by carbapenem-resistant Gram-negative bacteria.
Topics: Carbapenems; Colistin; Gram-Negative Bacteria; Meropenem | 2018 |
Evolution of carbapenem resistance in Acinetobacter baumannii during a prolonged infection.
Topics: Acinetobacter baumannii; Bacterial Proteins; beta-Lactamases; Carbapenems; Ciprofloxacin; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymorphism, Single Nucleotide; Protein Conformation; Sequence Analysis, DNA | 2018 |
Effect of Carbapenem Selection on Drug Acquisition Costs and Carbapenem Resistance.
Topics: Anti-Bacterial Agents; Carbapenems; Cohort Studies; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; United States | 2019 |
Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
Topics: beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Reagent Strips; Sensitivity and Specificity | 2018 |
Porin Deficiency in Carbapenem-Resistant Enterobacter aerogenes Strains.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Codon, Terminator; Down-Regulation; Enterobacter aerogenes; Humans; Meropenem; Microbial Sensitivity Tests; Porins; Whole Genome Sequencing | 2018 |
Colistin versus colistin plus meropenem for severe infections.
Topics: Carbapenems; Colistin; Gram-Negative Bacteria; Meropenem | 2018 |
Colistin versus colistin plus meropenem for severe infections.
Topics: Carbapenems; Colistin; Gram-Negative Bacteria; Meropenem | 2018 |
Colistin versus colistin plus meropenem for severe infections Authors' reply.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Meropenem | 2018 |
Intentional use of carbapenem antibiotics for valproic acid toxicity: A case report.
Topics: Anticonvulsants; Carbapenems; Drug Interactions; Humans; Male; Meropenem; Middle Aged; Valproic Acid | 2018 |
Molecular and computational approaches to understand resistance of New Delhi metallo β-lactamase variants (NDM-1, NDM-4, NDM-5, NDM-6, NDM-7)-producing strains against carbapenems.
Topics: Amino Acid Sequence; beta-Lactamases; Carbapenems; Hydrogen Bonding; Imipenem; Kinetics; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Structure, Secondary | 2019 |
Performance of the EUCAST disc diffusion method and two MIC methods in detection of Enterobacteriaceae with reduced susceptibility to meropenem: the NordicAST CPE study.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Clinical Laboratory Techniques; Disk Diffusion Antimicrobial Tests; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella; Meropenem; Microbial Sensitivity Tests | 2018 |
Does the intrinsic oxaAb (blaOXA-51-like) gene of Acinetobacter baumannii confer resistance to carbapenems when activated by ISAba1?
Topics: Acinetobacter baumannii; Acinetobacter Infections; Australia; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Disease Outbreaks; DNA Transposable Elements; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Transcriptional Activation | 2018 |
SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection Model.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Crystallography, X-Ray; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Inhibitory Concentration 50; Meropenem; Microbial Sensitivity Tests; Picolinic Acids; Protein Binding; Structure-Activity Relationship | 2019 |
Characterization of mutations in Escherichia coli PBP2 leading to increased carbapenem MICs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Escherichia coli; Escherichia coli Proteins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins | 2019 |
An improved carbapenem inactivation method, CIMTrisII, for carbapenemase production by Gram-negative pathogens.
Topics: Acinetobacter; Anti-Bacterial Agents; Asia, Southeastern; Bacterial Infections; Bacterial Proteins; beta-Lactamases; Carbapenems; DNA, Bacterial; Enterobacteriaceae; Humans; Imipenem; Japan; Meropenem; Microbial Sensitivity Tests; Nepal; Pseudomonas; Sensitivity and Specificity; Sequence Analysis, DNA; Time Factors | 2019 |
The plasmid-encoded transcription factor ArdK contributes to the repression of the IMP-6 metallo-β-lactamase gene blaIMP-6, leading to a carbapenem-susceptible phenotype in the blaIMP-6-positive Escherichia coli strain A56-1S.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Comparative Genomic Hybridization; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Phenotype; Plasmids; Repressor Proteins; Urine | 2018 |
Antimicrobial consumption in five adult intensive care units: a 33-month surveillance study.
Topics: Adult; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Colistin; Communicable Diseases; Cost-Benefit Analysis; Drug Utilization; Female; Humans; Intensive Care Units; Male; Meropenem; Middle Aged; Piperacillin, Tazobactam Drug Combination; Population Surveillance; Saudi Arabia; Tertiary Care Centers; Vancomycin; Young Adult | 2018 |
Inactivation of the oprD porin gene by a novel insertion sequence ISPa195 associated with large deletion in a carbapenem-resistant Pseudomonas aeruginosa clinical isolate.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Gene Components; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Deletion | 2019 |
Transcriptional response of OmpC and OmpF in Escherichia coli against differential gradient of carbapenem stress.
Topics: Anti-Bacterial Agents; Carbapenems; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Escherichia coli; Gene Expression Regulation, Bacterial; Imipenem; Meropenem; Microbial Sensitivity Tests; Porins; RNA, Antisense; RNA, Bacterial; Transcription, Genetic | 2019 |
Detection of carbapenemase-producing Pseudomonas aeruginosa: Evaluation of the carbapenem inactivation method (CIM).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteriological Techniques; beta-Lactamases; Carbapenems; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2019 |
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Meropenem; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; United States | 2019 |
Impact of specific inhibitors on metallo-β-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates.
Topics: Anti-Bacterial Agents; Ascorbic Acid; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Catalytic Domain; Ciprofloxacin; Citric Acid; Drug Combinations; Drug Synergism; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Malates; Meropenem; Microbial Sensitivity Tests; Zinc | 2019 |
Association of Adverse Drug Events with Broad-spectrum Antibiotic Use in Hospitalized Patients: A Single-center Study.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Male; Meropenem; Middle Aged; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Vancomycin; Young Adult | 2019 |
Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
Topics: Acylation; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Escherichia coli; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2019 |
Antibiotics with activity against intestinal anaerobes and the hazard of acquired colonization with ceftriaxone-resistant Gram-negative pathogens in ICU patients: a propensity score-based analysis.
Topics: Aged; Anti-Bacterial Agents; Bacteria, Anaerobic; Carbapenems; Ceftriaxone; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intensive Care Units; Intestines; Male; Meropenem; Middle Aged; Propensity Score; Retrospective Studies | 2019 |
Quercetin potentiates meropenem activity among pathogenic carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Drug Synergism; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Quercetin | 2019 |
Structural Insights into the Mechanism of Carbapenemase Activity of the OXA-48 β-Lactamase.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Catalytic Domain; Doripenem; Hydrophobic and Hydrophilic Interactions; Imipenem; Meropenem; Microbial Sensitivity Tests; Protein Structure, Secondary | 2019 |
Carbapenem-resistant
Topics: Carbapenems; Drug Resistance, Bacterial; Geography; Humans; Imipenem; Japan; Meropenem; Pseudomonas aeruginosa; Regression Analysis | 2019 |
Variable performance of different commercial systems for testing carbapenem susceptibility of KPC carbapenemase-producing Escherichia coli.
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Diagnostic Errors; Ertapenem; Escherichia coli; Escherichia coli Infections; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Typing; Random Amplified Polymorphic DNA Technique | 2019 |
TiO
Topics: Carbapenems; Catalysis; Imipenem; Meropenem; Photolysis; Sunlight; Titanium; Water Pollutants, Chemical | 2019 |
Evaluation of the Direct MacConkey Method for Identification of Carbapenem-Resistant Gram-Negative Organisms from Rectal Swabs: Reevaluating Zone Diameter Cutoffs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Rectum; ROC Curve; Sensitivity and Specificity | 2019 |
Synergistic Activities of Colistin Combinations with Meropenem, Sulbactam, Minocycline, Disodium Fosfomycin, or Vancomycin Against Different Clones of Carbapenem-Resistant
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteriological Techniques; Carbapenems; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Meropenem; Minocycline; Sulbactam; Vancomycin | 2020 |
An agar plate-based modified carbapenem inactivation method (p-mCIM) for detection of carbapenemase-producing Enterobacteriaceae.
Topics: Agar; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Enterobacteriaceae Infections; Humans; Meropenem; Microbial Sensitivity Tests; Sensitivity and Specificity | 2020 |
In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ambroxol; Amlodipine; Anti-Bacterial Agents; Carbapenems; Cefoperazone; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Sulbactam; Thienamycins | 2020 |
4-Chloromercuribenzoic acid enhances carbapenem sensitivity among pathogenic Gram negative bacteria by altering bla
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; p-Chloromercuribenzoic Acid; Porins; Reverse Transcriptase Polymerase Chain Reaction | 2020 |
Insertion sequences and sequence types profile of clinical isolates of carbapenem-resistant A. baumannii collected across India over four year period.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Bacterial; Humans; Imipenem; India; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymerase Chain Reaction | 2020 |
Higher rates of carbapenem-related seizures in older hospitalised adults.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ertapenem; Female; Hospitalization; Humans; Imipenem; Logistic Models; Male; Meropenem; Seizures; Singapore | 2020 |
Chemiluminescent Carbapenem-Based Molecular Probe for Detection of Carbapenemase Activity in Live Bacteria.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Proteins; beta-Lactamases; Carbapenems; Humans; Imipenem; Meropenem | 2020 |
KPC-producing Enterobacterales with uncommon carbapenem susceptibility profile in Vitek 2 system.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Gammaproteobacteria; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2020 |
The clinical profile and outcomes of adult patients given intravenous colistin for multidrug-resistant gram negative infections in a Philippine tertiary hospital.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Hospitalization; Humans; Male; Meropenem; Middle Aged; Organ Dysfunction Scores; Philippines; Respiratory Tract Infections; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Young Adult | 2020 |
Focal seizures with a migrating aspect in infants treated with beta-lactam antibiotics - Report of two cases.
Topics: Anti-Bacterial Agents; Carbapenems; Humans; Infant; Meropenem; Seizures | 2020 |
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Topics: Aged; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Boronic Acids; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Ceftazidime; Cohort Studies; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Female; Humans; Male; Meropenem; Middle Aged; Retrospective Studies; Treatment Outcome; Urinary Tract Infections | 2020 |
Differences between meropenem and imipenem disk to detect carbapenemase in gram-negative bacilli using simplified carbapenem inactivation method.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sensitivity and Specificity | 2020 |
ZN148 Is a Modular Synthetic Metallo-β-Lactamase Inhibitor That Reverses Carbapenem Resistance in Gram-Negative Pathogens
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Meropenem; Mice | 2020 |
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Re: 'Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes' by Nutman et al.
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Colistin; Humans; Meropenem | 2020 |
Topics: Adult; Animals; Anti-Bacterial Agents; Carbapenems; Humans; Meropenem; Mice; Urinary Tract Infections | 2020 |
The efficacy of colistin monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests | 2020 |
Re: 'Colistin plus meropenem for carbapenem-resistant gram-negative infections: in vitro synergism is not associated with better clinical outcomes'-Author's reply.
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Colistin; Humans; Meropenem | 2020 |
Interaction of LysM BON family protein domain with carbapenems: A putative mechanism of carbapenem resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Protein Domains | 2020 |
Prospective monitoring of carbapenem use and pseudomonal resistance across pediatric institutions.
Topics: Anti-Bacterial Agents; Carbapenems; Child; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2020 |
The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; Carbapenems; Colistin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Kidney; Kidney Diseases; Male; Meropenem; Middle Aged; Retrospective Studies; Thailand | 2020 |
Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Humans; Meropenem; Microbial Sensitivity Tests; Polymyxins; Sulbactam | 2020 |
Re: 'Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes' by Nutman et al.
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Colistin; Humans; Meropenem | 2021 |
Molecular docking, dynamics and free energy analyses of
Topics: Acinetobacter baumannii; Ampicillin; beta-Lactamases; Carbapenems; Catalytic Domain; Computer Simulation; Doripenem; Ertapenem; Hydrolysis; Meropenem; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation | 2020 |
Postprescription Review With Threat of Infectious Disease Consultation and Sustained Reduction in Meropenem Use Over Four Years.
Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Humans; Meropenem; Referral and Consultation; Retrospective Studies | 2021 |
Performance evaluation of automated BD Phoenix NMIC-500 panel for carbapenemase detection in carbapenem-resistant and carbapenem-susceptible Enterobacterales.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteriological Techniques; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Enterobacteriaceae; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Sensitivity and Specificity | 2020 |
High-risk clones and novel sequence type ST4497 of Klebsiella pneumoniae clinical isolates producing different alleles of NDM-type and other carbapenemases from a single tertiary-care centre in Egypt.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Bacterial; Egypt; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tertiary Care Centers | 2020 |
Neo-antigens for the serological diagnosis of IgE-mediated drug allergic reactions to antibiotics cephalosporin, carbapenem and monobactam.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Cefotaxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Humans; Immunoglobulin E; Immunoglobulin G; Meropenem; Monobactams; Penicillins; Skin Tests | 2020 |
Ruthenium complexes as prospective inhibitors of metallo-β-lactamases to reverse carbapenem resistance.
Topics: Amino Acid Sequence; Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Carbapenems; Coordination Complexes; Disease Models, Animal; Drug Development; Drug Resistance, Microbial; Escherichia coli; Infections; Meropenem; Mice; Microbial Sensitivity Tests; Prospective Studies; Protein Binding; Protein Conformation; Ruthenium; Structure-Activity Relationship; Zinc | 2020 |
A method to quantify viable carbapenem resistant gram-negative bacteria in treated and untreated wastewater.
Topics: Anti-Bacterial Agents; Bacterial Load; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Ertapenem; Imipenem; Meropenem; Wastewater; Water Purification | 2020 |
Restoring carbapenem efficacy: a novel carbapenem companion targeting metallo-β-lactamases in carbapenem-resistant Enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Humans; Meropenem; Microbial Sensitivity Tests | 2021 |
Transcriptome-based design of antisense inhibitors potentiates carbapenem efficacy in CRE
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Gene Expression Profiling; Genome, Bacterial; Genomics; High-Throughput Nucleotide Sequencing; Humans; Meropenem; Microbial Sensitivity Tests; Oligonucleotides, Antisense; Transcriptome | 2020 |
Geographical distribution of Enterobacterales with a carbapenemase IMP-6 phenotype and its association with antimicrobial use: An analysis using comprehensive national surveillance data on antimicrobial resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Japan; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Phenotype | 2020 |
Synthesis of Carbapenems Containing Peptidoglycan Mimetics and Inhibition of the Cross-Linking Activity of a Transpeptidase of l,d Specificity.
Topics: Anti-Bacterial Agents; Carbapenems; Cell Wall; Meropenem; Peptidoglycan; Peptidyl Transferases | 2021 |
Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region.
Topics: Anti-Bacterial Agents; Asia; Boronic Acids; Carbapenems; Escherichia coli; Meropenem; Phylogeny | 2021 |
In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E.coli and Klebsiella pneumoniae by checkerboard method.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Drug Resistance, Bacterial; Drug Synergism; Escherichia coli; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2021 |
Development of the computational antibiotic screening platform (CLASP) to aid in the discovery of new antibiotics.
Topics: Anti-Bacterial Agents; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Porins | 2021 |
Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Azoles; Carbapenems; Chromatography, High Pressure Liquid; Ciprofloxacin; Daptomycin; Doripenem; Drug Monitoring; Female; Fluconazole; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Linezolid; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Oxazines; Oxazolidinones; Quinolones; Tandem Mass Spectrometry; Tetrazoles; Voriconazole | 2021 |
Molecular characterization and antibiotic resistance of Acinetobacter baumannii in cerebrospinal fluid and blood.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blood; Carbapenems; Cerebrospinal Fluid; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests | 2021 |
Thinking out of the box: management of valproic acid toxicity with carbapenems.
Topics: Adult; Anticonvulsants; Carbapenems; Carnitine; Epilepsy; Female; Humans; Meropenem; Valproic Acid | 2021 |
Antimicrobial and antibiofilm activities of meropenem loaded-mesoporous silica nanoparticles against carbapenem-resistant
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Bacterial; Humans; Meropenem; Microbial Sensitivity Tests; Nanoparticles; Pseudomonas aeruginosa; Pseudomonas Infections; Silicon Dioxide | 2021 |
Acceptance and outcome of interventions in a meropenem de-escalation antimicrobial stewardship program in pediatrics.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Child; Humans; Meropenem; Pediatrics; Prospective Studies | 2021 |
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; Carbapenems; Colistin; Drug Resistance, Bacterial; Female; Greece; Humans; Israel; Italy; Logistic Models; Male; Meropenem; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Antibacterial activity and carbapenem re-sensitizing ability of 1,10-phenanthroline-5,6-dione and its metal complexes against KPC-producing Klebsiella pneumoniae clinical strains.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Coordination Complexes; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phenanthrolines | 2021 |
Clinical Characteristics, Risk Factors, and Outcomes of Patients with Polymicrobial
Topics: Adult; Aged; Bacteremia; Carbapenems; Ertapenem; Female; Hospitalization; Humans; Imipenem; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Odds Ratio; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2021 |
Interplay between Meropenem and Human Serum Albumin on Expression of Carbapenem Resistance Genes and Natural Competence in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Humans; Meropenem; Microbial Sensitivity Tests; Serum Albumin, Human | 2021 |
Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19).
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Boronic Acids; Carbapenems; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated | 2021 |
Treatment of Donor-derived Carbapenem-resistant Klebsiella pneumoniae Infection after Renal Transplantation with Tigecycline and Extended-infusion Meropenem.
Topics: Adolescent; Adult; Bacterial Proteins; beta-Lactamases; Carbapenems; Child; Drug Resistance, Bacterial; Female; Humans; Infant; Kidney Transplantation; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Tigecycline; Tissue Donors; Young Adult | 2021 |
Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Colistin; Colombia; Cost-Benefit Analysis; Drug Combinations; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Carbapenem-resistant K. pneumoniae exhibiting clinically undetected amikacin and meropenem heteroresistance leads to treatment failure in a murine model of infection.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Klebsiella pneumoniae; Meropenem; Mice; Microbial Sensitivity Tests; Treatment Failure | 2021 |
On the Offensive: the Role of Outer Membrane Vesicles in the Successful Dissemination of New Delhi Metallo-β-lactamase (NDM-1).
Topics: Animals; Anti-Bacterial Agents; Bacterial Outer Membrane; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Gene Transfer, Horizontal; Humans; Meropenem; Microbial Sensitivity Tests; Moths; Pseudomonas aeruginosa | 2021 |
Crystallography and QM/MM Simulations Identify Preferential Binding of Hydrolyzed Carbapenem and Penem Antibiotics to the L1 Metallo-β-Lactamase in the Imine Form.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Crystallography, X-Ray; Imines; Meropenem | 2021 |
Clinical outcome from hematopoietic cell transplant patients with bloodstream infection caused by carbapenem-resistant P. aeruginosa and the impact of antimicrobial combination in vitro.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Brazil; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Colistin; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Young Adult | 2022 |
In vitro activity of carvacrol in combination with meropenem against carbapenem-resistant Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Chlorocebus aethiops; Cymenes; Drug Synergism; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Vero Cells | 2022 |
Comparative study of phenotypic-based detection assays for carbapenemase-producing Acinetobacter baumannii with a proposed algorithm in resource-limited settings.
Topics: Acinetobacter baumannii; Algorithms; Bacterial Proteins; beta-Lactamases; Biological Assay; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests | 2021 |
Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections.
Topics: Adult; Anti-Bacterial Agents; Boronic Acids; Carbapenems; Humans; Meropenem; Retrospective Studies | 2021 |
Emerione A, a novel fungal metabolite as an inhibitor of New Delhi metallo-β-lactamase 1, restores carbapenem susceptibility in carbapenem-resistant isolates.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation | 2022 |
Variants of Tn
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Genome, Bacterial; Macrolides; Meropenem; Phylogeny; Sequence Alignment | 2022 |
Biapenem.
Topics: Anti-Bacterial Agents; Carbapenems; Humans; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2022 |
Geographical differences of carbapenem non-susceptible Enterobacterales and Acinetobacter spp. in Germany from 2017 to 2019.
Topics: Acinetobacter; Aged; Anti-Bacterial Agents; Carbapenems; Humans; Infant; Infant, Newborn; Meropenem; Microbial Sensitivity Tests | 2022 |
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Escherichia coli; Imipenem; Klebsiella pneumoniae; Lactams; Meropenem; Microbial Sensitivity Tests; Monobactams | 2022 |
Disulfiram enhances meropenem activity against NDM- and IMP-producing carbapenem-resistant Acinetobacter baumannii infections.
Topics: Acinetobacter baumannii; Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Disulfiram; Female; Meropenem; Mice; Microbial Sensitivity Tests | 2022 |
In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Effect of sigma E on carbapenem resistance in OXA-48-producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Porins | 2022 |
Evaluation of a carbapenem antimicrobial stewardship program and clinical outcomes in a Japanese hospital.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Fluoroquinolones; Hospitals; Humans; Japan; Levofloxacin; Meropenem; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2022 |
Whole-genome analysis and description of an IMP-8-producing Ochrobactrum anthropi.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ceftazidime; Gold Colloid; Humans; Meropenem; Microbial Sensitivity Tests; Ochrobactrum anthropi | 2022 |
An Outer Membrane Protein YiaD Contributes to Adaptive Resistance of Meropenem in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Membrane Proteins; Meropenem; Microbial Sensitivity Tests | 2022 |
In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Ciprofloxacin; Escherichia coli; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Nitroquinolines; Sulfamethoxazole; Trimethoprim; Urinary Tract; Urinary Tract Infections | 2022 |
The predominance of Klebsiella pneumoniae carbapenemase (KPC-type) gene among high-level carbapenem-resistant Klebsiella pneumoniae isolates in Baghdad, Iraq.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Humans; Imipenem; Iraq; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
[In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Colistin; Drug Combinations; Humans; Klebsiella pneumoniae; Meropenem | 2022 |
[Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens].
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Colistin; Drug Combinations; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Colistin; Drug Combinations; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Rifampin; Tazobactam; Tigecycline | 2022 |
Peptidoglycan Recycling Promotes Outer Membrane Integrity and Carbapenem Tolerance in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Meropenem; Microbial Sensitivity Tests; Peptidoglycan | 2022 |
TP0586532, a Novel Non-Hydroxamate LpxC Inhibitor: Potentiating Effect on
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Butanols; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Enterobacteriaceae Infections; Escherichia coli; Gram-Negative Bacteria; Humans; Imidazoles; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Bismuth complex of quinoline thiosemicarbazone restores carbapenem sensitivity in NDM-1-positive Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactamases; Bismuth; Carbapenems; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Quinolines; Thiosemicarbazones | 2022 |
Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Escherichia coli; Escherichia coli Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2022 |
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Humans; Imipenem; Meropenem; Tazobactam | 2022 |
Application of 1,1-ADEQUATE and DFT to correct
Topics: Anti-Bacterial Agents; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests | 2022 |
Comparison of carbapenem minimum inhibitory concentrations of Oxacillin-48-like Klebsiella pneumoniae by Sensititre, Vitek 2, MicroScan, and Etest.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Disk Diffusion Antimicrobial Tests; Ertapenem; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Oxacillin | 2022 |
Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefiderocol; Ceftazidime; Drug Combinations; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2023 |
Association between Antimicrobial Consumption and the Prevalence of Nosocomial Carbapenem-Resistant Escherichia coli and Klebsiella pneumoniae in a Tertiary Hospital in Northern Taiwan.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cross Infection; Doripenem; Escherichia coli; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Prevalence; Retrospective Studies; Taiwan; Tertiary Care Centers | 2022 |
Population analysis profiling: is it still the gold standard for the determination of heteroresistance in carbapenemase-producing Enterobacteriaceae?
Topics: Agar; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Enterobacteriaceae Infections; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Modulation of the Specificity of Carbapenems and Diazabicyclooctanes for Selective Activity against Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Escherichia coli; Meropenem; Microbial Sensitivity Tests; Mycobacterium tuberculosis | 2022 |
Criteria Restricting Inappropriate Meropenem Empiricism (CRIME): a quasi-experimental carbapenem restriction pilot at a large academic medical centre.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Carbapenems; Clostridium Infections; Crime; Empiricism; Humans; Meropenem | 2022 |
1,2,4-Triazole-3-thione analogues with an arylakyl group at position 4 as metallo-β-lactamase inhibitors.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ceftriaxone; Ethylenes; HeLa Cells; Humans; Ligands; Meropenem; Microbial Sensitivity Tests; Thiones; Triazoles; Zinc | 2022 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Escherichia coli; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
In vitro activity of celastrol in combination with thymol against carbapenem-resistant Klebsiella pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Thymol | 2022 |
Preferential Selection of Low-Frequency, Lipopolysaccharide-Modified, Colistin-Resistant Mutants with a Combination of Antimicrobials in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Ciprofloxacin; Colistin; Disinfectants; Drug Resistance, Multiple, Bacterial; Humans; Lipopolysaccharides; Meropenem; Microbial Sensitivity Tests | 2022 |
Structural insights into the substrate specificity of IMP-6 and IMP-1 metallo-β-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Substrate Specificity | 2022 |
Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease.
Topics: Animals; Anti-Bacterial Agents; Bacteroides; Carbapenems; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Meropenem; Mice; Mucins; Mucus; Polysaccharides; Xylose | 2022 |
In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Tigecycline | 2022 |
Whole genome sequencing of OXA-232-producing
Topics: Amikacin; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Chromosomes; Ciprofloxacin; DNA Transposable Elements; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Phylogeny; Plasmids; Sepsis; Virulence; Virulence Factors; Whole Genome Sequencing | 2022 |
Computing antimicrobial use/antimicrobial resistance ratios: A novel way to assess inpatient antimicrobial utilization using current National Healthcare Safety Network metrics.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Benchmarking; Carbapenems; COVID-19 Drug Treatment; Daptomycin; Delivery of Health Care; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Inpatients; Linezolid; Meropenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Retrospective Studies; Vancomycin | 2022 |
Molecular detection of Metallo-Beta-Lactamase and alginate in multidrug resistance
Topics: Alginates; beta-Lactamases; Carbapenems; Cross-Sectional Studies; Drug Resistance, Multiple; Hemolysin Proteins; Humans; Imipenem; Meropenem; Pseudomonas aeruginosa; Virulence Factors | 2022 |
Carbapenem resistance gene crisis in A. baumannii: a computational analysis.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Doripenem; Imipenem; Meropenem; Molecular Docking Simulation | 2022 |
The in vitro and in vivo potential of metal-chelating agents as metallo-beta-lactamase inhibitors against carbapenem-resistant Enterobacterales.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Chelating Agents; Meropenem; Mice; Microbial Sensitivity Tests | 2023 |
Baicalein Inhibits Plasmid-Mediated Horizontal Transmission of the blaKPC Multidrug Resistance Gene from Klebsiella pneumoniae to Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Escherichia coli; Genes, MDR; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Paraoxon; Plasmids | 2023 |
Preferred β-lactone synthesis can explain high rate of false-negative results in the detection of OXA-48-like carbapenemases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Enterobacteriaceae; Meropenem; Microbial Sensitivity Tests; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2022 |
Phenotypic and genotypic detection of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in Accra, Ghana.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cross-Sectional Studies; Ertapenem; Escherichia coli; Ghana; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Geographic patterns of carbapenem-resistant, multi-drug-resistant and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Leadership; Meropenem; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2023 |
Molecular docking and dynamic approach to screen the drug candidate against the Imipenem-resistant CarO porin in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Doripenem; Ertapenem; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Porins | 2023 |
Risk evaluation of carbapenem-induced liver injury based on machine learning analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Chemical and Drug Induced Liver Injury, Chronic; Doripenem; Humans; Meropenem | 2023 |
Molecular Dynamic Analysis of Carbapenem-Resistant
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Humans; Imipenem; Klebsiella; Klebsiella pneumoniae; Ligands; Meropenem; Metal Nanoparticles; Microbial Sensitivity Tests; Molecular Dynamics Simulation; Monobactams; Nanoparticles; Pneumonia; Porins; Spectroscopy, Fourier Transform Infrared; Zinc Oxide | 2023 |
Characterization of a novel carbapenem-hydrolysing β-lactamase OXA-1041 in Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation | 2023 |
Outer Membrane Vesicles Transmitting
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem | 2023 |
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; United States | 2023 |
Epidemiological and Genetic Characteristics of Clinical Carbapenem-Resistant
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Hong Kong; Humans; Imipenem; Intensive Care Units; Meropenem; Pseudomonas aeruginosa; Tazobactam | 2023 |
A Nationwide Genomic Study of Clinical Klebsiella pneumoniae Carrying
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Genomics; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Plasmids | 2023 |
Meropenem in combination with baicalein exhibits synergism against extensively drug resistant and pan-drug-resistant Acinetobacter baumannii clinical isolates in vitro.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests | 2023 |
Association of Biofilm Inducer with
Topics: Bacterial Proteins; beta-Lactamases; Biofilms; Carbapenems; Imipenem; Meropenem; Pseudomonas aeruginosa | 2022 |
The C5α-Methyl-Substituted Carbapenem NA-1-157 Exhibits Potent Activity against
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Escherichia coli; Kinetics; Klebsiella; Meropenem | 2023 |
Investigation of in vitro efficacy of meropenem/polymyxin B and meropenem/fosfomycin combinations against carbapenem resistant Klebsiella pneumoniae strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Fosfomycin; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Polymyxin B | 2023 |
Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Retrospective Studies; Urinary Tract Infections | 2023 |
In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymyxin B | 2023 |
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Carbapenem triggers dissemination of chromosomally integrated carbapenemase genes via conjugative plasmids in
Topics: Anti-Bacterial Agents; Carbapenems; Escherichia coli; Meropenem; Plasmids | 2023 |
Evaluation of real-time PCR and flow cytometry efficiency in rapid detection of carbapenemase-producing Enterobacteriales.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Flow Cytometry; Gammaproteobacteria; Humans; Meropenem; Microbial Sensitivity Tests; Real-Time Polymerase Chain Reaction | 2023 |
Multiplicity of
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Carbapenems; Ceftazidime; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Plasmids | 2023 |
Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin.
Topics: Amikacin; Carbapenems; Escherichia coli; Humans; Meropenem; Propranolol; Tigecycline | 2023 |
Detection of blaoxa-23 Gene from Carbapenem-resistant Acinetobacter Baumannii.
Topics: Acinetobacter baumannii; Carbapenems; Cross-Sectional Studies; Humans; Meropenem; Nepal | 2023 |
Resensitizing multidrug-resistant Gram-negative bacteria to carbapenems and colistin using disulfiram.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Disulfiram; Drug Combinations; Gram-Negative Bacteria; Meropenem | 2023 |
Novel metallo-β-lactamases inhibitors restore the susceptibility of carbapenems to New Delhi metallo-lactamase-1 (NDM-1)-harbouring bacteria.
Topics: Animals; Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Dexrazoxane; Masoprocol; Meropenem; Mice; Microbial Sensitivity Tests | 2024 |
Testing the mutant selection window hypothesis with meropenem: In vitro model study with OXA-48-producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2023 |
Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Combinations; Gammaproteobacteria; Meropenem; Microbial Sensitivity Tests | 2023 |
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Escherichia coli; Meropenem; Microbial Sensitivity Tests | 2023 |
Genomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals.
Topics: beta-Lactamase Inhibitors; Brazil; Carbapenems; Cefiderocol; Genomics; Klebsiella pneumoniae; Lactams; Meropenem | 2023 |
Discovery of 2-Aminothiazole-4-carboxylic Acids as Broad-Spectrum Metallo-β-lactamase Inhibitors by Mimicking Carbapenem Hydrolysate Binding.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Carboxylic Acids; Meropenem; Mice | 2023 |
Investigation of in vitro efficacy of quercetin-meropenem combination in carbapenemase-producing Klebsiella pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Quercetin | 2023 |
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2023 |
Carbapenem resistance determinants and their transmissibility among clinically isolated Enterobacterales in Lebanon.
Topics: Anti-Infective Agents; Carbapenems; Humans; Imipenem; Lebanon; Meropenem | 2023 |
A critical role of outer membrane vesicles in antibiotic resistance in carbapenem-resistant Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Chromatography, Liquid; Drug Resistance, Microbial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Tandem Mass Spectrometry; Tertiary Care Centers | 2023 |
Occurrence of some common carbapenemase genes in carbapenem-resistant Klebsiella pneumoniae isolates collected from clinical samples in Tabriz, northwestern Iran.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cross-Sectional Studies; Humans; Imipenem; Iran; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2023 |